US20200276326A1 - Compositions and methods for the depletion of cd5+ cells - Google Patents

Compositions and methods for the depletion of cd5+ cells Download PDF

Info

Publication number
US20200276326A1
US20200276326A1 US16/851,082 US202016851082A US2020276326A1 US 20200276326 A1 US20200276326 A1 US 20200276326A1 US 202016851082 A US202016851082 A US 202016851082A US 2020276326 A1 US2020276326 A1 US 2020276326A1
Authority
US
United States
Prior art keywords
optionally substituted
antibody
cells
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/851,082
Other languages
English (en)
Inventor
Anthony Boitano
Michael Cooke
Rahul Palchaudhuri
Sean McDonough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianthus Therapeutics Inc
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Priority to US16/851,082 priority Critical patent/US20200276326A1/en
Publication of US20200276326A1 publication Critical patent/US20200276326A1/en
Priority to US17/244,721 priority patent/US20210369854A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • hematopoietic stem cells have significant therapeutic potential
  • a limitation that has hindered their use in the clinic has been the difficulty associated with ensuring engraftment of hematopoietic stem cell transplants in a host.
  • a patient's own immune system often attacks the transplanted cells and mediates rejection of the transplanted hematopoietic stem cells.
  • a patient is treated with immune system destroying agents prior to hematopoietic stem cell transplantation, e.g., chemotherapeutic agents or radiation.
  • immune system destroying agents prior to hematopoietic stem cell transplantation e.g., chemotherapeutic agents or radiation.
  • efforts to induce tolerance of the hematopoietic stem cell transplantation in the patient often result in serious complications.
  • compositions and methods for treating disorders of the hematopoietic system such as autoimmune disorders
  • compositions and methods for promoting the engraftment of exogenous hematopoietic stem cell grafts such that the multi-potency and hematopoietic functionality of these cells is preserved following transplantation.
  • the present invention provides compositions and methods for the direct treatment of various disorders of the hematopoietic system, metabolic disorders, cancers, and autoimmune diseases, among others.
  • the compositions and methods disclosed herein target immune cells for conditioning a human patient for a hematopoietic stem cell transplantation for treatment of a disease such as, but not limited to, blood cancer or an autoimmune disease.
  • the invention additionally features compositions and methods for conditioning a patient, such as a human patient, prior to receiving hematopoietic stem cell transplant therapy so as to promote the engraftment of hematopoietic stem cell grafts.
  • a patient such as a human patient
  • the patient may be one that is suffering from an autoimmune disease or one or more blood disorders, such as cancer, hemoglobinopathy, or other hematopoietic pathology, and is thus in need of hematopoietic stem cell transplantation.
  • hematopoietic stem cells are capable of differentiating into a multitude of cell types in the hematopoietic lineage, and can be administered to a patient in order to populate or re-populate a cell type that is deficient in the patient.
  • the invention features antibodies and antibody-drug conjugates capable of binding CD5, as well as methods of administering the same to a patient so as to (i) directly treat a blood disorder, such as an autoimmune disease, by selectively depleting a population of immune cells that express CD5, such as an autoreactive T cell, B cell, or natural killer (NK) cell, and/or to (ii) deplete a population of T cells, B cells, or NK cells prior to administration of a hematopoietic stem cell transplant to the patient, thereby reducing the likelihood of hematopoietic stem cell graft rejection.
  • a blood disorder such as an autoimmune disease
  • CD5 an autoreactive T cell, B cell, or natural killer (NK) cell
  • NK natural killer
  • the former activity enables the direct treatment of a wide range of autoimmune disorders, as CD5 may be expressed by a T cell, B cell, or NK cell that cross-reacts with, and mounts an inappropriate immune response against, a self antigen.
  • Administration of an anti-CD5 antibody, antigen-binding fragment thereof, or an antibody-drug conjugate to a patient in this case can cause depletion of a population of CD5+ autoimmune cells, such as T cells, B cells, or NK cells that cross-react with one or more self antigens, thereby treating the autoimmune pathology.
  • the latter activity facilitates the generation of an environment that is conducive to hematopoietic stem cell engraftment, as T cells, B cells, and/or NK cells that cross-react with one or more non-self antigens expressed by a hematopoietic stem cell, such as one or more non-self MHC antigens expressed by a hematopoietic stem cell, can mount an immune response against transplanted hematopoietic stem cells and thus promote graft rejection.
  • patients suffering from a disorder such as cancer, an autoimmune disease, or other condition of the hematopoietic system can subsequently be administered a hematopoietic stem cell transplant in order, for instance, to repopulate one or more blood cell lineages that are defective or depleted in the patient.
  • the invention thus provides methods of treating a variety of hematopoietic conditions, such as sickle cell anemia, thalassemia, Fanconi anemia, Wiskott-Aldrich syndrome, adenosine deaminase deficiency-severe combined immunodeficiency, metachromatic leukodystrophy, Diamond-Blackfan anemia and Schwachman-Diamond syndrome, human immunodeficiency virus infection, and acquired immune deficiency syndrome, as well as cancers and autoimmune diseases, among others.
  • hematopoietic conditions such as sickle cell anemia, thalassemia, Fanconi anemia, Wiskott-Aldrich syndrome, adenosine deaminase deficiency-severe combined immunodeficiency, metachromatic leukodystrophy, Diamond-Blackfan anemia and Schwachman-Diamond syndrome, human immunodeficiency virus infection, and acquired immune deficiency syndrome, as well as cancers and autoimmune diseases
  • the invention provides a method of depleting a population of CD5+ cells, for instance, in a human patient, such as a population of CD5+ T cells, CD5+ B cells, and/or CD5+NK cells in a human patient, by administering to the patient an effective amount of an antibody, antigen-binding fragment thereof, or antibody-drug conjugate that binds to CD5.
  • the invention provides a method of depleting a population of CD5+ cells in a human patient in need of a hematopoietic stem cell transplant, such as a population of CD5+ T cells, CD5+ B cells, and/or CD5+NK cells in a human patient in need of hematopoietic stem cell transplant, by administering to the patient an effective amount of an antibody, antigen-binding fragment thereof, or antibody-drug conjugate that binds to CD5, for example, prior to the patient receiving a transplant including hematopoietic stem cells.
  • a hematopoietic stem cell transplant such as a population of CD5+ T cells, CD5+ B cells, and/or CD5+NK cells in a human patient in need of hematopoietic stem cell transplant
  • the invention provides a method of preventing or reducing the likelihood of rejection of a hematopoietic stem cell graft in a human patient in need of hematopoietic stem cell transplant therapy by administering, prior to the patient receiving a transplant including hematopoietic stem cells, an effective amount of an antibody, antigen-binding fragment thereof, or antibody-drug conjugate that binds to CD5.
  • the invention provides a method of depleting a population of endogenous T cells in a human patient in need of hematopoietic stem cell transplant therapy by administering, prior to the patient receiving a transplant including hematopoietic stem cells, an effective amount of an antibody, antigen-binding fragment thereof, or antibody-drug conjugate that binds to CD5.
  • the invention features a method, for example, of treating a human patient in need of a hematopoietic stem cell transplant, including administering to a human patient a transplant including hematopoietic stem cells, wherein the patient has been previously administered an antibody or antigen-binding fragment thereof that binds to CD5.
  • the antibody, antigen-binding fragment thereof, or antibody-drug conjugate may be administered to the patient in an amount sufficient to deplete a population of CD5+ cells in the patient, such as a population of CD5+ T cells, CD5+ B cells, and/or CD5+NK cells in the human patient.
  • the invention features a method, for example, of treating a human patient in need of a hematopoietic stem cell transplant, including: administering to a human patient an antibody, antigen-binding fragment thereof, or antibody-drug conjugate that binds to CD5 in an amount sufficient to deplete a population of CD5+ cells in the patient, such as a population of CD5+ T cells, CD5+ B cells, and/or CD5+NK cells in the patient, and subsequently administering to the patient a transplant including hematopoietic stem cells.
  • the antibody or antigen-binding fragment thereof is produced by the hybridoma cell line ATCC CRL 8000. In some embodiments, the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof produced by the hybridoma cell line ATCC CRL 8000.
  • the antibody or antigen-binding fragment thereof comprises the following variable domains:
  • V L having the amino acid sequence (SEQ ID NO: 1) DIQMTQSPSSMSASLGDRVTITCRASQDINSYLSWFQQKPGKSPKTLIYR ANRLVDGVPSRFSGSGSGTDYTLTISSLQYEDFGIYYCQQYDESPWTFGG GTKLEIK; and a V H having the amino acid sequence (SEQ ID NO: 2) QIQLVQSGPGLKKPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLRWMGW INTHTGEPTYADDFKGRFTFSLDTSKSTAYLQINSLRAEDTATYFCTRRG YDWYFDVWGQGTTVTVSS.
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing variable domains.
  • the antibody or antigen-binding fragment thereof includes the following CDRs:
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing CDRs.
  • the antibody or antigen-binding fragment thereof comprises the following variable domains:
  • V L having the amino acid sequence (SEQ ID NO: 9) DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKTLIYR ANRLESGVPSRFSGSGSGTDYTLTISSLQYEDFGIYYCQQYDESPWTFGG GTKLEIK; and a V H having the amino acid sequence (SEQ ID NO: 10) EIQLVQSGGGLVKPGGSVRISCAASGYTFTNYGMNWVRQAPGKGLEWMGW INTHYGEPTYADSFKGTRTFSLDDSKNTAYLQINSLRAEDTAVYFCTRRG YDWYFDVWGQGGTTVTVSS.
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing variable domains.
  • the antibody or antigen-binding fragment thereof includes the following CDRs:
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing CDRs.
  • the antibody or antigen-binding fragment thereof includes the following CDRs:
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing CDRs.
  • the antibody or antigen-binding fragment thereof includes the following CDRs:
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing CDRs.
  • the antibody or antigen-binding fragment thereof includes the following CDRs:
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing CDRs.
  • the antibody or antigen-binding fragment thereof contains a combination of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 regions set forth in Table 1, below. In some embodiments, the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises a combination of CDRs set forth in Table 1, below.
  • the antibody or antigen-binding fragment thereof is selected from the group consisting of a monoclonal antibody or antigen-binding fragment thereof, a polyclonal antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, a bispecific antibody or antigen-binding fragment thereof, a dual-variable immunoglobulin domain, a single-chain Fv molecule (scFv), a diabody, a triabody, a nanobody, an antibody-like protein scaffold, a Fv fragment, a Fab fragment, a F(ab′) 2 molecule, and a tandem di-scFv.
  • the antibody has an isotype selected from the group consisting of IgG, IgA, IgM, IgD, and IgE.
  • the antibody is conjugated to a cytotoxin.
  • the cytotoxin is selected from the group consisting of an amatoxin, pseudomonas exotoxin A, deBouganin, diphtheria toxin, saporin, maytansine, a maytansinoid, an auristatin, an anthracycline, a calicheamicin, irinotecan, SN-38, a duocarmycin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, an indolinobenzodiazepine, and an indolinobenzodiazepine dimer, or a variant thereof.
  • the invention provides a method of depleting a population of CD5+ cells in a human patient, such as a population of CD5+ T cells, CD5+ B cells, and/or CD5+NK cells in a human patient, by administering to the patient an effective amount of an antibody, fragment thereof, or antibody-drug conjugate capable of binding CD5.
  • the invention provides a method of depleting a population of CD5+ cells in a human patient in need of a hematopoietic stem cell transplant, such as a population of CD5+ T cells, CD5+ B cells, and/or CD5+NK cells in a human patient in need of hematopoietic stem cell transplant, by administering, prior to the patient receiving a transplant including hematopoietic stem cells, an effective amount of an antibody, fragment thereof, or antibody-drug conjugate capable of binding CD5.
  • a hematopoietic stem cell transplant such as a population of CD5+ T cells, CD5+ B cells, and/or CD5+NK cells in a human patient in need of hematopoietic stem cell transplant
  • the invention features a method, for example, of treating a human patient in need of a hematopoietic stem cell transplant, including administering to a human patient a transplant including hematopoietic stem cells, wherein the patient has been previously administered an antibody, fragment thereof, or antibody-drug conjugate that binds to CD5 in an amount sufficient to deplete a population of CD5+ cells in the patient, such as a population of CD5+ T cells, CD5+ B cells, and/or CD5+NK cells in the human patient.
  • the invention features a method, for example, of treating a human patient in need of a hematopoietic stem cell transplant, including: administering to a human patient an antibody, fragment thereof, or antibody-drug conjugate that binds to CD5 in an amount sufficient to deplete a population of CD5+ cells in the patient, such as a population of CD5+ T cells, CD5+ B cells, and/or CD5+NK cells in the patient, and subsequently administering to the patient a transplant including hematopoietic stem cells.
  • the antibody or fragment thereof that binds to CD5 is covalently bound to an Fc domain, such as a dimeric Fc domain isolated from a human antibody (for example, isolated from an IgG1, IgG2, IgG3, or IgG4 isotype human antibody).
  • the Fc domain is a monomeric Fc domain containing a single polypeptide strand.
  • the N-terminus of the antibody or fragment thereof is bound to the Fc domain.
  • the C-terminus of the antibody or fragment thereof is bound to the Fc domain.
  • the Fc domain may be conjugated to one or more copies of the antibody or fragment thereof.
  • conjugates that may be used in conjunction with the methods described herein include dimeric Fc domains in which each polypeptide strand of the Fc domain is conjugated to the antibody or fragment thereof.
  • the Fc domain may in turn be conjugated to a cytotoxin, such as a cytotoxin described herein (for example, an amatoxin, such as ⁇ -amanitin, pseudomonas exotoxin A, deBouganin, diphtheria toxin, saporin, maytansine, a maytansinoid, an auristatin, an anthracycline, a calicheamicin, irinotecan, SN-38, a duocarmycin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, an indolinobenzodiazepine, and an indolinobenzodiazepine dimer, or a variant thereof).
  • a cytotoxin such as a cytotoxin described herein (for example, an amatoxin, such as ⁇ -amanitin, pseudomonas exotoxin A, deBouganin, diphth
  • the anti-CD5 antibody or fragment thereof is covalently bound to a cytotoxin, such as a cytotoxin described herein (for example, an amatoxin, such as ⁇ -amanitin, pseudomonas exotoxin A, deBouganin, diphtheria toxin, saporin, maytansine, a maytansinoid, an auristatin, an anthracycline, a calicheamicin, irinotecan, SN-38, a duocarmycin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, an indolinobenzodiazepine, and an indolinobenzodiazepine dimer, or a variant thereof).
  • a cytotoxin such as a cytotoxin described herein (for example, an amatoxin, such as ⁇ -amanitin, pseudomonas exotoxin A, deBouganin
  • the N-terminus of the antibody or fragment thereof is bound to the cytotoxin. In some embodiments, the C-terminus of the antibody or fragment thereof is bound to the cytotoxin.
  • the cytotoxin may in turn be conjugated to an Fc domain.
  • the anti-CD5 antibody or fragment thereof is covalently bound to the cytotoxin at one site on the antibody or fragment thereof (for example, the N- or C-terminus of the antibody or fragment thereof) and is covalently bound to an Fc domain at another site on the antibody or fragment thereof (for example, the opposite terminus of the antibody or fragment thereof).
  • the Fc domain is a human IgG1 isotype Fc domain. In some embodiments, the Fc domain is a human IgG2 isotype Fc domain. In some embodiments, the Fc domain is a human IgG3 isotype Fc domain. In some embodiments, the Fc domain is a human IgG4 isotype Fc domain.
  • the cytotoxin is an amatoxin or derivative thereof, such as ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, amanullinic acid, and proamanullin.
  • the cytotoxin is an amanitin.
  • the cytotoxin is an amatoxin
  • the antibody, or the antigen-binding fragment thereof, conjugated to the cytotoxin is represented by the formula Ab-Z-L-Am, wherein Ab is the anti-CD5 antibody, antigen-binding fragment thereof, L is a linker, Z is a chemical moiety, and Am is the amatoxin.
  • the amatoxin is conjugated to a linker.
  • the amatoxin-linker conjugate Am-L-Z is represented by formula (I)
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group;
  • R 3 is H, R C , or R D ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , OR D , NHR C , or NR C R D ;
  • R 9 is H, OH, OR C , or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R C is -L-Z
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • alkyl e.g., C 1 -C 6 alkyl
  • optionally substituted heteroalkyl e.g., C 1 -C 6 heteroalkyl
  • optionally substituted alkenyl
  • L is a linker, such as optionally substituted alkylene (e.g., C 1 -C 6 alkylene), optionally substituted heteroalkylene (C 1 -C 6 heteroalkylene), optionally substituted alkenylene (e.g., C 2 -C 6 alkenylene), optionally substituted heteroalkenylene (e.g., C 2 -C 6 heteroalkenylene), optionally substituted alkynylene (e.g., C 2 -C 6 alkynylene), optionally substituted heteroalkynylene (e.g., C 2 -C 6 heteroalkynylene), optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene; a dipeptide, —C( ⁇ O)—, a peptide, or a combination thereof; and
  • Z is a chemical moiety formed from a coupling reaction between a reactive substituent present on L and a reactive substituent present within an antibody, or an antigen-binding fragment thereof, that binds to CD5, such as on the surface of a CD5+ T cell, CD5+ B cell, or CD5+NK cell.
  • Am contains exactly one R C substituent.
  • linker L and the chemical moiety Z, taken together as L-Z is
  • S is a sulfur atom which represents the reactive substituent present within an antibody, or antigen-binding fragment thereof, that binds CD5 (e.g., from the —SH group of a cysteine residue).
  • Am-L-Z-Ab is:
  • Am-L-Z is represented by formula (IA)
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group;
  • R 3 is H, R C , or R D ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , OR D , NHR C , or NR C R D ;
  • R 9 is H, OH, OR C , or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R C is -L-Z
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • alkyl e.g., C 1 -C 6 alkyl
  • optionally substituted heteroalkyl e.g., C 1 -C 6 heteroalkyl
  • optionally substituted alkenyl
  • L is a linker, such as optionally substituted alkylene (e.g., C 1 -C 6 alkylene), optionally substituted heteroalkylene (C 1 -C 6 heteroalkylene), optionally substituted alkenylene (e.g., C 2 -C 6 alkenylene), optionally substituted heteroalkenylene (e.g., C 2 -C 6 heteroalkenylene), optionally substituted alkynylene (e.g., C 2 -C 6 alkynylene), optionally substituted heteroalkynylene (e.g., C 2 -C 6 heteroalkynylene), optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, optionally substituted heteroarylene, a dipeptide, —C( ⁇ O)—, a peptide, or a combination thereof;
  • optionally substituted alkylene e.g., C 1 -C 6 alkylene
  • Z is a chemical moiety formed from a coupling reaction between a reactive substituent present on L and a reactive substituent present within an antibody, or an antigen-binding fragment thereof, that binds CD5, such as on the surface of a CD5+ T cell, CD5+ B cell, or CD5+NK cell;
  • linker L and the chemical moiety Z, taken together as L-Z is
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z is represented by formula (IB)
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , Or OR C ;
  • R A and R B when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group;
  • R 3 is H, R C , or R D ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , OR D , NHR C , or NR C R D ;
  • R 9 is H, OH, OR C , or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R C is -L-Z
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, a dipeptide, —C( ⁇ O)—, a peptide, or a combination thereof;
  • L is a linker, such as optionally substituted alkylene (e.g., C 1 -C 6 alkylene), optionally substituted heteroalkylene (C 1 -C 6 heteroalkylene), optionally substituted alkenylene (e.g., C 2 -C 6 alkenylene), optionally substituted heteroalkenylene (e.g., C 2 -C 6 heteroalkenylene), optionally substituted alkynylene (e.g., C 2 -C 6 alkynylene), optionally substituted heteroalkynylene (e.g., C 2 -C 6 heteroalkynylene), optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene;
  • Z is a chemical moiety formed from a coupling reaction between a reactive substituent present on L and a reactive substituent present within an antibody, or an antigen-binding fragment thereof, that binds CD5, such as on the surface of a CD5+ T cell, CD5+ B cell, or CD5+NK cell;
  • R A and R B together with the oxygen atoms to which they are bound, combine to form a 5-membered heterocycloalkyl group of formula:
  • R E and R E′ are each independently optionally substituted C 1 -C 6 alkylene-R C , optionally substituted C 1 -C 6 heteroalkylene-R C , optionally substituted C 2 -C 6 alkenylene-R C , optionally substituted C 2 -C 6 heteroalkenylene-R C , optionally substituted C 2 -C 6 alkynylene-R C , optionally substituted C 2 -C 6 heteroalkynylene-R C , optionally substituted cycloalkylene-R C , optionally substituted heterocycloalkylene-R C , optionally substituted arylene-R C , or optionally substituted heteroarylene-R C .
  • Am-L-Z is represented by formula (IA) or formula (IB), wherein R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B together with the oxygen atoms to which they are bound, combine to form:
  • R 3 is H or R C ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , or NHR C ;
  • R 9 is H or OH
  • R C and R D are each as defined above.
  • Am is represented by formula (IA) or formula (IB),
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B together with the oxygen atoms to which they are bound, combine to form:
  • R 3 is H or R C ;
  • R 4 and R 5 are each independently H, OH, OR C , R C , or OR D ;
  • R 6 and R 7 are each H
  • R 8 is OH, NH 2 , OR C , or NHR C ;
  • R 9 is H or OH
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 is H, OH, or OR A ;
  • R 2 is H, OH, or OR B ;
  • R A and R B together with the oxygen atoms to which they are bound, combine to form:
  • R 3 , R 4 , R 6 , and R 7 are each H;
  • R 5 is OR C ;
  • R 8 is OH or NH 2 ;
  • R 9 is H or OH
  • Am is represented by formula (IA) or formula (IB),
  • R 1 and R 2 are each independently H or OH;
  • R 3 is R C ;
  • R 4 , R 6 , and R 7 are each H;
  • R 5 is H, OH, or OC 1 -C 6 alkyl
  • R 8 is OH or NH 2 ;
  • R 9 is H or OH
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 and R 2 are each independently H or OH;
  • R 3 , R 6 , and R 7 are each H;
  • R 4 and R 5 are each independently H, OH, OR C , or R C ;
  • R 8 is OH or NH 2 ;
  • R 9 is H or OH
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 and R 2 are each independently H or OH;
  • R 3 , R 6 , and R 7 are each H;
  • R 4 and R 5 are each independently H or OH
  • R 8 is OH, NH 2 , OR C , or NHR C ;
  • R 9 is H or OH
  • linker L and the chemical moiety Z, taken together as L-Z is
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z is represented by formula (II), formula (IIA), or formula (IIB)
  • X is S, SO, or SO 2 ;
  • R 1 is H or a linker covalently bound to the antibody or antigen-binding fragment thereof through a chemical moeity Z, formed from a coupling reaction between a reactive substituent present on the linker and a reactive substituent present within an antibody, or antigen-binding fragment thereof;
  • R 2 is H or a linker covalently bound to the antibody or antigen-binding fragment thereof through a chemical moeity Z, formed from a coupling reaction between a reactive substituent present on the linker and a reactive substituent present within an antibody, or antigen-binding fragment thereof; wherein when R 1 is H, R 2 is the linker, and when R 2 is H, R 1 is the linker.
  • the linker comprises a —(CH) 2n — unit, where n is an integer from 2-6.
  • R 1 is the linker and R 2 is H, and the linker and chemical moiety, together as L-Z, is
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • the cytotoxin is a maytansinoid selected from the group consisting of DM1 and DM4.
  • the cytotoxin is an auristatin selected from the group consisting of monomethyl auristatin E and monomethyl auristatin F.
  • the cytotoxin is an anthracycline selected from the group consisting of daunorubicin, doxorubicin, epirubicin, and idarubicin.
  • the cytotoxin is a pyrrolobenzodiazepine dimer represented by formula (IV):
  • the cytotoxin is conjugated to the antibody, or the antigen-binding fragment thereof, by way of a maleimidocaproyl linker.
  • the cytotoxin is an auristatin selected from the group consisting of monomethyl auristatin E and monomethyl auristatin F.
  • the cytotoxin is an anthracycline selected from the group consisting of daunorubicin, doxorubicin, epirubicin, and idarubicin.
  • the anti-CD5 antibody, the antigen-binding fragment thereof, or antibody-drug conjugate is internalized by an immune cell, such as a T cell, B cell, or NK cell (e.g., a CD5+ T cell, CD5+ B cell, or CD5+NK cell) following administration to the patient.
  • an immune cell such as a T cell, B cell, or NK cell (e.g., a CD5+ T cell, CD5+ B cell, or CD5+NK cell) following administration to the patient.
  • the anti-CD5 antibody, antigen-binding fragment thereof, or antibody-drug conjugate may be internalized by T cells by receptor mediated endocytosis (e.g., upon binding to cell-surface CD5).
  • a cytotoxin covalently bound to the antibody, or the antigen-binding fragment thereof may be released intracellularly by chemical cleavage (for instance, by enzymatic or non-specific cleavage of a linker described herein).
  • the cytotoxin may then access its intracellular target (such as RNA polymerase, the mitotic spindle apparatus, nuclear DNA, ribosomal RNA, or topoisomerases, among others) so as to promote the death of an endogenous immune cell (e.g., CD5+ T cell, CD5+ B cell, or CD5+NK cell) prior to hematopoietic stem cell transplantation therapy.
  • an endogenous immune cell e.g., CD5+ T cell, CD5+ B cell, or CD5+NK cell
  • the anti-CD5 antibody, the antigen-binding fragment thereof, or the antibody-drug conjugate is capable of promoting necrosis of an immune cell, such as a T cell, B cell, or NK cell (e.g., a CD5+ T cell, CD5+ B cell, or CD5+NK cell).
  • an immune cell such as a T cell, B cell, or NK cell (e.g., a CD5+ T cell, CD5+ B cell, or CD5+NK cell).
  • the antibody, or the antigen-binding fragment thereof may promote the death of an endogenous immune cell (e.g., CD5+ T cell, CD5+ B cell, or CD5+NK cell) prior to transplantation therapy by recruiting one or more complement proteins, NK cells, macrophages, neutrophils, and/or eosinophils to the immune cell upon administration to the patient.
  • an autologous transplant containing hematopoietic stem cells is administered to the patient.
  • autologous hematopoietic stem cells can be removed from a patient, such as a patient in need of hematopoietic stem cell transplant therapy, and the cells can subsequently be administered to (e.g., infused into) the patient so as to re-populate one or more cell types of the hematopoietic lineage.
  • the withdrawn hematopoietic stem cells may be freshly re-infused into the subject, for instance, following maintenance ex vivo for one or more hours, days, or weeks.
  • the withdrawn hematopoietic stem cells may re-infused into the patient from 1 hour to about 1 week, from 1 hour to about 72 hours, from about 1 hour to about 48 hours, or from about 1 hour to about 24 hours following withdrawal from the patient.
  • the withdrawn hematopoietic stem cells are frozen for longer-term storage prior to re-infusion into the patient.
  • the withdrawn hematopoietic stem cells may be frozen and cryopreserved for from 1 week to 1 year, or longer, prior to re-infusion into the patient.
  • an allogenic transplant containing hematopoietic stem cells is administered to the patient.
  • allogeneic hematopoietic stem cells can be removed from a donor, such as donor that is HLA-matched with respect to the patient, for instance, a closely related family member of the patient.
  • the allogenic hematopoietic stem cells are HLA-mismatched with respect to the patient.
  • the cells can subsequently be administered to (e.g., infused into) the patient so as to re-populate one or more cell types of the hematopoietic lineage.
  • the withdrawn hematopoietic stem cells may be freshly infused into the subject, for instance, following maintenance ex vivo for one or more hours, days, or weeks.
  • the withdrawn hematopoietic stem cells may infused into the patient from 1 hour to about 1 week, from 1 hour to about 72 hours, from about 1 hour to about 48 hours, or from about 1 hour to about 24 hours following withdrawal from the donor.
  • the withdrawn hematopoietic stem cells are frozen for longer-term storage prior to infusion into the patient.
  • the withdrawn hematopoietic stem cells may be frozen and cryopreserved for from 1 week to 1 year, or longer, prior to infusion into the patient.
  • a transplant containing hematopoietic stem cells is administered to the patient after the concentration of the anti-CD5 antibody, the antigen-binding fragment thereof, or antibody-drug conjugate has substantially cleared from the blood of the patient.
  • a transplant containing hematopoietic stem cells is administered to the patient from 1 hour to 7 days (e.g., from 6 hours to 3 days, 12 hours to 36 hours, or about 24 hours) after the concentration of the anti-CD5 antibody, the antigen-binding fragment, or the antibody-drug conjugate has substantially cleared from the blood of the patient.
  • the hematopoietic stem cells or progeny thereof maintain hematopoietic stem cell functional potential after two or more days (for example, from about 2 to about 5 days, from about 2 to about 7 days, from about 2 to about 20 days, from about 2 to about 30 days, such as 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, or more) following transplantation of the hematopoietic stem cells into the patient.
  • days for example, from about 2 to about 5 days, from about 2 to about 7 days, from about 2 to about 20 days, from about 2 to about 30 days, such as 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days,
  • the population of CD5+ cells comprises CD34+ cells.
  • the proportion of CD34+ cells in the population of CD5+ cells may be about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100% of the total quantity of cells in the population.
  • the hematopoietic stem cells or progeny thereof are capable of localizing to hematopoietic tissue, such as the bone marrow, and/or reestablishing hematopoiesis following transplantation of the hematopoietic stem cells into the patient.
  • the hematopoietic stem cells upon transplantation into the patient, give rise to recovery of a population of cells selected from the group consisting of megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T lymphocytes, and B lymphocytes.
  • a population of cells selected from the group consisting of megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T lymphocytes, and B lymphocytes.
  • the patient is suffering from cancer.
  • the cancer can be a blood cancer or a type of leukemia, such as acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, or chronic lymphoid leukemia.
  • the CD5+ cells comprise cancer cells.
  • the anti-CD5 antibody, antigen-binding fragment thereof, or antibody-drug conjugate depletes cancer cells in a patient.
  • the antibody or antigen-binding fragment thereof may deplete 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or substantially all of the cancer cells in a patient.
  • the anti-CD5 antibody, antigen-binding fragment thereof, or antibody-drug conjugate depletes blood cancer cells (e.g., leukemic cells) in a patient.
  • the blood cancer cells are acute myeloid leukemic cells, acute lymphoid leukemic cells, chronic myeloid leukemic cells, or chronic lymphoid leukemic cells.
  • the blood cancer cells are megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T lymphocytes, or B lymphocytes.
  • the population of CD5+ cells comprises immune cells, such as CD5+ T cells, CD5+ B cells, and/or CD5+NK cells.
  • the method is used to treat one or more disorders, such as by depleting a population of immune cells in a patient, for instance, prior to hematopoietic stem cell transplant therapy so as to prevent or reduce the likelihood of rejection of the hematopoietic stem cell transplant that could otherwise be caused by a population of immune cells that cross-reacts with the hematopoietic stem cell graft, such as non-self MHC antigens expressed by the hematopoietic stem cell graft.
  • the hematopoietic stem cells may establish productive hematopoiesis, so as to replenish a deficient cell type in the patient or a cell type that is being actively killed or has been killed, for instance, by chemotherapeutic methods.
  • the patient may be one that is suffering from a stem cell disorder.
  • the patient is suffering from a hemoglobinopathy disorder, such as sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome.
  • the patient may be suffering from an immunodeficiency disorder, such as a congenital immunodeficiency disorder or an acquired immunodeficiency disorder (e.g., human immunodeficiency virus or acquired immune deficiency syndrome).
  • an immunodeficiency disorder such as a congenital immunodeficiency disorder or an acquired immunodeficiency disorder (e.g., human immunodeficiency virus or acquired immune deficiency syndrome).
  • the patient is suffering from a metabolic disorder, such as glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, and metachromatic leukodystrophy.
  • the patient is suffering from a disorder selected from the group consisting of adenosine deaminase deficiency and severe combined immunodeficiency, hyper immunoglobulin M syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, systemic sclerosis, systemic lupus erythematosus, and juvenile rheumatoid arthritis.
  • the patient is suffering from an autoimmune disease, such as scleroderma, multiple sclerosis, ulcerative colitis, Chron's disease, ant Type 1 diabetes.
  • the patient is suffering from cancer or myeloproliferative disease, such as a hematological cancer.
  • the patient is suffering from acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymohoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin's lymphoma.
  • the patient is suffering from a myelodysplastic disease, such as myelodysplastic syndrome.
  • the method is used to directly treat a cancer, such as a cancer characterized by CD5+ cells (e.g., a leukemia characterized by CD5+ cells), by administration of an antibody, antigen-binding fragment thereof, or antibody-drug conjugate that depletes a population of CD5+ cancer cells in the patient and/or by administration of an antibody, or the antigen-binding fragment thereof, prior to hematopoietic stem cell transplant therapy so as to prevent or reduce the likelihood of rejection of the hematopoietic stem cell transplant that could otherwise be caused by a population of immune cells that cross-reacts with non-self antigens expressed by the hematopoietic stem cell graft.
  • a cancer such as a cancer characterized by CD5+ cells (e.g., a leukemia characterized by CD5+ cells)
  • an antibody, antigen-binding fragment thereof, or antibody-drug conjugate that depletes a population of CD5+ cancer cells in the patient and/or by administration of an antibody
  • the transplantation may in turn re-constitute, for example, a population of cells depleted during the process of eradicating cancer cells.
  • the cancer may be a hematological cancer, such as acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymohoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin's lymphoma.
  • the method is used to treat an autoimmune disease, such as by administration of an anti-CD5 antibody, an antigen-binding fragment thereof, or an antibody-drug conjugate so as to deplete a population of CD5+ autoimmune cells (e.g., a population of autoreactive, CD5+ T cells, B cell, and/or NK cells) and/or by administration of an antibody, or an antigen-binding fragment thereof, prior to hematopoietic stem cell transplant therapy so as to prevent or reduce the likelihood of rejection of the hematopoietic stem cell transplant that could otherwise be caused by a population of immune cells that cross-reacts with the hematopoietic stem cell graft, such as with non-self MHC antigens expressed by the hematopoietic stem cell graft.
  • an autoimmune disease such as by administration of an anti-CD5 antibody, an antigen-binding fragment thereof, or an antibody-drug conjugate so as to deplete a population of CD5+ autoimmune cells (e.g.
  • the transplantation may in turn re-constitute, for example, a population of cells depleted during the process of eradicating autoimmune cells.
  • the autoimmune disease may be, for example, scleroderma, multiple sclerosis (MS), human systemic lupus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), treating psoriasis, Type 1 diabetes mellitus (Type 1 diabetes), acute disseminated encephalomyelitis (ADEM), Addison's disease, alopecia universalis, ankylosing spondylitisis, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune lymphoproliferative syndrome (ALPS), autoimmune oophoritis, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Chagas' disease, chronic fatigue immune dysfunction
  • the invention features a method of treating a hemoglobinopathy disorder, such as sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome.
  • a hemoglobinopathy disorder such as sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome.
  • an immunodeficiency disorder such as a congenital immunodeficiency disorder or an acquired immunodeficiency disorder (e.g., human immunodeficiency virus or acquired immune deficiency syndrome).
  • the invention features a method of treating a metabolic disorder, such as glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, and metachromatic leukodystrophy.
  • a metabolic disorder such as glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, and metachromatic leukodystrophy.
  • the invention features a method of treating a disorder selected from the group consisting of adenosine deaminase deficiency and severe combined immunodeficiency, hyper immunoglobulin M syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, systemic sclerosis, systemic lupus erythematosus, and juvenile rheumatoid arthritis
  • the invention features a method of treating an autoimmune disease, such as scleroderma, multiple sclerosis, ulcerative colitis, Chron's disease, ant Type 1 diabetes.
  • the invention features a method of treating a cancer or myeloproliferative disease, such as a hematological cancer.
  • the invention features a method of treating acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymohoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin's lymphoma.
  • the patient is suffering from a myelodyplastic disease, such as myelodysplastic syndrome.
  • the method may include administering to the patient an antibody, an antigen-binding fragment thereof, or conjugate thereof that binds CD5, such as the antibody, the antigen-binding fragment thereof, or conjugate thereof of any of the aspects or embodiments of the invention.
  • the method may additionally include administering to the patient a hematopoietic stem cell transplant, for instance, according to the method of any of the aspects or embodiments of the invention.
  • the invention provides a method of treating cancer directly, such as a cancer characterized by CD5+ cells (e.g., a leukemia characterized by CD5+ cells).
  • the method may include administering to the patient an antibody, an antigen-binding fragment thereof, or conjugate thereof that binds CD5, such as the such as the antibody, the antigen-binding fragment thereof, or conjugate thereof of any of the aspects or embodiments of the invention.
  • the cancer may be a hematological cancer, such as acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymohoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin's lymphoma.
  • a hematological cancer such as acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymohoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin's lymphoma.
  • the invention provides a method of treating an autoimmune disease, such as MS, SLE, RA, IBD, psoriasis, Type 1 diabetes, ADEM, Addison's disease, alopecia universalis, ankylosing spondylitisis, APS, aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, AIED, ALPS, autoimmune oophoritis, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Chagas' disease, CFIDS, chronic inflammatory demyelinating polyneuropathy, Crohn's disease, cicatrical pemphigoid, coeliac sprue-dermatitis herpetiformis, cold agglutinin disease, CREST syndrome, Degos disease, discoid lupus, dysautonomia, endometriosis, essential mixed cryoglobulinemia, fibromyalgia
  • an autoimmune disease such as MS, SLE
  • the method may include administering to the patient an antibody, an antigen-binding fragment thereof, or conjugate thereof that binds CD5, such as the antibody, the antigen-binding fragment thereof, or conjugate thereof of any of the aspects or embodiments of the invention.
  • the invention features an antibody, or an antigen-binding fragment thereof, capable of binding CD5, wherein the antibody or antigen-binding fragment thereof is conjugated to a toxin.
  • the antibody or antigen-binding fragment thereof is produced by the hybridoma cell line ATCC CRL 8000. In some embodiments, the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof produced by the hybridoma cell line ATCC CRL 8000.
  • the antibody or antigen-binding fragment thereof comprises the following variable domains:
  • V L having the amino acid sequence (SEQ ID NO: 1) DIQMTQSPSSMSASLGDRVTITCRASQDINSYLSWFQQKPGKSPKTLIYR ANRLVDGVPSRFSGSGSGTDYTLTISSLQYEDFGIYYCQQYDESPWTFGG GTKLEIK; and a V H having the amino acid sequence (SEQ ID NO: 2) QIQLVQSGPGLKKPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLRWMGW INTHTGEPTYADDFKGRFTFSLDTSKSTAYLQINSLRAEDTATYFCTRRG YDWYFDVWGQGTTVTVSS.
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing variable domains.
  • the antibody or antigen-binding fragment thereof includes the following CDRs:
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing CDRs.
  • the antibody or antigen-binding fragment thereof comprises the following variable domains:
  • V L having the amino acid sequence (SEQ ID NO: 9) DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKTLIYR ANRLESGVPSRFSGSGSGTDYTLTISSLQYEDFGIYYCQQYDESPWTFGG GTKLEIK; and a V H having the amino acid sequence (SEQ ID NO: 10) EIQLVQSGGGLVKPGGSVRISCAASGYTFTNYGMNWVRQAPGKGLEWMGW INTHYGEPTYADSFKGTRTFSLDDSKNTAYLQINSLRAEDTAVYFCTRRG YDWYFDVWGQGGTTVTVSS.
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing variable domains.
  • the antibody or antigen-binding fragment thereof includes the following CDRs:
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing CDRs.
  • the antibody or antigen-binding fragment thereof includes the following CDRs:
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing CDRs.
  • the antibody or antigen-binding fragment thereof includes the following CDRs:
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing CDRs.
  • the antibody or antigen-binding fragment thereof includes the following CDRs:
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises the foregoing CDRs.
  • the antibody or antigen-binding fragment thereof contains a combination of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 regions set forth in Table 1, below. In some embodiments, the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises a combination of CDRs set forth in Table 1, below.
  • the anti-CD5 antibody or antigen-binding fragment thereof comprises a heavy chain variable region as set forth in SEQ ID NO: 257 and a light chain variable region as set forth in SEQ ID NO: 258.
  • the antibody or antigen-binding fragment thereof competitively inhibits the binding of CD5 to an antibody or antigen-binding fragment thereof that comprises a heavy chain variable region as set forth in SEQ ID NO: 257 and a light chain variable region as set forth in SEQ ID NO: 258.
  • the antibody or antigen-binding fragment thereof is selected from the group consisting of a monoclonal antibody or antigen-binding fragment thereof, a polyclonal antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, a bispecific antibody or antigen-binding fragment thereof, a dual-variable immunoglobulin domain, an scFv, a diabody, a triabody, a nanobody, an antibody-like protein scaffold, a Fv fragment, a Fab fragment, a F(ab′) 2 molecule, and a tandem di-scFv.
  • the antibody has an isotype selected from the group consisting of IgG, IgA, IgM, IgD, and IgE.
  • the antibody, or the antigen-binding fragment thereof, conjugated to the cytotoxin is represented by the formula Ab-Cy, wherein Ab is the antibody, or the antigen-binding fragment thereof, and Cy is the cytotoxin.
  • the cytotoxin is selected from the group consisting of an amatoxin, pseudomonas exotoxin A, deBouganin, diphtheria toxin, saporin, maytansine, a maytansinoid, an auristatin, an anthracycline, a calicheamicin, irinotecan, SN-38, a duocarmycin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, an indolinobenzodiazepine, and an indolinobenzodiazepine dimer, or a variant thereof.
  • the cytotoxin is an amatoxin or derivative thereof, such as ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, amanullinic acid, and proamanullin.
  • the cytotoxin is an amatoxin
  • the antibody, or the antigen-binding fragment thereof, conjugated to the cytotoxin is represented by the formula Ab-Z-L-Am, wherein Ab is the antibody, or the antigen-binding fragment thereof, Z is a chemical moiety, Li is a linker, and Am is the amatoxin.
  • Am-L-Z is represented by formula (I)
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocycloalkyl group;
  • R 3 is H, R C , or R D ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , OR D , NHR C , or NR C R D ;
  • R 9 is H, OH, OR C , or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R C is -L-Z
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • alkyl e.g., C 1 -C 6 alkyl
  • optionally substituted heteroalkyl e.g., C 1 -C 6 heteroalkyl
  • optionally substituted alkenyl
  • L is a linker, such as optionally substituted alkylene (e.g., C 1 -C 6 alkylene), optionally substituted heteroalkylene (C 1 -C 6 heteroalkylene), optionally substituted alkenylene (e.g., C 2 -C 6 alkenylene), optionally substituted heteroalkenylene (e.g., C 2 -C 6 heteroalkenylene), optionally substituted alkynylene (e.g., C 2 -C 6 alkynylene), optionally substituted heteroalkynylene (e.g., C 2 -C 6 heteroalkynylene), optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, optionally substituted heteroarylene; a dipeptide, —C( ⁇ O)—, a peptide, or a combination thereof; and
  • Z is a chemical moiety formed from a coupling reaction between a reactive substituent present on L and a reactive substituent present within an antibody, or an antigen-binding fragment thereof, that binds CD5, such as on the surface of a CD5+ T cell, CD5+ B cell, or CD5+NK cell.
  • Am contains exactly one R C substituent.
  • Am-L-Z is represented by formula (IA)
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group;
  • R 3 is H, R C , or R D ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , OR D , NHR C , or NR C R D ;
  • R 9 is H, OH, OR C , or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R C is -L-Z
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • alkyl e.g., C 1 -C 6 alkyl
  • optionally substituted heteroalkyl e.g., C 1 -C 6 heteroalkyl
  • optionally substituted alkenyl
  • L is a linker, such as optionally substituted alkylene (e.g., C 1 -C 6 alkylene), optionally substituted heteroalkylene (C 1 -C 6 heteroalkylene), optionally substituted alkenylene (e.g., C 2 -C 6 alkenylene), optionally substituted heteroalkenylene (e.g., C 2 -C 6 heteroalkenylene), optionally substituted alkynylene (e.g., C 2 -C 6 alkynylene), optionally substituted heteroalkynylene (e.g., C 2 -C 6 heteroalkynylene), optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, optionally substituted heteroarylene, a dipeptide, —C( ⁇ O)—, a peptide, or a combination thereof;
  • optionally substituted alkylene e.g., C 1 -C 6 alkylene
  • Z is a chemical moiety formed from a coupling reaction between a reactive substituent present on L and a reactive substituent present within an antibody, an antigen-binding fragment thereof, that binds CD5, such as on the surface of a CD5+ T cell, CD5+ B cell, or CD5+NK cell;
  • linker L and the chemical moiety Z, taken together as L-Z is
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z is represented by formula (IB)
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group;
  • R 3 is H, R C , or R D ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , OR D , NHR C , or NR C R D ;
  • R 9 is H, OH, OR C , or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R C is -L-Z
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • alkyl e.g., C 1 -C 6 alkyl
  • optionally substituted heteroalkyl e.g., C 1 -C 6 heteroalkyl
  • optionally substituted alkenyl
  • L is a linker, such as optionally substituted alkylene (e.g., C 1 -C 6 alkylene), optionally substituted heteroalkylene (C 1 -C 6 heteroalkylene), optionally substituted alkenylene (e.g., C 2 -C 6 alkenylene), optionally substituted heteroalkenylene (e.g., C 2 -C 6 heteroalkenylene), optionally substituted alkynylene (e.g., C 2 -C 6 alkynylene), optionally substituted heteroalkynylene (e.g., C 2 -C 6 heteroalkynylene), optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, optionally substituted heteroarylene, a dipeptide, —C( ⁇ O)—, a peptide, or a combination thereof;
  • optionally substituted alkylene e.g., C 1 -C 6 alkylene
  • Z is a chemical moiety formed from a coupling reaction between a reactive substituent present on L and a reactive substituent present within an antibody, or an antigen-binding fragment thereof, that binds CD5, such as on the surface of a CD5+ T cell, CD5+ B cell, or CD5+NK cell;
  • linker L and the chemical moiety Z, taken together as L-Z is
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R A and R B together with the oxygen atoms to which they are bound, combine to form a 5 membered heterocycloalkyl group of formula:
  • Y is —C( ⁇ O)—, —C( ⁇ S)—, —C( ⁇ NR E )—, or —C(R E R E′ )—;
  • R E and R E′ are each independently optionally substituted C 1 -C 6 alkylene-R C , optionally substituted C 1 -C 6 heteroalkylene-R C , optionally substituted C 2 -C 6 alkenylene-R C , optionally substituted C 2 -C 6 heteroalkenylene-R C , optionally substituted C 2 -C 6 alkynylene-R C , optionally substituted C 2 -C 6 heteroalkynylene-R C , optionally substituted cycloalkylene-R C , optionally substituted heterocycloalkylene-R C , optionally substituted arylene-R C , or optionally substituted heteroarylene-R C .
  • Am-L-Z is represented by formula (IA) or formula (IB), wherein R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B together with the oxygen atoms to which they are bound, combine to form:
  • R 3 is H or R C ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , or NHR C ;
  • R 9 is H or OH
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B together with the oxygen atoms to which they are bound, combine to form:
  • R 3 is H or R C ;
  • R 4 and R 5 are each independently H, OH, OR C , R C , or OR D ;
  • R 6 and R 7 are each H
  • R 8 is OH, NH 2 , OR C , or NHR C ;
  • R 9 is H or OH
  • R C is as defined above.
  • Am is represented by formula (IA) or formula (IB),
  • R 1 is H, OH, or OR A ;
  • R 2 is H, OH, or OR B ;
  • R A and R B together with the oxygen atoms to which they are bound, combine to form:
  • R 3 , R 4 , R 6 , and R 7 are each H;
  • R 5 is OR C ;
  • R 8 is OH or NH 2 ;
  • R 9 is H or OH
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 and R 2 are each independently H or OH;
  • R 3 is R C ;
  • R 4 , R 6 , and R 7 are each H;
  • R 5 is H, OH, or OC 1 -C 6 alkyl
  • R 8 is OH or NH 2 ;
  • R 9 is H or OH
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 and R 2 are each independently H or OH;
  • R 3 , R 6 , and R 7 are each H;
  • R 4 and R 5 are each independently H, OH, OR C , or R C ;
  • R 8 is OH or NH 2 ;
  • R 9 is H or OH
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 and R 2 are each independently H or OH;
  • R 3 , R 6 , and R 7 are each H;
  • R 4 and R 5 are each independently H or OH
  • R 8 is OH, NH 2 , OR C , or NHR C ;
  • R 9 is H or OH
  • linker L and the chemical moiety Z, taken together as L-Z is
  • maleimide reacts with a thiol group found on a cysteine in the antibody.
  • maleimide reacts with a thiol group found on a cysteine in the antibody.
  • Am-L-Z is represented by formula (II), formula (IIA), or formula (IIB)
  • X is S, SO, or SO 2 ;
  • R 1 is H or a linker covalently bound to the antibody or antigen-binding fragment thereof through a chemical moeity Z, formed from a coupling reaction between a reactive substituent present on the linker and a reactive substituent present within an antibody, or antigen-binding fragment thereof;
  • R 2 is H or a linker covalently bound to the antibody or antigen-binding fragment thereof through a chemical moeity Z, formed from a coupling reaction between a reactive substituent present on the linker and a reactive substituent present within an antibody, or antigen-binding fragment thereof; wherein when R 1 is H, R 2 is the linker, and when R 2 is H, R 1 is the linker.
  • the linker comprises a —(CH) 2n — unit, where n is an integer from 2-6.
  • R 1 is the linker and R 2 is H, and the linker and chemical moiety, together as L-Z, is
  • Ab-Z-L-Am is
  • Ab-Z-L-Am is
  • the Am-L-Z precursor is one of:
  • maleimide reacts with a thiol group found on a cysteine in the antibody.
  • the cytotoxin is a maytansinoid selected from the group consisting of DM1 and DM4. In some embodiments, the cytotoxin is an auristatin selected from the group consisting of monomethyl auristatin E and monomethyl auristatin F. In some embodiments, the cytotoxin is an anthracycline selected from the group consisting of daunorubicin, doxorubicin, epirubicin, and idarubicin.
  • the cytotoxin is a pyrrolobenzodiazepine dimer represented by formula (IV):
  • the cytotoxin is conjugated to the antibody, or the antigen-binding fragment thereof, by way of a maleimidocaproyl linker.
  • the cytotoxin is an auristatin selected from the group consisting of monomethyl auristatin E and monomethyl auristatin F.
  • the cytotoxin is an anthracycline selected from the group consisting of daunorubicin, doxorubicin, epirubicin, and idarubicin.
  • the invention features a pharmaceutical composition
  • a pharmaceutical composition comprising the antibody, or the antigen-binding fragment thereof, of any of the above aspects or embodiments of the invention and a pharmaceutically acceptable excipient.
  • the pharmaceutical composition is formulated for administration to a human patient transdermally, subcutaneously, intranasally, intravenously, intramuscularly, intraocularly, intratumorally, parenterally, topically, intrathecally or intracerebroventricularly.
  • FIG. 1 graphically depicts the results of an in vitro cell line binding assay in which each of the indicated anti-CD5 antibodies or a negative control (i.e., mIgG1) was incubated with MOLT-4 cells (i.e., a human T lymphoblast cell line) followed by incubation of a fluorophore-conjugated anti-IgG antibody.
  • Signal was detected through flow cytometry and is indicated as the geometric mean fluorescence intensity (y-axis) as a function of anti-CD5 antibody concentration (x-axis).
  • FIG. 2 graphically depicts the results of an in vitro primary cell binding assay in which each of the indicated anti-CD5 antibodies or a negative control (i.e., hIgG1) was incubated with primary human T-cells followed by incubation of a fluorophore-conjugated anti-IgG antibody. Signal was detected through flow cytometry and is indicated as the geometric mean fluorescence intensity (y-axis) as a function of anti-CD5 antibody concentration (x-axis).
  • FIGS. 3A and 3B graphically depict results of an in vitro T cell killing assay including an anti-CD5-amanitin ADC (i.e., 5D7-AM or “CD5 AM”) having an interchain conjugated amanitin with an average drug-to-antibody ratio (DAR) of 6 ( FIG. 3A ) or a site-specific conjugated amanitin DAR of 2 ( FIG. 3B ).
  • an anti-CD5-amanitin ADC i.e., 5D7-AM or “CD5 AM
  • DAR drug-to-antibody ratio
  • FIG. 3B the anti-CD5-ADC T-cell killing analysis is shown in comparison to an unconjugated anti-CD5 5D7 antibody (i.e., “CD5 Naked”).
  • CD5 Naked unconjugated anti-CD5 5D7 antibody
  • the anti-CD5 antibody the results are shown in comparison to an anti-CD5 5D7 antibody having a H435A mutation that decreases the half life of the antibody (i.e., “CD5 Fast % Life AM”).
  • the results show the number of viable T-cells (y-axis) as a function of ADC (CD5 5D7 AM, CD5 5D7 D265C.H435A AM) or unconjugated antibody (CD5 5D7) concentration (x-axis) as assessed using flow cytometry.
  • FIGS. 4A-4B graphically depict the results of an in vivo T-cell depletion assay showing the absolute levels of T-cells (CD3+ cells; y-axis) in the peripheral blood ( FIG. 4A ) and bone marrow ( FIG. 4B ) of humanized NSG mice 7 days after a single administration of 0.3 mg/kg, 1 mg/kg, or 3 mg/kg of an anti-CD5 5D7amanitin ADC (i.e., CD5 5D7-AM) having an interchain DAR of 6.
  • FIGS. 4A-4B graphically depict the results of an in vivo T-cell depletion assay showing the absolute levels of T-cells (CD3+ cells; y-axis) in the peripheral blood ( FIG. 4A ) and bone marrow ( FIG. 4B ) of humanized NSG mice 7 days after a single administration of 0.3 mg/kg, 1 mg/kg, or 3 mg/kg of an anti-CD5 5D7amanitin ADC
  • 4A-4B also show the level of T-cell depletion following treatment of humanized NSG mice with the indicated controls (i.e., 25 mg/kg anti-CD52 antibody; 3 mg/kg hIgG1-amanitin ADC (i.e., hIgG1-AM), 25 mg/kg hIgG1, or PBS).
  • controls i.e., 25 mg/kg anti-CD52 antibody; 3 mg/kg hIgG1-amanitin ADC (i.e., hIgG1-AM), 25 mg/kg hIgG1, or PBS).
  • FIGS. 5A-5C graphically depict the results of an in vivo T-cell depletion assay showing the absolute levels of T-cells (CD3+ cells; y-axis) in the peripheral blood ( FIG. 5A ), bone marrow ( FIG. 5B ), and thymus ( FIG. 5C ) of humanized NSG mice 7 days after a single administration of 1 mg/kg or 3 mg/kg of an anti-CD5 5D7-amanitin ADC (i.e., 5D7-AM) having a site-specific DAR of 2.
  • FIGS. 5D7-AM an anti-CD5 5D7-amanitin ADC
  • 5A-5C also show the level of T-cell depletion following treatment of humanized NSG mice with 3 mg/kg of an unconjugated anti-CD5 antibody or with the indicated controls (i.e., 3 mg/kg hIgG1-amanitan-ADC (“hIgG1-AM”) or PBS).
  • hIgG1-AM hIgG1-amanitan-ADC
  • the present invention is based in part on the discovery that antibodies, or the antigen-binding fragments thereof, that bind to CD5 (also referred to as Lymphocyte antigen T1/Leu-1) can be used as therapeutic agents to (i) directly treat cancers and autoimmune diseases characterized by CD5+ cells and (ii) promote the engraftment of transplanted hematopoietic stem cells in a patient in need of transplant therapy by depleting populations of immune cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cell grafts.
  • CD5 also referred to as Lymphocyte antigen T1/Leu-1
  • These therapeutic activities can arise, for instance, by the binding of anti-CD5 antibodies, or antigen-binding fragments thereof, to CD5 expressed on the surface of a cell, such as a cancer cell, autoimmune cell, or immune cell that cross-reacts with a non-self hematopoietic stem cell antigen, thereby inducing death of the bound cell.
  • a cell such as a cancer cell, autoimmune cell, or immune cell that cross-reacts with a non-self hematopoietic stem cell antigen, thereby inducing death of the bound cell.
  • the anti-CD5 antibody, or the antigen-binding fragment thereof can be used to directly treat a cancer or autoimmune disease, such as a cancer autoimmune disease described herein.
  • the anti-CD5 antibody, or the antigen-binding fragment thereof can be used to prevent or reduce the likelihood of graft rejection in a patient that is suffering from a stem cell disorder, cancer, or autoimmune disease and that is undergoing hematopoietic stem cell transplant therapy.
  • a non-self hematopoietic stem cell antigen e.g., a non-self MHC antigen expressed by the hematopoietic stem cell graft
  • the anti-CD5 antibody, or the antigen-binding fragment thereof can be used to prevent or reduce the likelihood of graft rejection in a patient that is suffering from a stem cell disorder, cancer, or autoimmune disease and that is undergoing hematopoietic stem cell transplant therapy.
  • the depletion of CD5+ immune cells that cross-react with one or more non-self hematopoietic stem cell antigens enables the successful engraftment of transplanted hematopoietic stem cells within the transplant recipient.
  • one or more non-self hematopoietic stem cell antigens e.g., one or more non-self MHC antigens
  • the transplanted cells can home to hematopoietic tissue, where productive hematopoiesis can then ensue.
  • the transplanted hematopoietic stem cells can subsequently give rise to a population of cells that is deficient or defective in the transplant recipient, such as megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T lymphocytes, and B lymphocytes.
  • anti-CD5 antibodies, or the fragments thereof can be used to promote the successful engraftment of hematopoietic stem cells in a patient, such as human patient suffering from a stem cell disorder described herein.
  • the term “about” refers to a value that is within 10% above or below the value being described.
  • the term “about 5 nM” indicates a range of from 4.5 nM to 5.5 nM.
  • amatoxin refers to a member of the amatoxin family of peptides produced by Amanita phalloides mushrooms, a synthetic amatoxin, a variant amatoxin, or a derivative thereof, such as a variant or derivative thereof capable of inhibiting RNA polymerase II activity.
  • synthetic amatoxins see, e.g., U.S. Pat. No. 9,676,702, incorporated by reference herein.
  • amatoxins may be conjugated to an antibody, or antigen-binding fragment thereof, for instance, by way of a linker moiety (L) (thus forming a conjugate (also referred to as an antibody drug conjugate (ADC)).
  • L linker moiety
  • ADC antibody drug conjugate
  • Exemplary methods of amatoxin conjugation and linkers useful for such processes are described below.
  • Exemplary linker-containing amatoxins useful for conjugation to an antibody, or antigen-binding fragment, in accordance with the compositions and methods are also described herein.
  • amatoxins useful in conjunction with the compositions and methods described herein include compounds according to formula (III), below, such as ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, amanullinic acid, and proamanullin.
  • formula (III) is as follows:
  • R 1 is H, OH, or OR A ;
  • R 2 is H, OH, or OR B ;
  • R A and R B when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group;
  • R 3 is H or R D ;
  • R 4 is H, OH, OR D , or R D ;
  • R 5 is H, OH, OR D , Or R D ;
  • R 6 is H, OH, OR D , or R D ;
  • R 7 is H, OH, OR D , or R D ;
  • R 8 is OH, NH 2 , or OR D ;
  • R 9 is H, OH, or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • alkyl e.g., C 1 -C 6 alkyl
  • optionally substituted heteroalkyl e.g., C 1 -C 6 heteroalkyl
  • optionally substituted alkenyl
  • amatoxins useful in conjunction with the compositions and methods described herein include compounds according to formula (IIIA), below:
  • R 1 is H, OH, or OR A ;
  • R 2 is H, OH, or OR B ;
  • R A and R B when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group;
  • R 3 is H or R D ;
  • R 4 is H, OH, OR D , Or R D ;
  • R 5 is H, OH, OR D , or R D ;
  • R 6 is H, OH, OR D , or R D ;
  • R 7 is H, OH, OR D , or R D ;
  • R 8 is OH, NH 2 , or OR D ;
  • R 9 is H, OH, or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • alkyl e.g., C 1 -C 6 alkyl
  • optionally substituted heteroalkyl e.g., C 1 -C 6 heteroalkyl
  • optionally substituted alkenyl
  • amatoxins useful in conjunction with the compositions and methods described herein also include compounds according to formula (IIIB), below:
  • R 1 is H, OH, or OR A ;
  • R 2 is H, OH, or OR B ;
  • R A and R B when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group;
  • R 3 is H or R D ;
  • R 4 is H, OH, OR D , or R D ;
  • R 5 is H, OH, OR D , or R D ;
  • R 6 is H, OH, OR D , Or R D ;
  • R 7 is H, OH, OR D , or R D ;
  • R 8 is OH, NH 2 , or OR D ;
  • R 9 is H, OH, or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • alkyl e.g., C 1 -C 6 alkyl
  • optionally substituted heteroalkyl e.g., C 1 -C 6 heteroalkyl
  • optionally substituted alkenyl
  • amatoxins may be conjugated to an antibody, or an antigen-binding fragment thereof, for instance, by way of a linker moiety.
  • exemplary methods of amatoxin conjugation and linkers useful for such processes are described in the section entitled “Linkers for chemical conjugation,” as well as in Table 1, below.
  • Exemplary linker-containing amatoxins useful for conjugation to an antibody, an antigen-binding fragment, in accordance with the compositions and methods described herein are shown in structural formulas (I), (IA), (IB), (II), (IIA), and (IIB) recited herein.
  • antibody refers to an immunoglobulin molecule that specifically binds to, or is immunologically reactive with, a particular antigen.
  • antibodies include polyclonal, monoclonal, genetically engineered, and otherwise modified forms of antibodies, including but not limited to chimeric antibodies, humanized antibodies, heteroconjugate antibodies (e.g., bi- tri- and quad-specific antibodies, diabodies, triabodies, and tetrabodies), and antigen binding fragments of antibodies, including, for example, Fab′, F(ab′) 2 , Fab, Fv, rIgG, and scFv fragments.
  • the Fab and F(ab′) 2 fragments refer to antibody fragments that lack the Fc fragment of an intact antibody. Examples of these antibody fragments are described herein.
  • antibodies comprise heavy and light chains containing antigen binding regions.
  • Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region.
  • the heavy chain constant region is comprised of three domains, CH1, CH2 and CH3.
  • Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region.
  • the light chain constant region is comprised of one domain, CL.
  • the VH, and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDR complementarity determining regions
  • Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
  • the constant regions of the antibodies can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
  • antigen-binding fragment refers to a molecule other than an intact antibody that comprises a portion of an intact antibody and that binds the antigen to which the intact antibody binds.
  • the antigen-binding function of an antibody can be performed by fragments of a full-length antibody.
  • the antibody fragments can be, for example, a Fv, Fab, Fab′, F(ab′) 2 , scFv, diabody, single chain antibody molecules (e.g., scFv), a triabody, an affibody, a nanobody, an aptamer, or a domain antibody.
  • binding fragments encompassed of the term “antigen-binding fragment” of an antibody include, but are not limited to: (i) a Fab fragment, a monovalent fragment consisting of the V L , V H , C L , and C H1 domains; (ii) a F(ab′) 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V H and C H1 domains; (iv) a Fv fragment consisting of the V L and V H domains of a single arm of an antibody, (v) a dAb including V H and V L domains; (vi) a dAb fragment that consists of a V H domain (see, e.g., Ward et al., Nature 341:544-546, 1989); (vii) a dAb which consists of a V H or a V L domain; (viii) an isolated complementarity determining
  • the two domains of the Fv fragment, V L and V H are coded for by separate genes, they can be joined, using recombinant methods, by a linker that enables them to be made as a single protein chain in which the V L and V H regions pair to form monovalent molecules (known as single chain Fv (scFv); see, for example, Bird et al., Science 242:423-426, 1988 and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988).
  • scFv single chain Fv
  • These antibody fragments can be obtained using conventional techniques known to those of skill in the art, and the fragments can be screened for utility in the same manner as intact antibodies.
  • Antigen-binding fragments can be produced by recombinant DNA techniques, enzymatic or chemical cleavage of intact immunoglobulins, or, in certain cases, by chemical peptide synthesis procedures known in the art.
  • an antibody that binds to CD5 refers to an antibody that specifically binds to CD5.
  • An antibody “which binds” an antigen of interest, i.e., CD5, is one capable of binding that antigen with sufficient affinity such that the antibody is useful in targeting a cell expressing the antigen.
  • the antibody specifically binds to human CD5 (hCD5), the amino acid sequence of which is described in SEQ ID NO: 261.
  • bispecific antibody refers to a hybrid antibody having two different antigen binding sites.
  • Bispecific antibodies are a species of multispecific antibody and may be produced by a variety of methods including, but not limited to, fusion of hybridomas or linking of Fab′ fragments. See, e.g., Songsivilai and Lachmann, 1990, Clin. Exp. Immunol. 79:315-321; Kostelny et al., 1992, J. Immunol. 148:1547-1553.
  • the two binding sites of a bispecific antibody will bind to two different epitopes, which may reside on the same or different protein targets.
  • one of the binding specificities can be directed towards a T cell surface antigen, such as CD5, the other can be for a different T cell surface antigen or another cell surface protein, such as a receptor or receptor subunit involved in a signal transduction pathway that potentiates cell growth, among others.
  • a T cell surface antigen such as CD5
  • the other can be for a different T cell surface antigen or another cell surface protein, such as a receptor or receptor subunit involved in a signal transduction pathway that potentiates cell growth, among others.
  • CDR complementarity determining region
  • FRs framework regions
  • the amino acid positions that delineate a hypervariable region of an antibody can vary, depending on the context and the various definitions known in the art. Some positions within a variable domain may be viewed as hybrid hypervariable positions in that these positions can be deemed to be within a hypervariable region under one set of criteria while being deemed to be outside a hypervariable region under a different set of criteria. One or more of these positions can also be found in extended hypervariable regions.
  • variable domains of native heavy and light chains each comprise four framework regions that primarily adopt a ⁇ -sheet configuration, connected by three CDRs, which form loops that connect, and in some cases form part of, the ⁇ -sheet structure.
  • the CDRs in each chain are held together in close proximity by the framework regions in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 and, with the CDRs from the other antibody chains, contribute to the formation of the target binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, National Institute of Health, Bethesda, Md., 1987).
  • numbering of immunoglobulin amino acid residues is performed according to the immunoglobulin amino acid residue numbering system of Kabat et al., unless otherwise indicated.
  • condition refers to processes by which a patient is prepared for receipt of a transplant containing hematopoietic stem cells. Such procedures promote the engraftment of a hematopoietic stem cell transplant (for instance, as inferred from a sustained increase in the quantity of viable hematopoietic stem cells within a blood sample isolated from a patient following a conditioning procedure and subsequent hematopoietic stem cell transplantation.
  • a patient may be conditioned for hematopoietic stem cell transplant therapy by administration to the patient of an antibody or antigen-binding fragment thereof capable of binding an antigen expressed by T cells, such as CD5.
  • the anti-CD5 antibody may be covalently conjugated to a cytotoxin so as to form an antibody-drug conjugate (ADC).
  • ADC antibody-drug conjugate
  • Administration of an antibody, antigen-binding fragment thereof, or antibody-drug conjugate capable of binding one or more of the foregoing antigens to a patient in need of hematopoietic stem cell transplant therapy can promote the engraftment of a hematopoietic stem cell graft, for example, by selectively depleting endogenous immune cells, such as CD5+ T cells (e.g., CD4+ and/or CD8+ T cells), CD5+ B cells, and/or CD5+NK cells that cross-react with one or more non-self antigens expressed by a hematopoietic stem cell, such as one or more non-self MHC antigens expressed by the hematopoietic stem cell graft.
  • CD5+ T cells e.g., CD4+ and/
  • conjugate refers to a compound formed by the chemical bonding of a reactive functional group of one molecule, such as an antibody or antigen-binding fragment thereof, with an appropriately reactive functional group of another molecule, such as a cytotoxin described herein.
  • Conjugates may include a linker between the two molecules (e.g., an anti-CD5 antibody and a cytotoxin) bound to one another.
  • linkers that can be used for the formation of a conjugate include peptide-containing linkers, such as those that contain naturally occurring or non-naturally occurring amino acids, such as D-amino acids. Linkers can be prepared using a variety of strategies described herein and known in the art.
  • a linker may be cleaved, for example, by enzymatic hydrolysis, photolysis, hydrolysis under acidic conditions, hydrolysis under basic conditions, oxidation, disulfide reduction, nucleophilic cleavage, or organometallic cleavage (see, for example, Leriche et al., Bioorg. Med. Chem., 20:571-582, 2012).
  • the term “coupling reaction” refers to a chemical reaction in which two or more substituents suitable for reaction with one another react so as to form a chemical moiety that joins (e.g., covalently) the molecular fragments bound to each substituent.
  • Coupling reactions include those in which a reactive substituent bound to a fragment that is a cytotoxin, such as a cytotoxin known in the art or described herein, reacts with a suitably reactive substituent bound to a fragment that is an antibody, antigen-binding fragment thereof, or antibody, such as an antibody, antigen-binding fragment thereof, or antibody specific for CD5 known in the art or described herein.
  • suitably reactive substituents include a nucleophile/electrophile pair (e.g., a thiol/haloalkyl pair, an amine/carbonyl pair, or a thiol/ ⁇ , ⁇ -unsaturated carbonyl pair, among others), a diene/dienophile pair (e.g., an azide/alkyne pair, among others), and the like.
  • a nucleophile/electrophile pair e.g., a thiol/haloalkyl pair, an amine/carbonyl pair, or a thiol/ ⁇ , ⁇ -unsaturated carbonyl pair, among others
  • diene/dienophile pair e.g., an azide/alkyne pair, among others
  • Coupling reactions include, without limitation, thiol alkylation, hydroxyl alkylation, amine alkylation, amine condensation, amidation, esterification, disulfide formation, cycloaddition (e.g., [4+2] Diels-Alder cycloaddition, [3+2] Huisgen cycloaddition, among others), nucleophilic aromatic substitution, electrophilic aromatic substitution, and other reactive modalities known in the art or described herein.
  • cycloaddition e.g., [4+2] Diels-Alder cycloaddition, [3+2] Huisgen cycloaddition, among others
  • nucleophilic aromatic substitution e.g., [4+2] Diels-Alder cycloaddition, [3+2] Huisgen cycloaddition, among others
  • nucleophilic aromatic substitution e.g., [4+2] Diels-Alder cycloa
  • CRU competitive repopulating unit
  • drug-to-antibody ratio refers to the number of cytotoxins, e.g., amatoxin, attached to the antibody of an ADC.
  • the DAR of an ADC can range from 1 to 8, although higher loads are also possible depending on the number of linkage sites on an antibody.
  • an ADC described herein has a DAR of about 1, 2, 3, 4, 5, 6, 7, or 8.
  • the term “donor” refers to a human or animal from which one or more cells are isolated prior to administration of the cells, or progeny thereof, into a recipient.
  • the one or more cells may be, for example, a population of hematopoietic stem cells.
  • the term “diabody” refers to a bivalent antibody containing two polypeptide chains, in which each polypeptide chain includes V H and V L domains joined by a linker that is too short (e.g., a linker composed of five amino acids) to allow for intramolecular association of V H and V L domains on the same peptide chain. This configuration forces each domain to pair with a complementary domain on another polypeptide chain so as to form a homodimeric structure.
  • the term “triabody” refers to trivalent antibodies comprising three peptide chains, each of which contains one V H domain and one V L domain joined by a linker that is exceedingly short (e.g., a linker composed of 1-2 amino acids) to permit intramolecular association of V H and V L domains within the same peptide chain.
  • a linker that is exceedingly short (e.g., a linker composed of 1-2 amino acids) to permit intramolecular association of V H and V L domains within the same peptide chain.
  • peptides configured in this way typically trimerize so as to position the V H and V L domains of neighboring peptide chains spatially proximal to one another (see, for example, Holliger et al., Proc. Natl. Acad. Sci. USA 90:6444-48, 1993).
  • DVD-Ig dual variable domain immunoglobulin
  • the term “endogenous” describes a substance, such as a molecule, cell, tissue, or organ (e.g., a hematopoietic stem cell or a cell of hematopoietic lineage, such as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell, myoblast, basophil, neutrophil, eosinophil, microglial cell, granulocyte, monocyte, osteoclast, antigen-presenting cell, macrophage, dendritic cell, natural killer cell, T lymphocyte (e.g., a CD4+ or CD8+T lymphocyte), or B lymphocyte) that is found naturally in a particular organism, such as a human patient, for instance, a human patient undergoing hematopoietic stem cell transplant therapy as described herein.
  • a hematopoietic stem cell or a cell of hematopoietic lineage such as a megakaryocyte, thrombocyte, platelet, ery
  • the term “engraftment potential” is used to refer to the ability of hematopoietic stem and progenitor cells to repopulate a tissue, whether such cells are naturally circulating or are provided by transplantation.
  • the term encompasses all events surrounding or leading up to engraftment, such as tissue homing of cells and colonization of cells within the tissue of interest.
  • the engraftment efficiency or rate of engraftment can be evaluated or quantified using any clinically acceptable parameter as known to those of skill in the art and can include, for example, assessment of competitive repopulating units (CRU); incorporation or expression of a marker in tissue(s) into which stem cells have homed, colonized, or become engrafted; or by evaluation of the progress of a subject through disease progression, survival of hematopoietic stem and progenitor cells, or survival of a recipient.
  • Engraftment can also be determined by measuring white blood cell counts in peripheral blood during a post-transplant period. Engraftment can also be assessed by measuring recovery of marrow cells by donor cells in a bone marrow aspirate sample.
  • the term “excipient” refers to a substance formulated alongside the active ingredient of a medication. They may be included, for example, for the purpose of long-term stabilization, or to confer a therapeutic enhancement on the active ingredient in the final dosage form.
  • exogenous describes a substance, such as a molecule, cell, tissue, or organ (e.g., a T cell, hematopoietic stem cell, or a cell of hematopoietic lineage, such as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell, myoblast, basophil, neutrophil, eosinophil, microglial cell, granulocyte, monocyte, osteoclast, antigen-presenting cell, macrophage, dendritic cell, natural killer cell, T lymphocyte, or B lymphocyte) that is not found naturally in a particular organism, such as a human patient.
  • Exogenous substances include those that are provided from an external source to an organism or to cultured matter extracted therefrom.
  • frame region includes amino acid residues that are adjacent to the CDRs of an antibody or antigen-binding fragment thereof.
  • FW region residues may be present in, for example, human antibodies, humanized antibodies, monoclonal antibodies, antibody fragments, Fab fragments, single chain antibody fragments, scFv fragments, antibody domains, and bispecific antibodies, among others.
  • full length antibody “intact antibody,” and “whole antibody” are used herein interchangeably to refer to antibody generally comprising at least two full-length heavy chains and two full-length light chains, but in some instances may include fewer chains such as antibodies naturally occurring in camelids which may comprise only heavy chains.
  • HSCs hematopoietic stem cells
  • granulocytes e.g., promyelocytes, neutrophils, eosinophils, basophils
  • erythrocytes e.g., reticulocytes, erythrocytes
  • thrombocytes e.g., megakaryoblasts, platelet producing megakaryocytes, platelets
  • monocytes e.g., monocytes, macrophages
  • dendritic cells e.g., NK cells, B cells and T cells.
  • Such cells may include CD34 + cells.
  • CD34 + cells are immature cells that express the CD34 cell surface marker.
  • CD34+ cells are believed to include a subpopulation of cells with the stem cell properties defined above, whereas in mice, HSCs are CD34-.
  • HSCs also refer to long term repopulating HSCs (LT-HSC) and short term repopulating HSCs (ST-HSC).
  • LT-HSCs and ST-HSCs are differentiated, based on functional potential and on cell surface marker expression.
  • human HSCs are CD34+, CD38 ⁇ , CD45RA ⁇ , CD90+, CD49F+, and lin ⁇ (negative for mature lineage markers, including CD5, CD3, CD4, CD7, CD8, CD10, CD11B, CD19, CD20, CD56, and CD235A).
  • bone marrow LT-HSCs are CD34 ⁇ , SCA-1+, C-kit+, CD135 ⁇ , Slamfl/CD150+, CD48 ⁇ , and lin ⁇ (negative for mature lineage markers, including Ter119, CD11b, Gr1, CD3, CD4, CD8, B220, and IL7ra), whereas ST-HSCs are CD34+, SCA-1+, C-kit+, CD135 ⁇ , Slamfl/CD150+, and lin ⁇ (negative for mature lineage markers, including Ter19, CD11b, Gr1, CD3, CD4, CD8, B220, and IL7ra).
  • ST-HSCs are less quiescent and more proliferative than LT-HSCs under homeostatic conditions.
  • LT-HSC have greater self-renewal potential (i.e., they survive throughout adulthood, and can be serially transplanted through successive recipients), whereas ST-HSCs have limited self-renewal (i.e., they survive for only a limited period of time, and do not possess serial transplantation potential). Any of these HSCs can be used in the methods described herein. ST-HSCs are particularly useful because they are highly proliferative and thus, can more quickly give rise to differentiated progeny.
  • hematopoietic stem cell functional potential refers to the functional properties of hematopoietic stem cells which include 1) multi-potency (which refers to the ability to differentiate into multiple different blood lineages including, but not limited to, granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g., megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B cells and T cells), 2) self-renewal (which refers to the ability of hematopoietic stem cells to give rise to daughter cells that have equivalent potential as the mother cell, and further that this ability can repeatedly occur throughout the
  • MHC Major histocompatibility complex antigens
  • HLA human leukocyte antigens
  • HLA class I antigens (A, B, and C in humans) render each cell recognizable as “self,” whereas HLA class II antigens (DR, DP, and DQ in humans) are involved in reactions between lymphocytes and antigen presenting cells. Both have been implicated in the rejection of transplanted organs.
  • An important aspect of the HLA gene system is its polymorphism. Each gene, MHC class I (A, B and C) and MHC class II (DP, DQ and DR) exists in different alleles. HLA alleles are designated by numbers and subscripts. For example, two unrelated individuals may carry class I HLA-B, genes B5, and Bw41, respectively. Allelic gene products differ in one or more amino acids in the ⁇ and/or ⁇ domain(s).
  • HLA haplotypes Large panels of specific antibodies or nucleic acid reagents are used to type HLA haplotypes of individuals, using leukocytes that express class I and class II molecules.
  • the genes commonly used for HLA typing are the six MHC Class I and Class II proteins, two alleles for each of HLA-A; HLA-B and HLA-DR.
  • the HLA genes are clustered in a “super-locus” present on chromosome position 6p21, which encodes the six classical transplantation HLA genes and at least 132 protein coding genes that have important roles in the regulation of the immune system as well as some other fundamental molecular and cellular processes.
  • the complete locus measures roughly 3.6 Mb, with at least 224 gene loci.
  • haplotypes i.e. the set of alleles present on a single chromosome, which is inherited from one parent, tend to be inherited as a group.
  • the set of alleles inherited from each parent forms a haplotype, in which some alleles tend to be associated together. Identifying a patient's haplotypes can help predict the probability of finding matching donors and assist in developing a search strategy, because some alleles and haplotypes are more common than others and they are distributed at different frequencies in different racial and ethnic groups.
  • HLA-matched refers to a donor-recipient pair in which none of the HLA antigens are mismatched between the donor and recipient, such as a donor providing a hematopoietic stem cell graft to a recipient in need of hematopoietic stem cell transplant therapy.
  • HLA-matched i.e., where all of the 6 alleles are matched
  • donor-recipient pairs have a decreased risk of graft rejection, as endogenous T cells and NK cells are less likely to recognize the incoming graft as foreign, and are thus less likely to mount an immune response against the transplant.
  • HLA-mismatched refers to a donor-recipient pair in which at least one HLA antigen, in particular with respect to HLA-A, HLA-B and HLA-DR, is mismatched between the donor and recipient, such as a donor providing a hematopoietic stem cell graft to a recipient in need of hematopoietic stem cell transplant therapy.
  • HLA-A, HLA-B and HLA-DR HLA-mismatched
  • HLA-mismatched donor-recipient pairs may have an increased risk of graft rejection relative to HLA-matched donor-recipient pairs, as endogenous T cells and NK cells are more likely to recognize the incoming graft as foreign in the case of an HLA-mismatched donor-recipient pair, and such T cells and NK cells are thus more likely to mount an immune response against the transplant.
  • human antibody refers to an antibody in which substantially every part of the protein (for example, all CDRs, framework regions, C L , C H domains (e.g., C H 1, C H2 , C H3 ), hinge, and V L and V H domains) is substantially non-immunogenic in humans, with only minor sequence changes or variations.
  • a human antibody can be produced in a human cell (for example, by recombinant expression) or by a non-human animal or a prokaryotic or eukaryotic cell that is capable of expressing functionally rearranged human immunoglobulin (such as heavy chain and/or light chain) genes.
  • a human antibody When a human antibody is a single chain antibody, it can include a linker peptide that is not found in native human antibodies.
  • an Fv can contain a linker peptide, such as two to about eight glycine or other amino acid residues, which connects the variable region of the heavy chain and the variable region of the light chain.
  • linker peptides are considered to be of human origin.
  • Human antibodies can be made by a variety of methods known in the art including phage display methods using antibody libraries derived from human immunoglobulin sequences. Human antibodies can also be produced using transgenic mice that are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes (see, for example, PCT Publication Nos.
  • a human antibody is made using recombinant methods such that the glycosylation pattern of the antibody is different than an antibody having the same sequence if it were to exist in nature.
  • a humanized antibody refers to a chimeric antibody generally comprising amino acid sequences from non-human CDRs and human framework regions.
  • a humanized antibody is a human antibody (recipient antibody) in which residues from the CDRs of the recipient are replaced by residues from the CDRs of a non-human species (donor antibody) such as mouse, rat, rabbit, or nonhuman primate having the desired specificity, affinity, and/or capacity.
  • donor antibody such as mouse, rat, rabbit, or nonhuman primate having the desired specificity, affinity, and/or capacity.
  • a humanized antibody contains substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin.
  • All or substantially all of the FW regions may also be those of a human immunoglobulin sequence.
  • the humanized antibody can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin consensus sequence.
  • Fc immunoglobulin constant region
  • immune cell refers to a cell of the immune system that participates in the mounting and maintaining of an innate or adaptive immune response.
  • Immune cells include lymphocytes that contain a receptor that specifically binds, and mounts an immune response against, an antigen of interest, such as a self antigen in the case of an autoimmune cell.
  • exemplary immune cells include mast cells, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T lymphocytes, and B lymphocytes.
  • patients that are “in need of” a hematopoietic stem cell transplant include patients that exhibit a defect or deficiency in one or more blood cell types, as well as patients having a stem cell disorder.
  • Hematopoietic stem cells generally exhibit 1) multi-potency, and can thus differentiate into multiple different blood lineages including, but not limited to, granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g., megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B cells and T cells), 2) self-renewal, and can thus give rise to daughter cells that have equivalent potential as the mother
  • Hematopoietic stem cells can thus be administered to a patient defective or deficient in one or more cell types of the hematopoietic lineage in order to re-constitute the defective or deficient population of cells in vivo.
  • the patient may be suffering from cancer, and the deficiency may be caused by administration of a chemotherapeutic agent or other medicament that depletes, either selectively or non-specifically, the cancerous cell population.
  • the patient may be suffering from a non-malignant hemoglobinopathy that may cause a defect or deficiency in one or more blood cell types, such as sickle cell anemia, thalassemia, Fanconi anemia, and Wiskott-Aldrich syndrome.
  • the subject may be one that is suffering from adenosine deaminase severe combined immunodeficiency (ADA SCID), HIV/AIDS, metachromatic leukodystrophy, Diamond-Blackfan anemia, and Schwachman-Diamond syndrome.
  • ADA SCID adenosine deaminase severe combined immunodeficiency
  • the subject may have or be affected by an inherited blood disorder (e.g., sickle cell anemia) or an autoimmune disorder.
  • the subject may have or be affected by a malignancy, such as a malignancy selected from the group consisting of hematologic cancers (e.g., leukemia, lymphoma, multiple myeloma, or myelodysplastic syndrome) and neuroblastoma.
  • the subject has or is otherwise affected by a metabolic disorder.
  • the subject may suffer or otherwise be affected by a metabolic disorder selected from the group consisting of glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, metachromatic leukodystrophy, or any other diseases or disorders which may benefit from the treatments and therapies disclosed herein and including, without limitation, severe combined immunodeficiency, Wiscott-Aldrich syndrome, hyper immunoglobulin M (IgM) syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, sickle cell disease, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, juvenile rheumatoid arthritis and those diseases, or disorders described in “Bone Marrow Transplantation for Non-Malignant Disease,” ASH Education Book, 1:319-338 (2000), the disclosure of which is incorporated herein by reference in its entirety
  • a patient “in need of” a hematopoietic stem cell transplant may be one that is or is not suffering from one of the foregoing pathologies, but nonetheless exhibits a reduced level (e.g., as compared to that of an otherwise healthy subject) of one or more endogenous cell types within the hematopoietic lineage, such as megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T lymphocytes, and B lymphocytes.
  • endogenous cell types within the hematopoietic lineage such as megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils
  • FACS fluorescence activated cell sorting
  • isolated when used in the context of a protein, e.g., an antibody, refers to a protein that by virtue of its origin or source of derivation is not associated with naturally associated components that accompany it in its native state; is substantially free of other proteins from the same species; is expressed by a cell from a different species; or does not occur in nature.
  • a protein that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be “isolated” from its naturally associated components.
  • a protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art.
  • mAb refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind to the same epitope, except for possible variant antibodies, e.g., naturally occurring mutations or variants arising during production of a monoclonal antibody preparation, where such variants may be present in minor amounts.
  • polyclonal antibody preparations typically include different antibodies directed against different determinants (epitopes)
  • each mAb is directed against a single determinant on the antigen.
  • the modifier “monoclonal” is not to be construed as requiring production of the antibody by any particular method.
  • the term “pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms, which are suitable for contact with the tissues of a subject, such as a mammal (e.g., a human) without excessive toxicity, irritation, allergic response and other problem complications commensurate with a reasonable benefit/risk ratio.
  • the term “pharmaceutical composition” means a mixture containing a therapeutic compound to be administered to a subject, such as a mammal, e.g., a human, in order to prevent, treat or control a particular disease or condition affecting the mammal, such as an autoimmune disorder, cancer, or blood disorder, among others, e.g., as described herein.
  • the term “recipient” refers to a patient that receives a transplant, such as a transplant containing a population of hematopoietic stem cells.
  • the transplanted cells administered to a recipient may be, e.g., autologous, syngeneic, or allogeneic cells.
  • the term “rejection” in the context of a transplant refers to the process by which a recipient mounts an immune response against an incoming transplant, thereby reducing the ability of the transplanted matter (e.g., hematopoietic stem cells) to persist in the recipient.
  • Rejection of a transplanted graft can be quantified, for instance, by measuring the quantity or concentration of transplanted cells in various samples isolated from a patient at distinct time points following transplantation.
  • graft rejection can be quantified by measuring the quantity or concentration of immune cells, such as T cells and/or NK cells, that cross-react with MHC antigens expressed by the transplanted cells in various samples isolated from a patient at distinct time points following transplantation.
  • a finding that the quantity or concentration of immune cells, such as T cells and/or NK cells, that cross-react with MHC antigens expressed by the transplanted cells in samples isolated from the patient increases over time, for instance, by 10%, 15%, 20%, 25%, 30%, 35%, 40%, 56%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, or more, indicates that the patient is suffering from graft rejection.
  • immune cells such as T cells and/or NK cells
  • sample refers to a specimen (e.g., blood, blood component (e.g., serum or plasma), urine, saliva, amniotic fluid, cerebrospinal fluid, tissue (e.g., placental or dermal), pancreatic fluid, chorionic villus sample, and cells) taken from a subject.
  • a specimen e.g., blood, blood component (e.g., serum or plasma), urine, saliva, amniotic fluid, cerebrospinal fluid, tissue (e.g., placental or dermal), pancreatic fluid, chorionic villus sample, and cells
  • scFv refers to a single chain Fv antibody in which the variable domains of the heavy chain and the light chain from an antibody have been joined to form one chain.
  • scFv fragments contain a single polypeptide chain that includes the variable region of an antibody light chain (V L ) (e.g., CDR-L1, CDR-L2, and/or CDR-L3) and the variable region of an antibody heavy chain (V H ) (e.g., CDR-H1, CDR-H2, and/or CDR-H3) separated by a linker.
  • V L variable region of an antibody light chain
  • V H variable region of an antibody heavy chain
  • the linker that joins the V L and V H regions of a scFv fragment can be a peptide linker composed of proteinogenic amino acids.
  • linkers can be used so as to increase the resistance of the scFv fragment to proteolytic degradation (for example, linkers containing D-amino acids), in order to enhance the solubility of the scFv fragment (for example, hydrophilic linkers such as polyethylene glycol-containing linkers or polypeptides containing repeating glycine and serine residues), to improve the biophysical stability of the molecule (for example, a linker containing cysteine residues that form intramolecular or intermolecular disulfide bonds), or to attenuate the immunogenicity of the scFv fragment (for example, linkers containing glycosylation sites).
  • linkers containing D-amino acids for example, hydrophilic linkers such as polyethylene glycol-containing linkers or polypeptides containing repeating glycine and serine residues
  • hydrophilic linkers such as polyethylene glycol-containing linkers or polypeptides containing repeating glycine and serine residues
  • variable regions of the scFv molecules described herein can be modified such that they vary in amino acid sequence from the antibody molecule from which they were derived.
  • nucleotide or amino acid substitutions leading to conservative substitutions or changes at amino acid residues can be made (e.g., in CDR and/or framework residues) so as to preserve or enhance the ability of the scFv to bind to the antigen recognized by the corresponding antibody.
  • telomere binding means that the interaction is dependent upon the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species; for example, an antibody recognizes and binds to a specific protein structure rather than to proteins generally. If an antibody is specific for epitope “A”, the presence of a molecule containing epitope A (or free, unlabeled A), in a reaction containing labeled “A” and the antibody, will reduce the amount of labeled A bound to the antibody.
  • a particular structure e.g., an antigenic determinant or epitope
  • an antibody specifically binds to a target, e.g., CD5, if the antibody has a K D for the target of at least about 10 ⁇ 4 M, 10 ⁇ 5 M, 10 ⁇ 6 M, 10 ⁇ 7 M, 10 ⁇ 8 M, 10 ⁇ 9 M, 10 ⁇ 10 M, 10 ⁇ 11 M, 10 ⁇ 12 M, or less (less meaning a number that is less than 10 ⁇ 12 , e.g. 10 ⁇ 13 ).
  • the term “specific binding to CD5” or “specifically binds to CD5,” as used herein, refers to an antibody or that binds to CD5 and has a dissociation constant (K D ) of 1.0 ⁇ 10 ⁇ 7 M or less, as determined by surface plasmon resonance.
  • K D is determined according to standard bio-layer interferometery (BLI).
  • BLI bio-layer interferometery
  • an antibody may be capable of specifically binding to two or more antigens which are related in sequence.
  • an antibody can specifically bind to both human and a non-human (e.g., mouse or non-human primate) orthologs of CD5.
  • a patient such as a human patient, may be one that is suffering from an autoimmune disease described herein, and may be administered an anti-CD5 antibody or antibody-drug conjugate described herein so as to (i) deplete a population of autoimmune cells (e.g., a population of autoimmune CD5+ T cells, B cells, and/or NK cells) and/or (ii) deplete a population of CD5+ immune cells (e.g., CD5+ T cells, B cells, and/or NK cells that cross-react with a non-self antigen expressed by hematopoietic stem cells, such as a non-self MHC antigen expressed by a hematopoietic stem cell graft, thereby preventing or reducing the likelihood of graft rejection prior to hematopoietic stem cell transplant
  • the phrase “substantially cleared from the blood” refers to a point in time following administration of a therapeutic agent (such as an anti-CD5 antibody, or an antigen-binding fragment thereof) to a patient when the concentration of the therapeutic agent in a blood sample isolated from the patient is such that the therapeutic agent is not detectable by conventional means (for instance, such that the therapeutic agent is not detectable above the noise threshold of the device or assay used to detect the therapeutic agent).
  • a therapeutic agent such as an anti-CD5 antibody, or an antigen-binding fragment thereof
  • a variety of techniques known in the art can be used to detect antibodies, or antibody fragments, such as ELISA-based detection assays known in the art or described herein. Additional assays that can be used to detect antibodies, and antibody fragments, include immunoprecipitation techniques and immunoblot assays, among others known in the art.
  • stem cell disorder broadly refers to any disease, disorder, or condition that may be treated or cured by conditioning a subject's target tissues, for instance, by ablating an endogenous T cell population in a target tissue) and/or by engrafting or transplanting stem cells in a subject's target tissues.
  • a subject's target tissues for instance, by ablating an endogenous T cell population in a target tissue
  • stem cells for example, Type I diabetes patients have been shown to be cured by hematopoietic stem cell transplant and may benefit from conditioning in accordance with the compositions and methods described herein.
  • Additional disorders that can be treated using the compositions and methods described herein include, without limitation, sickle cell anemia, thalassemias, Fanconi anemia, Wiskott-Aldrich syndrome, ADA SCID, HIV/AIDS, metachromatic leukodystrophy, Diamond-Blackfan anemia, and Schwachman-Diamond syndrome.
  • the subject may have or be affected by an inherited blood disorder (e.g., sickle cell anemia) or an autoimmune disorder.
  • the subject may have or be affected by a malignancy, such as a malignancy selected from the group consisting of hematologic cancers (e.g., leukemia, lymphoma, multiple myeloma, or myelodysplastic syndrome) and neuroblastoma.
  • a malignancy selected from the group consisting of hematologic cancers (e.g., leukemia, lymphoma, multiple myeloma, or myelodysplastic syndrome) and neuroblastoma.
  • the subject has or is otherwise affected by a metabolic disorder.
  • the subject may suffer or otherwise be affected by a metabolic disorder selected from the group consisting of glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, metachromatic leukodystrophy, or any other diseases or disorders which may benefit from the treatments and therapies disclosed herein and including, without limitation, severe combined immunodeficiency, Wiscott-Aldrich syndrome, hyper immunoglobulin M (IgM) syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, sickle cell disease, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, juvenile rheumatoid arthritis and those diseases, or disorders described in “Bone Marrow Transplantation for Non-Malignant Disease,” ASH Education Book, 1:319-338 (2000), the disclosure of which is incorporated herein by reference in its entirety
  • transfection refers to any of a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, such as electroporation, lipofection, calcium-phosphate precipitation, DEAE-dextran transfection and the like.
  • the terms “treat” or “treatment” refer to therapeutic treatment, in which the object is to prevent or slow down (lessen) an undesired physiological change or disorder or to promote a beneficial phenotype in the patient being treated.
  • Beneficial or desired clinical results include, but are not limited to, a reduction in the quantity of autoimmune cells present in a sample isolated from the patient, such as a population of CD5+ T cells, B cells, and/or NK cells that cross-react with a self antigen in the case of treating an autoimmune disorder directly, or an antigen expressed by hematopoietic stem cells prior to hematopoietic stem cell transplantation in the case of treating an autoimmune disease by administration an anti-CD5 antibody, or antigen-binding fragment thereof, and a hematopoietic stem cell graft.
  • Additional beneficial results include an increase in the cell count or relative concentration of hematopoietic stem cells in a patient in need of a hematopoietic stem cell transplant following conditioning therapy and subsequent administration of an exogenous hematopoietic stem cell graft to the patient.
  • Beneficial results of therapy described herein may also include an increase in the cell count or relative concentration of one or more cells of hematopoietic lineage, such as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell, myoblast, basophil, neutrophil, eosinophil, microglial cell, granulocyte, monocyte, osteoclast, antigen-presenting cell, macrophage, dendritic cell, natural killer cell, T lymphocyte, or B lymphocyte, following conditioning therapy and subsequent hematopoietic stem cell transplant therapy.
  • hematopoietic lineage such as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell, myoblast, basophil, neutrophil, eosinophil, microglial cell, granulocyte, monocyte, osteoclast, antigen-presenting cell, macrophage, dendritic cell, natural killer cell, T lymphocyte, or B lymphocyte, following conditioning therapy and subsequent hematopo
  • variants and “derivative” are used interchangeably and refer to naturally-occurring, synthetic, and semi-synthetic analogues of a compound, peptide, protein, or other substance described herein.
  • a variant or derivative of a compound, peptide, protein, or other substance described herein may retain or improve upon the biological activity of the original material.
  • vector includes a nucleic acid vector, such as a plasmid, a DNA vector, a plasmid, a RNA vector, virus, or other suitable replicon.
  • Expression vectors described herein may contain a polynucleotide sequence as well as, for example, additional sequence elements used for the expression of proteins and/or the integration of these polynucleotide sequences into the genome of a mammalian cell.
  • Certain vectors that can be used for the expression of antibodies and antibody fragments of the invention include plasmids that contain regulatory sequences, such as promoter and enhancer regions, which direct gene transcription.
  • kits for expression of antibodies and antibody fragments contain polynucleotide sequences that enhance the rate of translation of these genes or improve the stability or nuclear export of the mRNA that results from gene transcription. These sequence elements may include, for example, 5′ and 3′ untranslated regions and a polyadenylation signal site in order to direct efficient transcription of the gene carried on the expression vector.
  • the expression vectors described herein may also contain a polynucleotide encoding a marker for selection of cells that contain such a vector. Examples of a suitable marker include genes that encode resistance to antibiotics, such as ampicillin, chloramphenicol, kanamycin, and nourseothricin.
  • alkyl refers to a straight- or branched-chain alkyl group having, for example, from 1 to 20 carbon atoms in the chain.
  • alkyl groups include methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like.
  • alkylene refers to a straight- or branched-chain divalent alkyl group. The divalent positions may be on the same or different atoms within the alkyl chain. Examples of alkylene include methylene, ethylene, propylene, isopropylene, and the like.
  • heteroalkyl refers to a straight or branched-chain alkyl group having, for example, from 1 to 20 carbon atoms in the chain, and further containing one or more heteroatoms (e.g., oxygen, nitrogen, or sulfur, among others) in the chain.
  • heteroalkylene refers to a straight- or branched-chain divalent heteroalkyl group.
  • the divalent positions may be on the same or different atoms within the heteroalkyl chain.
  • the divalent positions may be one or more heteroatoms.
  • alkenyl refers to a straight- or branched-chain alkenyl group having, for example, from 2 to 20 carbon atoms in the chain.
  • alkenyl groups include vinyl, propenyl, isopropenyl, butenyl, tert-butylenyl, hexenyl, and the like.
  • alkenylene refers to a straight- or branched-chain divalent alkenyl group. The divalent positions may be on the same or different atoms within the alkenyl chain. Examples of alkenylene include ethenylene, propenylene, isopropenylene, butenylene, and the like.
  • heteroalkenyl refers to a straight- or branched-chain alkenyl group having, for example, from 2 to 20 carbon atoms in the chain, and further containing one or more heteroatoms (e.g., oxygen, nitrogen, or sulfur, among others) in the chain.
  • heteroalkenylene refers to a straight- or branched-chain divalent heteroalkenyl group.
  • the divalent positions may be on the same or different atoms within the heteroalkenyl chain.
  • the divalent positions may be one or more heteroatoms.
  • alkynyl refers to a straight- or branched-chain alkynyl group having, for example, from 2 to 20 carbon atoms in the chain.
  • alkynyl groups include propargyl, butynyl, pentynyl, hexynyl, and the like.
  • alkynylene refers to a straight- or branched-chain divalent alkynyl group. The divalent positions may be on the same or different atoms within the alkynyl chain.
  • heteroalkynyl refers to a straight- or branched-chain alkynyl group having, for example, from 2 to 20 carbon atoms in the chain, and further containing one or more heteroatoms (e.g., oxygen, nitrogen, or sulfur, among others) in the chain.
  • heteroalkynylene refers to a straight- or branched-chain divalent heteroalkynyl group.
  • the divalent positions may be on the same or different atoms within the heteroalkynyl chain.
  • the divalent positions may be one or more heteroatoms.
  • cycloalkyl refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated and has, for example, from 3 to 12 carbon ring atoms.
  • cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[3.1.0]hexane, and the like.
  • cycloalkylene refers to a divalent cycloalkyl group.
  • the divalent positions may be on the same or different atoms within the ring structure.
  • examples of cycloalkylene include cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, and the like.
  • heterocycloalkyl refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated and has, for example, from 3 to 12 ring atoms per ring structure selected from carbon atoms and heteroatoms selected from, e.g., nitrogen, oxygen, and sulfur, among others.
  • the ring structure may contain, for example, one or more oxo groups on carbon, nitrogen, or sulfur ring members.
  • heterocycloalkyls include by way of example and not limitation dihydroypyridyl, tetrahydropyridyl (piperidyl), tetrahydrothiophenyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, tetrahydrofuranyl, tetrahydropyranyl, bis-tetrahydropyranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, piperazinyl, quinuclidinyl, and morpholinyl.
  • heterocycloalkylene refers to a divalent heterocyclolalkyl group.
  • the divalent positions may be on the same or different atoms within the ring structure.
  • aryl refers to a monocyclic or multicyclic aromatic ring system containing, for example, from 6 to 19 carbon atoms.
  • Aryl groups include, but are not limited to, phenyl, fluorenyl, naphthyl, and the like.
  • the divalent positions may be one or more heteroatoms.
  • arylene refers to a divalent aryl group.
  • the divalent positions may be on the same or different atoms.
  • heteroaryl refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group in which one or more ring atoms is a heteroatom, e.g., nitrogen, oxygen, or sulfur.
  • Heteroaryl groups include pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadia-zolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, be
  • heteroarylene refers to a divalent heteroaryl group.
  • the divalent positions may be on the same or different atoms.
  • the divalent positions may be one or more heteroatoms.
  • alkyl Unless otherwise constrained by the definition of the individual substituent, the foregoing chemical moieties, such as “alkyl”, “alkylene”, “heteroalkyl”, “heteroalkylene”, “alkenyl”, “alkenylene”, “heteroalkenyl”, “heteroalkenylene”, “alkynyl”, “alkynylene”, “heteroalkynyl”, “heteroalkynylene”, “cycloalkyl”, “cycloalkylene”, “heterocyclolalkyl”, heterocycloalkylene”, “aryl,” “arylene”, “heteroaryl”, and “heteroarylene” groups can optionally be substituted with, for example, from 1 to 5 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkyl aryl, alkyl heteroaryl, alkyl cycloalkyl, alky
  • Typical substituents include, but are not limited to, —X, —R, —OH, —OR, —SH, —SR, NH 2 , —NHR, —N(R) 2 , —N + (R) 3 , —CX 3 , —CN, —OCN, —SCN, —NCO, —NCS, —NO, —NO 2 , —N 3 , —NC( ⁇ O)H, —NC( ⁇ O)R, —C( ⁇ O)H, —C( ⁇ O)R, —C( ⁇ O)NH 2 , —C( ⁇ O)N(R) 2 , —SO 3 —, —SO 3 H, —S( ⁇ O) 2 R, —OS( ⁇ O) 2 OR, —S( ⁇ O) 2 NH 2 , —S( ⁇ O) 2 N(R) 2 , —S( ⁇ O)R, —OP( ⁇ O)(OH)
  • substitution may include situations in which neighboring substituents have undergone ring closure, such as ring closure of vicinal functional substituents, to form, for instance, lactams, lactones, cyclic anhydrides, acetals, hemiacetals, thioacetals, aminals, and hemiaminals, formed by ring closure, for example, to furnish a protecting group.
  • ring closure such as ring closure of vicinal functional substituents, to form, for instance, lactams, lactones, cyclic anhydrides, acetals, hemiacetals, thioacetals, aminals, and hemiaminals, formed by ring closure, for example, to furnish a protecting group.
  • radical naming conventions can include either a mono-radical or a di-radical, depending on the context.
  • a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a di-radical.
  • a substituent identified as alkyl that requires two points of attachment includes di-radicals such as —CH 2 —, —CH 2 CH 2 —, —CH 2 CH(CH 3 )CH 2 —, and the like.
  • Other radical naming conventions clearly indicate that the radical is a di-radical such as “alkylene,” “alkenylene,” “arylene,” “heterocycloalkylene,” and the like.
  • the present invention is based in part on the discovery that anti-CD5 antibodies, or antigen-binding fragments thereof, can be used to treat cancers and autoimmune diseases directly, for instance, due to the ability of such agents to kill CD5+ cancer cells (e.g., CD5+ leukemic cells) and CD5+ autoimmune cells (e.g., CD5+ autoimmune T cells, B cells, and/or NK cells).
  • CD5+ cancer cells e.g., CD5+ leukemic cells
  • CD5+ autoimmune cells e.g., CD5+ autoimmune T cells, B cells, and/or NK cells.
  • an anti-CD5 antibody described herein is conjugated to a cytotoxin via a linker.
  • conjugates thereof are also contemplated unless otherwise indicated.
  • the invention is additionally based in part on the discovery that antibodies, or antigen-binding fragments thereof, capable of binding CD5 can be used as therapeutic agents to promote the engraftment of transplanted hematopoietic stem cells in a patient in need of transplant therapy by preventing or reducing the likelihood of immune cell-mediated graft rejection.
  • anti-CD5 antibodies, and antigen binding fragments can bind cell-surface CD5 expressed by immune cells such as T cells, B cells, or NK cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cell antigens, such as non-self MHC antigens expressed by a hematopoietic stem cell graft.
  • the binding of such antibodies, and antigen-binding fragments, to hematopoietic stem cell-specific CD5+ immune cells can induce death of the bound immune cell, for instance, by antibody-dependent cell-mediated cytotoxicity or by the action of a cytotoxic agent that is conjugated to the antibody, or the antigen-binding fragment thereof.
  • the depletion of a population of CD5+ immune cells that cross-react with non-self hematopoietic stem cells can thus facilitate the engraftment of hematopoietic stem cell transplants in a patient in need thereof by attenuating the ability of the recipient's immune system to mount an immune response against the incoming graft.
  • a patient suffering from a stem cell disorder, cancer, autoimmune disease, or other blood disorder described herein can be treated, as a hematopoietic stem cell transplant can be provided to a subject in order to repopulate a lineage of cells that is defective and/or deficient in the subject.
  • the subject may be deficient in a population of cells due to, for instance, chemotherapy that has been administered to the subject with the aim of eradicating cancerous cells but that has, in the process, depleted healthy hematopoietic cells as well.
  • the invention thus provides compositions and methods of promoting the engraftment of transplanted hematopoietic stem cells by administration of an antibody, or an antigen-binding fragment thereof, capable of binding an antigen expressed by T cells.
  • This administration can cause the selective depletion of a population of endogenous T cells, such as CD4+ and CD8+ T cells.
  • This selective depletion of T cells can, in turn, prevent graft rejection following transplantation of an exogenous (for instance, an autologous, allogeneic, or syngeneic) hematopoietic stem cell graft.
  • the selective depletion of CD4+ and/or CD8+ T cells using an anti-CD5 antibody, antigen-binding fragment, antibody-drug conjugate, or antibody-drug conjugate as described herein can attenuate a T cell-mediated immune response that may occur against a transplanted hematopoietic stem cell graft.
  • the invention is based in part on the discovery that antibodies, and antigen-binding fragments thereof, capable of binding CD5 can be administered to a patient in need of hematopoietic stem cell transplant therapy in order to promote the survival and engraftment potential of transplanted hematopoietic stem cells.
  • Engraftment of hematopoietic stem cell transplants due to the administration of anti-CD5 antibodies, or antigen-binding fragments thereof, can manifest in a variety of empirical measurements. For instance, engraftment of transplanted hematopoietic stem cells can be evaluated by assessing the quantity of competitive repopulating units (CRU) present within the bone marrow of a patient following administration of an antibody or antigen-binding fragment thereof capable of binding CD5 and subsequent administration of a hematopoietic stem cell transplant.
  • CRU competitive repopulating units
  • a reporter gene such as an enzyme that catalyzes a chemical reaction yielding a fluorescent, chromophoric, or luminescent product
  • a reporter gene such as an enzyme that catalyzes a chemical reaction yielding a fluorescent, chromophoric, or luminescent product
  • a reporter gene such as an enzyme that catalyzes a chemical reaction yielding a fluorescent, chromophoric, or luminescent product
  • the sections that follow provide a description of antibodies, or antigen-binding fragments thereof, that can be administered to a patient in need of hematopoietic stem cell transplant therapy in order to promote engraftment of hematopoietic stem cell grafts, as well as methods of administering such therapeutics to a patient prior to hematopoietic stem cell transplantation.
  • Compositions and methods described herein include an antibody, or fragment thereof, that specifically binds to human CD5.
  • Human CD5 is also referred to as LEU1 or T1.
  • Human CD5 is a type-I transmembrane glycoprotein found on the surface of thymocytes, T lymphocytes and a subset of B lymphocytes. Two isoforms of human CD5 have been identified. Isoform 1 contains 438 amino acids and is described in Jones. et al. (1988) Nature 323 (6086), 346-349 and below (NCBI Reference Sequence: NP_001333385.1):
  • T cells have been shown to express CD5, which is a cell adhesion molecule and has been implicated both in the proliferative response of activated T cells and in T cell helper function. It has also been shown to function as a receptor, delivering co-stimulatory signals to T cells by interacting with CD72, a cell surface protein exclusive to B cells.
  • Antibodies, or antigen-binding fragments thereof, that bind CD5 may suppress T cell activation and T cell-mediated immune responses against hematopoietic stem cell grafts, for example, by inhibiting the interaction between CD5 and CD72.
  • Antibodies, and antigen-binding fragments thereof, that bind CD5 can also be used to kill CD5+ T cells directly, for instance, by conjugating the antibody, or antigen-binding fragment thereof, to a cytotoxin (such as a cytotoxin described herein or known in the art) or by using an unconjugated antibody, or antigen-binding fragment thereof, capable of recruiting complement proteins to the T cell.
  • a cytotoxin such as a cytotoxin described herein or known in the art
  • CD5 has also been shown to be expressed by subsets of NK cells; particularly among patients that have multiple myeloma have been shown to harbor populations of low density CD5+(CD5LOW+) NK cells, and this surface antigen has been implicated in NK cell activation (Ishiyama et al., Anticancer Research 14:725-730 (1994), the disclosure of which is incorporated herein by reference in its entirety).
  • Antibodies, or antigen-binding fragments thereof, that specifically bind CD5 can thus be used to attenuate the activation of B cells and NK cells.
  • Antibodies, or antigen-binding fragments thereof, that bind CD5 can also be used to kill CD5+ B cells and NK cells directly, for instance, by conjugating the antibody, or antigen-binding fragment thereof, to a cytotoxin (such as a cytotoxin described herein or known in the art) or by using an unconjugated antibody, or antigen-binding fragment thereof, capable of recruiting complement proteins to the B cell or NK cell.
  • a cytotoxin such as a cytotoxin described herein or known in the art
  • the present invention encompasses antibodies, and antigen-binding fragments thereof, that specifically bind to a CD5 polypeptide, e.g., a human CD5 polypeptide, and uses thereof.
  • a CD5 polypeptide e.g., a human CD5 polypeptide
  • the antibody, or antigen-binding fragment thereof, that specifically binds to a CD5 polypeptide comprises a heavy chain variable region and a light chain variable region.
  • the heavy chain variable region comprises one or more complementarity determining regions (CDRs).
  • CDRs complementarity determining regions
  • the heavy chain variable region comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 17.
  • the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 18.
  • the heavy chain variable region comprises a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 19.
  • the heavy chain variable region comprises one or more VH CDRs selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.
  • the heavy chain variable region comprises two or more VH CDRs selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19. In one embodiment, the heavy chain variable region comprises a VH CDR1 comprising SEQ ID NO: 17, a VH CDR2 comprising SEQ ID NO: 18, and a VH CDR3 comprising SEQ ID NO: 19.
  • the light chain variable region comprises one or more complementarity determining regions (CDRs).
  • the light chain variable region comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 20.
  • the light chain variable region comprises a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 21.
  • the light chain variable region comprises a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 22.
  • the light chain variable region comprises one or more VL CDRs selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22.
  • the light chain variable region comprises two or more VL CDRs selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22.
  • the light chain variable region comprises a VL CDR1 comprising SEQ ID NO: 20, a VL CDR2 comprising SEQ ID NO: 21, and a VL CDR3 comprising SEQ ID NO: 22.
  • the antibody, or antigen-binding fragment thereof comprises a heavy chain variable region that comprises a VH CDR1 comprising SEQ ID NO: 17, a VH CDR2 comprising SEQ ID NO: 18, and a VH CDR3 comprising SEQ ID NO: 19, and a light chain variable region that comprises a VL CDR1 comprising SEQ ID NO: 20, a VL CDR2 comprising SEQ ID NO: 21, and a VL CDR3 comprising SEQ ID NO: 22.
  • one or more of the CDRs can comprise a conservative amino acid substitution (or 2, 3, 4, or 5 amino acid substitutions) while retaining the CD5 specificity of the antibody (i.e., specificity similar to an antibody, or antigen-binding fragment thereof, comprising heavy chain CDRs of SEQ ID NOs: 17 to 19, and light chain CDRs of SEQ ID NOs:20 to 22).
  • the anti-CD5 antibody, or antigen binding fragment thereof is murine antibody 5D7, or a humanized version thereof.
  • Murine antibody 5D7 binds to human CD5 and is described in US Patent Publication No. 20008/0245027, the contents of which relating to the antibody sequences disclosed therein are incorporated by reference herein.
  • SEQ ID Nos: 29 to 34 described in Table 4 correspond to the CDRs of murine anti-CD5 antibody 5D7.
  • a humanized version of anti-CD5 antibody 5D7 is described in SEQ ID NO: 257 (humanized heavy chain variable region) and SEQ ID NO: 258 (humanized light chain variable region).
  • the ADCs and uses thereof described herein include an antibody comprising the CDRs set forth in SEQ ID Nos: 29 to 34. In one embodiment, the ADCs and uses thereof described herein include an antibody comprising the heavy and light chain variable regions as set forth in SEQ ID Nos: 257 and 258, respectively.
  • the antibody, or antigen-binding fragment thereof comprises a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 257.
  • the antibody, or antigen-binding fragment thereof comprises a heavy chain variable region that comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 257, e.g., at least 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 257.
  • an antibody comprises a modified heavy chain (HC) variable region comprising an HC variable domain comprising SEQ ID NO: 257, or a variant of SEQ ID NO: 257, which variant (i) differs from SEQ ID NO: 257 in 1, 2, 3, 4 or 5 amino acids substitutions, additions or deletions; (ii) differs from SEQ ID NO: 257 in at most 5, 4, 3, 2, or 1 amino acids substitutions, additions or deletions; (iii) differs from SEQ ID NO: 257 in 1-5, 1-3, 1-2, 2-5 or 3-5 amino acids substitutions, additions or deletions and/or (iv) comprises an amino acid sequence that is at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 257, wherein in any of (i)-(iv), an amino acid substitution may be a conservative amino acid substitution or a non-conservative amino acid substitution; and wherein the modified heavy chain variable region can have
  • the antibody, or antigen-binding fragment thereof comprises a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 258.
  • the antibody, or antigen-binding fragment thereof comprises a light chain variable region that comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 258, e.g., at least 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 258.
  • an antibody comprises a modified light chain (LC) variable region comprising an LC variable domain comprising SEQ ID NO: 258, or a variant of SEQ ID NO: 258, which variant (i) differs from SEQ ID NO: 258 in 1, 2, 3, 4 or 5 amino acids substitutions, additions or deletions; (ii) differs from SEQ ID NO: 258 in at most 5, 4, 3, 2, or 1 amino acids substitutions, additions or deletions; (iii) differs from SEQ ID NO: 258 in 1-5, 1-3, 1-2, 2-5 or 3-5 amino acids substitutions, additions or deletions and/or (iv) comprises an amino acid sequence that is at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 258, wherein in any of (i)-(iv), an amino acid substitution may be a conservative amino acid substitution or a non-conservative amino acid substitution; and wherein the modified light chain variable region can have an enhanced biological
  • the antibody, or antigen-binding fragment thereof comprises a heavy chain variable region that comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 257, e.g., at least 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 257, and a light chain variable region that comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 258, e.g., at least 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 258.
  • the antibody, or antigen-binding fragment thereof comprises a heavy chain variable region that comprises SEQ ID NO: 257, and a light chain variable region that comprises SEQ ID NO: 258.
  • the anti-CD5 antibody, or antigen-binding fragment thereof can contain a heavy chain variable region that comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 29.
  • the heavy chain variable region comprises a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 30.
  • the heavy chain variable region comprises a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 31.
  • the heavy chain variable region comprises one or more VH CDRs selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31.
  • the heavy chain variable region comprises two or more VH CDRs selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31. In one embodiment, the heavy chain variable region comprises a VH CDR1 comprising SEQ ID NO: 29, a VH CDR2 comprising SEQ ID NO: 30, and a VH CDR3 comprising SEQ ID NO: 31.
  • the light chain variable region comprises one or more complementarity determining regions (CDRs).
  • the light chain variable region comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 32.
  • the light chain variable region comprises a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 33.
  • the light chain variable region comprises a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 34.
  • the light chain variable region comprises one or more VL CDRs selected from the group consisting of SEQ ID NO: 32, SEQ ID NO: 33, and SEQ ID NO: 34.
  • the light chain variable region comprises two or more VL CDRs selected from the group consisting of SEQ ID NO: 32, SEQ ID NO: 33, and SEQ ID NO: 34.
  • the light chain variable region comprises a VL CDR1 comprising SEQ ID NO: 32, a VL CDR2 comprising SEQ ID NO: 33, and a VL CDR3 comprising SEQ ID NO: 34.
  • the antibody, or antigen-binding fragment thereof comprises a heavy chain variable region that comprises a VH CDR1 comprising SEQ ID NO: 29, a VH CDR2 comprising SEQ ID NO: 30, and a VH CDR3 comprising SEQ ID NO: 31, and a light chain variable region that comprises a VL CDR1 comprising SEQ ID NO: 32, a VL CDR2 comprising SEQ ID NO: 33, and a VL CDR3 comprising SEQ ID NO: 34.
  • one or more of the CDRs can comprise a conservative amino acid substitution (or 2, 3, 4, or 5 amino acid substitutions) while retaining the CD5 specificity of the antibody (i.e., specificity similar to an antibody, or antigen-binding fragment thereof, comprising heavy chain CDRs of SEQ ID NOs: 29 to 31, and light chain CDRs of SEQ ID NOs:32 to 34).
  • Antibodies and antigen-binding fragments thereof capable of binding CD5 antigen can be identified using techniques known in the art and described herein, such as by immunization, computational modeling techniques, and in vitro selection methods, such as the phage display and cell-based display platforms described below.
  • Anti-CD5 antibodies that can be used in conjunction with the compositions and methods described herein include those that have one or both of the following variable regions, or an amino acid sequence having at least 85% sequence identity thereto (e.g., an amino acid sequence having 85%, 90%, 95%, 97%, 98%, 99%, or more, sequence identity thereto):
  • V L having the amino acid sequence (SEQ ID NO: 1) DIQMTQSPSSMSASLGDRVTITCRASQDINSYLSWFQQKPGKSPKTLIYR ANRLVDGVPSRFSGSGSGTDYTLTISSLQYEDFGIYYCQQYDESPWTFGG GTKLEIK; and a V H having the amino acid sequence (SEQ ID NO: 2) QIQLVQSGPGLKKPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLRWMGW INTHTGEPTYADDFKGRFTFSLDTSKSTAYLQINSLRAEDTATYFCTRRG YDWYFDVWGQGTTVTVSS.
  • Antibodies and antigen-binding fragments thereof containing the foregoing V L and V H sequences are described, e.g., in U.S. Pat. No. 5,869,619, the disclosure of which is incorporated herein by reference as it pertains to anti-CD5 antibodies and antigen-binding fragments thereof, such as the he1 antibody.
  • the anti-CD5 antibody or antigen-binding fragment thereof includes the VL and V H chains of SEQ ID NO: 1 and SEQ ID NO: 2.
  • the anti-CD5 antibody or antigen-binding fragment thereof includes the CDRs contained in the VL and V H chains of SEQ ID NO: 1 and SEQ ID NO: 2.
  • the anti-CD5 antibody or antigen-binding fragment thereof includes the CDRs contained in the V L and V H chains of SEQ ID NO: 1 and SEQ ID NO: 2 and the remainder of the V L and V H sequences have at least 85% sequence identity (e.g., 85%, 90%, 95%, 97%, 98%, 99%, or greater sequence identity) to the V L and V H sequences of SEQ ID NO: 1 and SEQ ID NO: 2.
  • the anti-CD5 antibody or antigen-binding fragment thereof includes the following CDRs:
  • Additional anti-CD5 antibodies that can be used in conjunction with the compositions and methods described herein include those that have one or both of the following variable regions, or an amino acid sequence having at least 85% sequence identity thereto (e.g., an amino acid sequence having 85%, 90%, 95%, 97%, 98%, 99%, or more, sequence identity thereto):
  • V L having the amino acid sequence (SEQ ID NO: 9) DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKTLIYR ANRLESGVPSRFSGSGSGTDYTLTISSLQYEDFGIYYCQQYDESPWTFGG GTKLEIK; and a V H having the amino acid sequence (SEQ ID NO: 10) EIQLVQSGGGLVKPGGSVRISCAASGYTFTNYGMNWVRQAPGKGLEWMGW INTHYGEPTYADSFKGTRTFSLDDSKNTAYLQINSLRAEDTAVYFCTRRG YDWYFDVWGQGGTTVTVSS.
  • Antibodies and antigen-binding fragments thereof containing the foregoing V L and V H sequences are described, e.g., in U.S. Pat. No. 5,869,619, the disclosure of which is incorporated herein by reference as it pertains to anti-CD5 antibodies and antigen-binding fragments thereof, such as the he3 antibody.
  • the anti-CD5 antibody or antigen-binding fragment thereof includes the CDRs contained in the V L and V H chains of the antibody that includes the V L and V H chains of SEQ ID NO:3 and SEQ ID NO: 4.
  • the anti-CD5 antibody or antigen-binding fragment thereof includes the CDRs contained in the V L and V H chains of SEQ ID NO:3 and SEQ ID NO: 4 and the remainder of the V L and V H sequences have at least 85% sequence identity (e.g., 85%, 90%, 95%, 97%, 98%, 99%, or greater sequence identity) to the V L and V H sequences of SEQ ID NO:3 and SEQ ID NO: 4.
  • the anti-CD5 antibody or antigen-binding fragment thereof includes the following CDRs:
  • Antibodies and antigen-binding fragments thereof containing the foregoing CDR sequences are described, e.g., in U.S. Pat. No. 5,869,619, the disclosure of which is incorporated herein by reference as it pertains to anti-CD5 antibodies and antigen-binding fragments thereof.
  • anti-CD5 antibodies that can be used in conjunction with the compositions and methods described herein include, for instance, anti-CD5 antibodies that are described in U.S. Pat. Nos. 5,821,123; 5,766,886; 5,770,196; 7,153,932; 5,621,083; 6,649,742; 6,146,631; 5,756,699; 5,744,580; 6,376,217; 5,837,491; and 6,146,850, the disclosures of each of which are incorporated herein by reference as they pertain to anti-CD5 antibodies and antigen-binding fragments thereof.
  • anti-CD5 antibodies that can be used in conjunction with the compositions and methods described herein include, for instance, those produced by the hybridoma cell line deposited as ATCC CRL 8000 (anti-CD5 murine antibody OKT1). Such antibodies are described in U.S. Pat. Nos. 4,515,894; 4,657,760; and 4,363,799, the disclosures of each of which are incorporated herein by reference as they pertains to anti-CD5 antibodies and antigen-binding fragments thereof.
  • Anti-CD5 antibodies that can be used in conjunction with the compositions and methods described herein include those that have one or more, or all, of the following CDRs:
  • Antibodies and antigen-binding fragments thereof containing the foregoing CDR sequences are described, e.g., in U.S. Pat. No. 8,679,500, the disclosure of which is incorporated herein by reference as it pertains to anti-CD5 antibodies and antigen-binding fragments thereof.
  • Anti-CD5 antibodies that can be used in conjunction with the compositions and methods described herein include those that have one or more, or all, of the following CDRs:
  • Antibodies and antigen-binding fragments thereof containing the foregoing CDR sequences are described, e.g., in U.S. Pat. No. 8,679,500.
  • Anti-CD5 antibodies that can be used in conjunction with the compositions and methods described herein include those that have one or more, or all, of the following CDRs:
  • Antibodies and antigen-binding fragments thereof containing the foregoing CDR sequences are described, e.g., in US Patent Application Publication No. 2008/0254027, the disclosure of which is incorporated herein by reference as it pertains to anti-CD5 antibodies and antigen-binding fragments thereof.
  • anti-CD5 antibodies that can be used in conjunction with the compositions and methods described herein include, for instance, anti-CD5 antibodies that are described in PCT Application Publication No. WO1992/014491, such as the anti-CD5 antibodies produced by hybridoma cell line deposited at the Institut Pasteur under No. 1-1025 on Jan. 10, 1991.
  • the disclosure of PCT Application Publication No. WO1992/014491 is incorporated herein by reference as it pertains to anti-CD5 antibodies and antigen-binding fragments thereof.
  • anti-CD5 antibodies that can be used in conjunction with the compositions and methods described herein include, for instance, anti-CD5 antibodies that are described in U.S. Pat. Nos. 6,010,902 and 7,192,736, US Patent Application Publication Nos. 2011/0250203 and 2017/0129128, and PCT Application Publication Nos. WO2016/172606; WO1994/023747; and WO1996/041608; the disclosures of each of which are incorporated herein by reference as they pertain to anti-CD5 antibodies and antigen binding fragments thereof.
  • the anti-CD5 antibodies that can be used in conjunction with the compositions and methods described herein include those that contain a combination of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 regions set forth in Table 1, below.
  • Antibodies and antigen-binding fragments thereof containing the foregoing CDR sequences of Table 1 are described, e.g., in US Patent Application Publication No. 2011/0250203, the disclosure of which is incorporated herein by reference as it pertains to anti-CD5 antibodies and antigen binding fragments thereof.
  • Antibodies and fragments thereof for use in conjunction with the compositions and methods described herein include variants of those antibodies described above, such as antibody fragments that contain or lack an Fc domain, as well as humanized variants of non-human antibodies described herein and antibody-like protein scaffolds (e.g., 10 Fn3 domains) containing one or more, or all, of the CDRs or equivalent regions thereof of an antibody, or an antibody fragment, described herein.
  • Exemplary antigen-binding fragments of the foregoing antibodies include a dual-variable immunoglobulin domain, a single-chain Fv molecule (scFv), a diabody, a triabody, a nanobody, an antibody-like protein scaffold, a Fv fragment, a Fab fragment, a F(ab′) 2 molecule, and a tandem di-scFv, among others.
  • scFv single-chain Fv molecule
  • anti-CD5 antibodies, or antigen-binding fragments thereof can be used in various aspects of the invention set forth herein, including, for example, in methods for depletion of CD5+ cells in a human subject.
  • the foregoing anti-CD5 antibodies, or antigen-binding fragments thereof can also be conjugated to an agent, e.g., a cytotoxin, for example, an amatoxin, as described herein.
  • an agent e.g., a cytotoxin, for example, an amatoxin
  • Additional anti-CD5 antibodies that may be used in aspects of the instant invention are described in U.S. Pat. No. 8,679,500, U.S. Patent Application Publication No. US2011/0250203, and U.S. Patent Application Publication No.
  • Additional anti-CD5 antibodies which may be used in aspects of the instant invention include, for example, monoclonal antibody T101 described by Dillman et al., J. Clin. Oncol. (1984), 2(8):881-891, and monoclonal antibody Leu-1 described by Miller et al., Blood (1983), 62(5):988-95.
  • the anti-CD5 antibody or binding fragment thereof comprises a modified Fc region, wherein said modified Fc region comprises at least one amino acid modification relative to a wild-type Fc region, such that said molecule has an altered affinity for or binding to an FcgammaR (Fc ⁇ R).
  • Fc ⁇ R FcgammaR
  • Certain amino acid positions within the Fc region are known through crystallography studies to make a direct contact with Fc ⁇ R. Specifically amino acids 234-239 (hinge region), amino acids 265-269 (B/C loop), amino acids 297-299 (C′/E loop), and amino acids 327-332 (F/G) loop. (see Sondermann et al., 2000 Nature, 406: 267-273).
  • the antibodies described herein may comprise variant Fc regions comprising modification of at least one residue that makes a direct contact with an Fc ⁇ R based on structural and crystallographic analysis.
  • the Fc region of the anti-CD5 antibody (or fragment thereof) comprises an amino acid substitution at amino acid 265 according to the EU index as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, NH1, MD (1991), expressly incorporated herein by references.
  • the “EU index as in Kabat” refers to the numbering of the human IgG1 EU antibody.
  • the Fc region comprises a D265A mutation.
  • the Fc region comprises a D265C mutation.
  • the Fc region of the antibody comprises an amino acid substitution at amino acid 234 according to the EU index as in Kabat. In one embodiment, the Fc region comprises a L234A mutation. In some embodiments, the Fc region of the anti-CD5 antibody (or fragment thereof) comprises an amino acid substitution at amino acid 235 according to the EU index as in Kabat. In one embodiment, the Fc region comprises a L235A mutation. In yet another embodiment, the Fc region comprises a L234A and L235A mutation. In a D265C, L234A, and L235A mutation. In yet a further embodiment, the Fc region comprises a D265C, L234A, L235A, and H435A mutation. In a further embodiment, the Fc region comprises a D265C and H435A mutation.
  • the antibodies of the invention may be further engineered to further modulate antibody half-life by introducing additional Fc mutations, such as those described for example in (Dall'Acqua et al. (2006) J Biol Chem 281: 23514-24), (Zalevsky et al. (2010) Nat Biotechnol 28: 157-9), (Hinton et al. (2004) J Biol Chem 279: 6213-6), (Hinton et al. (2006) J Immunol 176: 346-56), (Shields et al. (2001) J Biol Chem 276: 6591-604), (Petkova et al. (2006) Int Immunol 18: 1759-69), (Datta-Mannan et al.
  • Fc mutations such as those described for example in (Dall'Acqua et al. (2006) J Biol Chem 281: 23514-24), (Zalevsky et al. (2010) Nat Biotechnol 28: 157-9), (Hinton et al
  • Exemplary mutations that may be made singularly or in combination are T250Q, M252Y, 1253A, S254T, T256E, P2571, T307A, D376V, E380A, M428L, H433K, N434S, N434A, N434H, N434F, H435A and H435R mutations.
  • the anti-CD5 antibody or antigen-binding fragment thereof is conjugated to a cytotoxin (e.g., amatoxin) by way of a cysteine residue in the Fc domain of the antibody or antigen-binding fragment thereof.
  • the cysteine residue is introduced by way of a mutation in the Fc domain of the antibody or antigen-binding fragment thereof.
  • the cysteine residue may be selected from the group consisting of Cys118, Cys239, and Cys265.
  • the Fc region of the anti-CD5 antibody (or fragment thereof) comprises an amino acid substitution at amino acid 265 according to the EU index as in Kabat.
  • the Fc region comprises a D265C mutation.
  • the Fc region comprises a D265C and a H435A mutation.
  • the Fc region comprises a mutation resulting in a decrease in half life.
  • An antibody having a short half life may be advantageous in certain instances where the antibody is expected to function as a short-lived therapeutic, e.g., the conditioning step described herein where the antibody is administered followed by HSCs. Ideally, the antibody would be substantially cleared prior to delivery of the HSCs, which may also generally express CD5 but are not the target of the anti-CD5 antibody, unlike the endogenous stem cells.
  • the Fc region comprises a mutation at position 435 (EU index according to Kabat). In one embodiment, the mutation is an H435A mutation.
  • anti-CD5 antibodies can be used in various aspects of the invention set forth herein, including, for example, in methods for depletion of CD5+ cells in a human subject.
  • the foregoing anti-CD5 antibodies, or antigen-binding fragments thereof can also be conjugated to an agent, e.g., a cytotoxin, for example, an amatoxin, as described herein.
  • Methods for high throughput screening of libraries of antibodies, or antibody fragments, for molecules that bind to CD5 can be used to identify and affinity mature agents useful for conditioning a patient (e.g., a human patient) in need of hematopoietic stem cell therapy and/or for directly treating a cancer or autoimmune disease as described herein.
  • Such methods include in vitro display techniques known in the art, such as phage display, bacterial display, yeast display, mammalian cell display, ribosome display, mRNA display, and cDNA display, among others.
  • phage display to isolate antibodies, or antigen-binding fragments, that bind biologically relevant molecules has been reviewed, for example, in Felici et al., Biotechnol. Annual Rev.
  • Randomized combinatorial peptide libraries have been constructed to select for polypeptides that bind cell surface antigens as described in Kay, Perspect. Drug Discovery Des. 2:251-268, 1995 and Kay et al., Mol. Divers. 1:139-140, 1996, the disclosures of each of which are incorporated herein by reference as they pertain to the discovery of antigen-binding molecules.
  • Proteins such as multimeric proteins have been successfully phage-displayed as functional molecules (see, for example, EP 0349578; EP 4527839; and EP 0589877, as well as Chiswell and McCafferty, Trends Biotechnol. 10:80-84 1992, the disclosures of each of which are incorporated herein by reference as they pertain to the use of in vitro display techniques for the discovery of antigen-binding molecules.
  • functional antibody fragments such as Fab and scFv fragments, have been expressed in in vitro display formats (see, for example, McCafferty et al., Nature 348:552-554, 1990; Barbas et al., Proc. Natl. Acad. Sci.
  • Additional techniques can be used to identify antibodies, and antigen-binding fragments thereof, that bind CD5 on the surface of a cell (e.g., a T cell, B cell, or NK cell) and that are internalized by the cell, for instance, by receptor-mediated endocytosis.
  • a cell e.g., a T cell, B cell, or NK cell
  • the in vitro display techniques described above can be adapted to screen for antibodies, and antigen-binding fragments thereof, that bind CD5 on the surface of a T cell, B cell, or NK cell and that are subsequently internalized.
  • Phage display represents one such technique that can be used in conjunction with this screening paradigm.
  • anti-CD5 antibodies and fragments thereof, that bind CD5 and are subsequently internalized by T cells, B cells, and/or NK cells
  • phage display techniques described in Williams et al., Leukemia 19:1432-1438, 2005, the disclosure of which is incorporated herein by reference in its entirety.
  • recombinant phage libraries can be produced that encode antibodies, antibody fragments, such as scFv fragments, Fab fragments, diabodies, triabodies, and 10 Fn3 domains, among others, or antibodies that contain randomized amino acid cassettes (e.g., in one or more, or all, of the CDRs or equivalent regions thereof or an antibody or antibody fragment).
  • the framework regions, hinge, Fc domain, and other regions of the antibodies or antibody fragments may be designed such that they are non-immunogenic in humans, for instance, by virtue of having human germline antibody sequences or sequences that exhibit only minor variations relative to human germline antibodies.
  • phage libraries containing randomized antibodies, or antibody fragments, covalently bound to the phage particles can be incubated with CD5 antigen, for instance, by first incubating the phage library with blocking agents (such as, for instance, milk protein, bovine serum albumin, and/or IgG so as to remove phage encoding antibodies, or fragments thereof, that exhibit non-specific protein binding and phage that encode antibodies or fragments thereof that bind Fc domains, and then incubating the phage library with a population of T cells, B cells, or NK cells that are CD5+.
  • blocking agents such as, for instance, milk protein, bovine serum albumin, and/or IgG so as to remove phage encoding antibodies, or fragments thereof, that exhibit non-specific protein binding and phage that encode antibodies or fragments thereof that bind Fc domains
  • the phage library can be incubated with the T cells, B cells, or NK cells for a time sufficient to allow CD5-specific antibodies, or antigen-binding fragments thereof, to bind cell-surface CD5 and to subsequently be internalized by the T cells, B cells, or NK cells (e.g., from 30 minutes to 6 hours at 4° C., such as 1 hour at 4° C.).
  • Phage containing antibodies, or fragments thereof, that do not exhibit sufficient affinity for CD5 so as to permit binding to, and internalization by, T cells, B cells, or NK cells can subsequently be removed by washing the cells, for instance, with cold (4° C.) 0.1 M glycine buffer at pH 2.8.
  • Phage bound to antibodies, or fragments thereof, that have been internalized by the T cells, B cells, and/or NK cells can be identified, for instance, by lysing the cells and recovering internalized phage from the cell culture medium.
  • the phage can then be amplified in bacterial cells, for example, by incubating bacterial cells with recovered phage in 2 ⁇ YT medium using methods known in the art.
  • Phage recovered from this medium can then be characterized, for instance, by determining the nucleic acid sequence of the gene(s) encoding the antibodies, or fragments thereof, inserted within the phage genome.
  • the encoded antibodies, or fragments thereof can subsequently be prepared de novo by chemical synthesis (for instance, of antibody fragments, such as scFv fragments) or by recombinant expression (for instance, of full-length antibodies).
  • Phage display libraries can be created by making a designed series of mutations or variations within a coding sequence for the CDRs of an antibody or the analogous regions of an antibody-like scaffold (e.g., the BC, CD, and DE loops of 10 Fn3 domains).
  • the template antibody-encoding sequence into which these mutations are introduced may be, for example, a naive human germline sequence. These mutations can be performed using standard mutagenesis techniques known in the art. Each mutant sequence thus encodes an antibody corresponding to the template save for one or more amino acid variations.
  • Retroviral and phage display vectors can be engineered using standard vector construction techniques known in the art. P3 phage display vectors along with compatible protein expression vectors can be used to generate phage display vectors for antibody diversification.
  • the mutated DNA provides sequence diversity, and each transformant phage displays one variant of the initial template amino acid sequence encoded by the DNA, leading to a phage population (library) displaying a vast number of different but structurally related amino acid sequences. Due to the well-defined structure of antibody hypervariable regions, the amino acid variations introduced in a phage display screen are expected to alter the binding properties of the binding peptide or domain without significantly altering its overall molecular structure.
  • a phage library may be contacted with and allowed to bind CD5 or an epitope thereof.
  • Phage bearing a CD5-binding moiety can form a complex with the target on the solid support, whereas non-binding phage remain in solution and can be washed away with excess buffer.
  • Bound phage can then liberated from the target by changing the buffer to an extreme pH (pH 2 or pH 10), changing the ionic strength of the buffer, adding denaturants, or other known means.
  • the recovered phage can then be amplified through infection of bacterial cells, and the screening process can be repeated with the new pool that is now depleted in non-binding antibodies and enriched for antibodies that bind CD5.
  • the recovery of even a few binding phage is sufficient to amplify the phage for a subsequent iteration of screening.
  • the gene sequences encoding the antibodies or antigen-binding fragments thereof derived from selected phage clones in the binding pool are determined by conventional methods, thus revealing the peptide sequence that imparts binding affinity of the phage to the target.
  • the sequence diversity of the population diminishes with each round of selection until desirable peptide-binding antibodies remain.
  • the sequences may converge on a small number of related antibodies or antigen-binding fragments thereof.
  • An increase in the number of phage recovered at each round of selection is an indication that convergence of the library has occurred in a screen.
  • Another method for identifying anti-CD5 antibodies includes using humanizing non-human antibodies that bind CD5, for instance, according to the following procedure.
  • Non-human antibodies that bind CD5 can be humanized, for instance, according to the following procedure.
  • Consensus human antibody heavy chain and light chain sequences are known in the art (see e.g., the “VBASE” human germline sequence database; Kabat et al. Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, 1991; Tomlinson et al., J. Mol. Biol. 227:776-798, 1992; and Cox et al., Eur. J. Immunol.
  • variable domain framework residues and CDRs of a consensus antibody sequence e.g., by sequence alignment.
  • This CDR exchange can be performed using gene editing techniques described herein or known in the art.
  • variable domain of a consensus human antibody contains the heavy chain variable domain EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAMSVVVRQAPGKGLEWVAVISENGSDTYYADS VKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCARDRGGAVSYFDVWGQGTLVTVSS (SEQ ID NO: 259) and the light chain variable domain DIQMTQSPSSLSASVGDRVTITCRASQDVSSYLAWYQQKPGKAPKLLIYAASSLESGVPSRFSGS GSGTDFTLTISSLQPEDFATYYCQQYNSLPYTFGQGTKVEIKRT (SEQ ID NO: 260), identified in U.S. Pat. No. 6,054,297, the disclosure of which is incorporated herein by reference as it pertains to human antibody consensus sequences. The CDRs in the above sequences are shown in bold.
  • the affinity of the antibody for CD5 is determined primarily by the CDR sequences, the resulting humanized antibody is expected to exhibit an affinity for CD5 that is about the same as that of the non-human antibody from which the humanized antibody was derived.
  • Methods of determining the affinity of an antibody for a target antigen include, for instance, ELISA-based techniques described herein and known in the art, as well as surface plasmon resonance, fluorescence anisotropy, and isothermal titration calorimetry, among others.
  • the internalizing capacity of the prepared antibodies, or fragments thereof can be assessed, for instance, using radionuclide internalization assays known in the art.
  • anti-CD5 antibodies, or fragments thereof, identified using in vitro display techniques described herein or known in the art can be functionalized by incorporation of a radioactive isotope, such as 18 F, 75 Br, 77 Br, 122 I, 123 I, 124 I, 125 I, 129 I, 131 I, 211 At, 67 Ga, 111 In, 99 Tc, 169 Yb, 186 Re, 64 CU, 67 CU, 177 Lu, 77 As, 72 As, 86 Y, 90 Y, 89 Zr, 212 Bi, 213 Bi, or 225 Ac.
  • a radioactive isotope such as 18 F, 75 Br, 77 Br, 122 I, 123 I, 124 I, 125 I, 129 I, 131 I, 211 At, 67 Ga, 111 In, 99 Tc, 169
  • radioactive halogens such as 18 F, 75 Br, 77 Br, 122 I, 123 I, 124 I, 125 I, 129 I, 131 I, 211 At, can be incorporated into antibodies, or fragments thereof, using beads, such as polystyrene beads, containing electrophilic halogen reagents (e.g., Iodination Beads, Thermo Fisher Scientific, Inc., Cambridge, Mass.).
  • Radiolabeled antibodies, or fragments thereof can be incubated with T cells, B cells, and/or NK cells for a time sufficient to permit internalization (e.g., from 30 minutes to 6 hours at 4° C., such as 1 hour at 4° C.).
  • the cells can then be washed to remove non-internalized antibodies, or fragments thereof, (e.g., using cold (4° C.) 0.1 M glycine buffer at pH 2.8).
  • Internalized antibodies, or fragments thereof can be identified by detecting the emitted radiation (e.g., ⁇ -radiation) of the resulting T cells, B cells, and/or NK cells in comparison with the emitted radiation (e.g., ⁇ -radiation) of the recovered wash buffer.
  • nucleic acid encoding an antibody is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
  • nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
  • Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein.
  • antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed.
  • For expression of antibody fragments and polypeptides in bacteria see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, N.J., 2003), pp. 245-254, describing expression of antibody fragments in E. coli .)
  • the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
  • Vertebrate cells may also be used as hosts.
  • mammalian cell lines that are adapted to grow in suspension may be useful.
  • Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod.
  • monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells.
  • Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR ⁇ CHO cells (Urlaub et al., Proc. Natl. Acad. Sci.
  • the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell).
  • CHO Chinese Hamster Ovary
  • ADCs Antibody-Drug Conjugates
  • Antibodies, and antigen-binding fragments thereof, described herein can be conjugated to a cytotoxin, such as pseudomonas exotoxin A, deBouganin, diphtheria toxin, an amatoxin, such as ⁇ -amanitin, saporin, maytansine, a maytansinoid, an auristatin, an anthracycline, a calicheamicin, irinotecan, SN-38, a duocarmycin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, an indolinobenzodiazepine, and an indolinobenzodiazepine dimer, or a variant thereof, or another cytotoxic compound described herein or known in the art in order to (i) directly treat a cancer or autoimmune disease described herein or (ii) deplete endogenous cytotoxin, such as pseudomonas exotoxin A, deBou
  • the cytotoxic molecule is conjugated to an internalizing antibody, or antigen-binding fragment thereof, such that following the cellular uptake of the antibody, or antigen-binding fragment, the cytotoxin may access its intracellular target and kill endogenous T cells, B cells, and/or NK cells.
  • Suitable cytotoxins suitable for use with the compositions and methods described herein include DNA-intercalating agents, (e.g., anthracyclines), agents capable of disrupting the mitotic spindle apparatus (e.g., vinca alkaloids, maytansine, maytansinoids, and derivatives thereof), RNA polymerase inhibitors (e.g., an amatoxin, such as ⁇ -amanitin, and derivatives thereof), agents capable of disrupting protein biosynthesis (e.g., agents that exhibit rRNA N-glycosidase activity, such as saporin and ricin A-chain), among others known in the art.
  • DNA-intercalating agents e.g., anthracyclines
  • agents capable of disrupting the mitotic spindle apparatus e.g., vinca alkaloids, maytansine, maytansinoids, and derivatives thereof
  • RNA polymerase inhibitors e.g., an amatoxin, such as ⁇ -amanitin
  • the cytotoxin of the antibody-drug conjugate is an RNA polymerase inhibitor.
  • the RNA polymerase inhibitor is an amatoxin or derivative thereof.
  • the cytotoxin is an amatoxin or derivative thereof, such as ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, amanullinic acid, and proamanullin.
  • amatoxin or derivative thereof, such as ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, amanullinic acid, and proamanullin.
  • Structures of the various naturally occurring amatoxins are represented by formula III, and are disclosed in, e.g., Zanotti et al., Int. J. Peptide Protein Res. 30, 1987, 450-459.
  • the cytotoxin is an amanitin.
  • the antibodies, or antigen-binding fragments, described herein may be bound to an amatoxin so as to form a conjugate represented by the formula Ab-Z-L-Am, wherein Ab is the antibody, or antigen-binding fragment thereof, L is a linker, Z is a chemical moiety and Am is an amatoxin.
  • Ab-Z-L-Am conjugate represented by the formula Ab-Z-L-Am, wherein Ab is the antibody, or antigen-binding fragment thereof, L is a linker, Z is a chemical moiety and Am is an amatoxin.
  • Many positions on amatoxins or derivatives thereof can serve as the position to covalently bond the linking moiety L, and, hence the antibodies or antigen-binding fragments thereof.
  • the antibodies, and antigen-binding fragments, described herein may be bound to an amatoxin so as to form a conjugate represented by the formula Ab-Z-L-Am, wherein Ab is the antibody, or antigen-binding fragment thereof, Z is a chemical moiety, L is a linker, and Am is an amatoxin.
  • Ab-Z-L-Am is represented by formula (I)
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group;
  • R 3 is H, R C , or R D ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , OR D , NHR C , or NR C R D ;
  • R 9 is H, OH, OR C , or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R C is -L-Z
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • alkyl e.g., C 1 -C 6 alkyl
  • optionally substituted heteroalkyl e.g., C 1 -C 6 heteroalkyl
  • optionally substituted alkenyl
  • L is a linker, such as optionally substituted alkylene (e.g., C 1 -C 6 alkylene), optionally substituted heteroalkylene (C 1 -C 6 heteroalkylene), optionally substituted alkenylene (e.g., C 2 -C 6 alkenylene), optionally substituted heteroalkenylene (e.g., C 2 -C 6 heteroalkenylene), optionally substituted alkynylene (e.g., C 2 -C 6 alkynylene), optionally substituted heteroalkynylene (e.g., C 2 -C 6 heteroalkynylene), optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, optionally substituted heteroarylene, a dipeptide, —C( ⁇ O)—, a peptide, or a combination thereof; and
  • Z is a chemical moiety formed from a coupling reaction between a reactive substituent present on L and a reactive substituent present within an antibody, or antigen-binding fragment thereof, that binds CD5.
  • Am contains exactly one R C substituent.
  • the linker comprises a —(CH) 2n — unit, where n is an integer from 2-6. In some embodiments, the linker includes —((CH 2 ) n where n is 6. In some embodiments, L-Z is
  • S is a sulfur atom which represents the reactive substituent present within an antibody, or antigen-binding fragment thereof, that binds CD117 (e.g., from the —SH group of a cysteine residue).
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z is represented by formula (IA)
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group;
  • R 3 is H, R C , or R D ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , OR D , NHR C , or NR C R D ;
  • R 9 is H, OH, OR C , or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R C is -L-Z
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • alkyl e.g., C 1 -C 6 alkyl
  • optionally substituted heteroalkyl e.g., C 1 -C 6 heteroalkyl
  • optionally substituted alkenyl
  • L is a linker, such as optionally substituted alkylene (e.g., C 1 -C 6 alkylene), optionally substituted heteroalkylene (C 1 -C 6 heteroalkylene), optionally substituted alkenylene (e.g., C 2 -C 6 alkenylene), optionally substituted heteroalkenylene (e.g., C 2 -C 6 heteroalkenylene), optionally substituted alkynylene (e.g., C 2 -C 6 alkynylene), optionally substituted heteroalkynylene (e.g., C 2 -C 6 heteroalkynylene), optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, optionally substituted heteroarylene, a dipeptide, —C( ⁇ O)—, a peptide, or a combination thereof;
  • optionally substituted alkylene e.g., C 1 -C 6 alkylene
  • Z is a chemical moiety formed from a coupling reaction between a reactive substituent present on L and a reactive substituent present within an antibody, or antigen-binding fragment thereof, that binds CD5;
  • the linker includes —((CH 2 ) n where n is 6. In some embodiments, L-Z is
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z is represented by formula (IB)
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, ORB, or OR C ;
  • R A and RB when present, together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group;
  • R 3 is H, R C , or R D ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , OR D , NHR C , or NR C R D ;
  • R 9 is H, OH, OR C , or OR D ;
  • X is —S—, —S(O)—, or —SO 2 —;
  • R C is -L-Z
  • R D is optionally substituted alkyl (e.g., C 1 -C 6 alkyl), optionally substituted heteroalkyl (e.g., C 1 -C 6 heteroalkyl), optionally substituted alkenyl (e.g., C 2 -C 6 alkenyl), optionally substituted heteroalkenyl (e.g., C 2 -C 6 heteroalkenyl), optionally substituted alkynyl (e.g., C 2 -C 6 alkynyl), optionally substituted heteroalkynyl (e.g., C 2 -C 6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • alkyl e.g., C 1 -C 6 alkyl
  • optionally substituted heteroalkyl e.g., C 1 -C 6 heteroalkyl
  • optionally substituted alkenyl
  • L is a linker, such as optionally substituted alkylene (e.g., C 1 -C 6 alkylene), optionally substituted heteroalkylene (C 1 -C 6 heteroalkylene), optionally substituted alkenylene (e.g., C 2 -C 6 alkenylene), optionally substituted heteroalkenylene (e.g., C 2 -C 6 heteroalkenylene), optionally substituted alkynylene (e.g., C 2 -C 6 alkynylene), optionally substituted heteroalkynylene (e.g., C 2 -C 6 heteroalkynylene), optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, optionally substituted heteroarylene, a dipeptide, —C( ⁇ O)—, a peptide, or a combination thereof;
  • optionally substituted alkylene e.g., C 1 -C 6 alkylene
  • Z is a chemical moiety formed from a coupling reaction between a reactive substituent present on L and a reactive substituent present within an antibody, or antigen-binding fragment thereof, that binds CD5;
  • linker L and the chemical moiety Z, taken together as L-Z is
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Am-L-Z-Ab is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R A and RB together with the oxygen atoms to which they are bound, combine
  • Y is —C( ⁇ O)—, —C( ⁇ S)—, —C( ⁇ NR E )—, or —C(R E R E′ )—;
  • R E and R E′ are each independently optionally substituted C 1 -C 6 alkylene-R C , optionally substituted C 1 -C 6 heteroalkylene-R C , optionally substituted C 2 -C 6 alkenylene-R C , optionally substituted C 2 -C 6 heteroalkenylene-R C , optionally substituted C 2 -C 6 alkynylene-R C , optionally substituted C 2 -C 6 heteroalkynylene-R C , optionally substituted cycloalkylene-R C , optionally substituted heterocycloalkylene-R C , optionally substituted arylene-R C , or optionally substituted heteroarylene-R C .
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B together with the oxygen atoms to which they are bound, combine to form:
  • R 3 is H or R C ;
  • R 4 is H, OH, OR C , OR D , R C , or R D ;
  • R 5 is H, OH, OR C , OR D , R C , or R D ;
  • R 6 is H, OH, OR C , OR D , R C , or R D ;
  • R 7 is H, OH, OR C , OR D , R C , or R D ;
  • R 8 is OH, NH 2 , OR C , or NHR C ;
  • R 9 is H or OH
  • R C and R D are each as defined above.
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 is H, OH, OR A , or OR C ;
  • R 2 is H, OH, OR B , or OR C ;
  • R A and R B together with the oxygen atoms to which they are bound, combine to form:
  • R 3 is H or R C ;
  • R 4 and R 5 are each independently H, OH, OR C , R C , or OR D ;
  • R 6 and R 7 are each H
  • R 8 is OH, NH 2 , OR C , or NHR C ;
  • R 9 is H or OH
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 is H, OH, or OR A ;
  • R 2 is H, OH, or OR B ;
  • R A and R B together with the oxygen atoms to which they are bound, combine to form:
  • R 3 , R 4 , R 6 , and R 7 are each H;
  • R 5 is OR C ;
  • R 8 is OH or NH 2 ;
  • R 9 is H or OH
  • amatoxin conjugates are described, for example, in US Patent Application Publication No. 2016/0002298, the disclosure of which is incorporated herein by reference in its entirety.
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 and R 2 are each independently H or OH;
  • R 3 is R C ;
  • R 4 , R 6 , and R 7 are each H;
  • R 5 is H, OH, or OC 1 -C 6 alkyl
  • R 8 is OH or NH 2 ;
  • R 9 is H or OH
  • R C is as defined above.
  • amatoxin conjugates are described, for example, in US Patent Application Publication No. 2014/0294865, the disclosure of which is incorporated herein by reference in its entirety.
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 and R 2 are each independently H or OH;
  • R 3 , R 6 , and R 7 are each H;
  • R 4 and R 5 are each independently H, OH, OR C , or R C ;
  • R 8 is OH or NH 2 ;
  • R 9 is H or OH
  • R C is as defined above.
  • amatoxin conjugates are described, for example, in US Patent Application Publication No. 2015/0218220, the disclosure of which is incorporated herein by reference in its entirety.
  • Am-L-Z is represented by formula (IA) or formula (IB),
  • R 1 and R 2 are each independently H or OH;
  • R 3 , R 6 , and R 7 are each H;
  • R 4 and R 5 are each independently H or OH
  • R 8 is OH, NH 2 , OR C , or NHR C ;
  • R 9 is H or OH
  • amatoxin conjugates are described, for example, in U.S. Pat. Nos. 9,233,173 and 9,399,681, as well as in US 2016/0089450, the disclosures of each of which are incorporated herein by reference in their entirety.
  • Am-L-Z is represented by formula (II), formula (IIA), or formula (IIB)
  • X is S, SO, or SO 2 ;
  • R 1 is H or a linker covalently bound to the antibody or antigen-binding fragment thereof through a chemical moeity Z, formed from a coupling reaction between a reactive substituent present on the linker and a reactive substituent present within an antibody, or antigen-binding fragment thereof;
  • R 2 is H or a linker covalently bound to the antibody or antigen-binding fragment thereof through a chemical moeity Z, formed from a coupling reaction between a reactive substituent present on the linker and a reactive substituent present within an antibody, or antigen-binding fragment thereof; wherein when R 1 is H, R 2 is the linker, and when R 2 is H, R 1 is the linker.
  • the linker includes a —(CH 2 ) n — unit, where n is an integer from 2-6.
  • R 1 is the linker and R 2 is H, and the linker and chemical moiety, together as L-Z, is
  • Am-L-Z-Ab is one of:
  • the cytotoxin is an ⁇ -amanitin.
  • the ⁇ -amanitin is a compound of formula III.
  • the ⁇ -amanitin of formula III is attached to an antibody, or antigen-binding fragment thereof, that binds CD5 via a linker L.
  • the linker L may be attached to the ⁇ -amanitin of formula III at any one of several possible positions (e.g., any of R 1 -R 9 ) to provide an ⁇ -amanitin-linker conjugate of formula I, IA, IB, II, IIA, or IIB.
  • the linker is attached at position R 1 .
  • the linker is attached at position R 2 . In some embodiments, the linker is attached at position R 3 . In some embodiments, the linker is attached at position R 4 . In some embodiments, the linker is attached at position R 5 . In some embodiments, the linker is attached at position R 6 . In some embodiments, the linker is attached at position R 7 . In some embodiments, the linker is attached at position R 8 . In some embodiments, the linker is attached at position R 9 . In some embodiments, the linker includes a hydrazine, a disulfide, a thioether or a dipeptide. In some embodiments, the linker includes a dipeptide selected from Val-Ala and Val-Cit.
  • the linker includes a para-aminobenzyl group (PAB). In some embodiments, the linker includes the moiety PAB-Cit-Val. In some embodiments, the linker includes the moiety PAB-Ala-Val. In some embodiments, the linker includes a —((C ⁇ O)(CH 2 ) n — unit, wherein n is an integer from 1-6
  • the linker includes a —(CH 2 ) n — unit, where n is an integer from 2-6. In some embodiments, the linker is -PAB-Cit-Val-((C ⁇ O)(CH 2 ) n —. In some embodiments, the linker is -PAB-Ala-Val-((C ⁇ O)(CH 2 ) n —. In some embodiments, the linker L and the chemical moiety Z, taken together as L-Z, is
  • Antibodies, and antigen-binding fragments, for use with the compositions and methods described herein can be conjugated to an amatoxin, such as ⁇ -amanitin or a variant thereof, using conjugation techniques known in the art or described herein.
  • antibodies, and antigen-binding fragments thereof, that recognize and bind CD5 can be conjugated to an amatoxin, such as ⁇ -amanitin or a variant thereof, as described in US 2015/0218220, the disclosure of which is incorporated herein by reference as it pertains, for example, to amatoxins, such as ⁇ -amanitin and variants thereof, as well as covalent linkers that can be used for covalent conjugation.
  • Synthetic methods of making amatoxins are described in, for example, U.S. Pat. No. 9,676,702, which is incorporated by reference herein with respect to the synthetic methods disclosed therein.
  • Antibodies, or antigen-binding fragments, for use with the compositions and methods described herein can be conjugated to an amatoxin, such as ⁇ -amanitin or a variant thereof, using conjugation techniques known in the art or described herein.
  • an amatoxin such as ⁇ -amanitin or a variant thereof
  • antibodies, or antigen-binding fragments thereof, that recognize and bind CD5 can be conjugated to an amatoxin, such as ⁇ -amanitin or a variant thereof, as described in US 2015/0218220, the disclosure of which is incorporated herein by reference as it pertains, for example, to amatoxins, such as ⁇ -amanitin and variants thereof, as well as covalent linkers that can be used for covalent conjugation.
  • Exemplary antibody-drug conjugates useful in conjunction with the methods described herein may be formed by the reaction of an antibody, or an antigen-binding fragment thereof, with an amatoxin that is conjugated to a linker containing a substituent suitable for reaction with a reactive residue on the antibody, or the antigen-binding fragment thereof.
  • Amatoxins that are conjugated to a linker containing a substituent suitable for reaction with a reactive residue on the antibody, or antigen-binding fragment thereof, described herein include, without limitation, 7′C-(4-(6-(maleimido)hexanoyl)piperazin-1-yl)-amatoxin; 7′C-(4-(6-(maleimido)hexanamido)piperidin-1-yl)-amatoxin; 7′C-(4-(6-(6-(maleimido)hexanamido)hexanoyl)piperazin-1-yl)-amatoxin; 7′C-(4-(4-((maleimido)methyl)cyclohexanecarbonyl)piperazin-1-yl)-amatoxin; 7′C-(4-(6-(4-((maleimido)methyl)cyclohexanecarboxamido)hexanoyl)piperaz
  • Additional cytotoxins that can be conjugated to antibodies, and antigen-binding fragments thereof, that recognize and bind CD5 for use in directly treating a cancer, autommine condition, or for conditioning a patient (e.g., a human patient) in preparation for hematopoietic stem cell transplant therapy include, without limitation, 5-ethynyluracil, abiraterone, acylfulvene, adecypenol, adozelesin, aldesleukin, altretamine, ambamustine, amidox, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, andrographolide, angiogenesis inhibitors, antarelix, anti-dorsalizing morphogenetic protein-1, antiandrogen, prostatic carcinoma, antiestrogen, antineoplaston, antisense oligonucleotides, aphidicolin glycinate, apoptos
  • the cytotoxin is a pyrrolobenzodiazepine dimer represented by formula (IV):
  • linkers can be used to conjugate antibodies, and antigen-binding fragments, described herein (e.g., antibodies, antigen-binding fragments thereof, that recognize and bind CD5 with a cytotoxic molecule.
  • Linker means a divalent chemical moiety comprising a covalent bond or a chain of atoms that covalently attaches an antibody or fragment thereof (Ab) to a drug moiety (D) to form antibody-drug conjugates of the present disclosure (ADCs; Ab-Z-L-D, where D is a cytotoxin).
  • Suitable linkers have two reactive termini, one for conjugation to an antibody and the other for conjugation to a cytotoxin.
  • the antibody conjugation reactive terminus of the linker is typically a site that is capable of conjugation to the antibody through a cysteine thiol or lysine amine group on the antibody, and so is typically a thiol-reactive group such as a double bond (as in maleimide) or a leaving group such as a chloro, bromo, iodo, or an R-sulfanyl group, or an amine-reactive group such as a carboxyl group; while the antibody conjugation reactive terminus of the linker is typically a site that is capable of conjugation to the cytotoxin through formation of an amide bond with a basic amine or carboxyl group on the cytotoxin, and so is typically a carboxyl or basic amine group.
  • linker when the term “linker” is used in describing the linker in conjugated form, one or both of the reactive termini will be absent (such as reactive moiety Z, having been converted to chemical moiety Z) or incomplete (such as being only the carbonyl of the carboxylic acid) because of the formation of the bonds between the linker and/or the cytotoxin, and between the linker and/or the antibody or antigen-binding fragment thereof.
  • conjugation reactions are described further herein below.
  • the linker is cleavable under intracellular conditions, such that cleavage of the linker releases the drug unit from the antibody in the intracellular environment.
  • the linker unit is not cleavable and the drug is released, for example, by antibody degradation.
  • the linkers useful for the present ADCs are preferably stable extracellularly, prevent aggregation of ADC molecules and keep the ADC freely soluble in aqueous media and in a monomeric state. Before transport or delivery into a cell, the ADC is preferably stable and remains intact, i.e. the antibody remains linked to the drug moiety.
  • the linkers are stable outside the target cell and may be cleaved at some efficacious rate inside the cell.
  • An effective linker will: (i) maintain the specific binding properties of the antibody; (ii) allow intracellular delivery of the conjugate or drug moiety; (iii) remain stable and intact, i.e. not cleaved, until the conjugate has been delivered or transported to its targeted site; and (iv) maintain a cytotoxic, cell-killing effect or a cytostatic effect of the cytotoxic moiety.
  • Stability of the ADC may be measured by standard analytical techniques such as mass spectroscopy, HPLC, and the separation/analysis technique LC/MS. Covalent attachment of the antibody and the drug moiety requires the linker to have two reactive functional groups, i.e. bivalency in a reactive sense.
  • Bivalent linker reagents which are useful to attach two or more functional or biologically active moieties, such as peptides, nucleic acids, drugs, toxins, antibodies, haptens, and reporter groups are known, and methods have been described their resulting conjugates (Hermanson, G. T. (1996) Bioconjugate Techniques; Academic Press: New York, p. 234-242).
  • Linkers include those that may be cleaved, for instance, by enzymatic hydrolysis, photolysis, hydrolysis under acidic conditions, hydrolysis under basic conditions, oxidation, disulfide reduction, nucleophilic cleavage, or organometallic cleavage (see, for example, Leriche et al., Bioorg. Med. Chem., 20:571-582, 2012, the disclosure of which is incorporated herein by reference as it pertains to linkers suitable for covalent conjugation).
  • Linkers hydrolyzable under acidic conditions include, for example, hydrazones, semicarbazones, thiosemicarbazones, cis-aconitic amides, orthoesters, acetals, ketals, or the like.
  • linkers suitable for covalent conjugation include, for example, hydrazones, semicarbazones, thiosemicarbazones, cis-aconitic amides, orthoesters, acetals, ketals, or the like.
  • Linkers cleavable under reducing conditions include, for example, a disulfide.
  • a variety of disulfide linkers are known in the art, including, for example, those that can be formed using SATA (N-succinimidyl-S-acetylthioacetate), SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB (N-succinimidyl-3-(2-pyridyldithio)butyrate) and SMPT (N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyl-dithio)toluene), SPDB and SMPT (See, e.g., Thorpe et al., 1987, Cancer Res.
  • linkers useful for the synthesis of drug-antibody conjugates include those that contain electrophiles, such as Michael acceptors (e.g., maleimides), activated esters, electron-deficient carbonyl compounds, and aldehydes, among others, suitable for reaction with nucleophilic substituents present within antibodies or antigen-binding fragments, such as amine and thiol moieties.
  • electrophiles such as Michael acceptors (e.g., maleimides), activated esters, electron-deficient carbonyl compounds, and aldehydes, among others, suitable for reaction with nucleophilic substituents present within antibodies or antigen-binding fragments, such as amine and thiol moieties.
  • linkers suitable for the synthesis of drug-antibody conjugates include, without limitation, succinimidyl 4-(N-maleimidomethyl)-cyclohexane-L-carboxylate (SMCC), N-succinimidyl iodoacetate (SIA), sulfo-SMCC, m-maleimidobenzoyl-N-hydroxysuccinimidyl ester (MBS), sulfo-MBS, and succinimidyl iodoacetate, among others described, for instance, Liu et al., 18:690-697, 1979, the disclosure of which is incorporated herein by reference as it pertains to linkers for chemical conjugation.
  • SMCC succinimidyl 4-(N-maleimidomethyl)-cyclohexane-L-carboxylate
  • SIA N-succinimidyl iodoacetate
  • MBS m-maleimidobenzoyl-N-hydroxysuccin
  • Additional linkers include the non-cleavable maleimidocaproyl linkers, which are particularly useful for the conjugation of microtubule-disrupting agents such as auristatins, are described by Doronina et al., Bioconjugate Chem. 17:14-24, 2006, the disclosure of which is incorporated herein by reference as it pertains to linkers for chemical conjugation.
  • Additional linkers suitable for the synthesis of drug-antibody conjugates as described herein include those capable of releasing a cytotoxin by a 1,6-elimination process, (a “self-immolative” group), such as p-aminobenzyl alcohol (PABC), 6-maleimidohexanoic acid, pH-sensitive carbonates, and other reagents described in Jain et al., Pharm. Res. 32:3526-3540, 2015, the disclosure of which is incorporated herein by reference in its entirety.
  • PABC p-aminobenzyl alcohol
  • 6-maleimidohexanoic acid 6-maleimidohexanoic acid
  • pH-sensitive carbonates pH-sensitive carbonates
  • the linker includes a self-immolative group such as the afore-mentioned PAB or PABC (para-aminobenzyloxycarbonyl), which are disclosed in, for example, Carl et al., J. Med. Chem. (1981) 24:479-480; Chakravarty et al (1983) J. Med. Chem. 26:638-644; U.S. Pat. No. 6,214,345; US20030130189; US20030096743; U.S. Pat. No. 6,759,509; US20040052793; U.S. Pat. Nos.
  • PAB PABC
  • self-immolative linkers include methylene carbamates and heteroaryl groups such as aminothiazoles, aminoimidazoles, aminopyrimidines, and the like. Linkers containing such heterocyclic self-immolative groups are disclosed in, for example, U.S. Patent Publication Nos. 20160303254 and 20150079114, and U.S. Pat. No. 7,754,681; Hay et al.
  • Linkers susceptible to enzymatic hydrolysis can be, e.g., a peptide-containing linker that is cleaved by an intracellular peptidase or protease enzyme, including, but not limited to, a lysosomal or endosomal protease.
  • intracellular proteolytic release of the therapeutic agent is that the agent is typically attenuated when conjugated and the serum stabilities of the conjugates are typically high.
  • the peptidyl linker is at least two amino acids long or at least three amino acids long.
  • Exemplary amino acid linkers include a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide.
  • suitable peptides include those containing amino acids such as Valine, Alanine, Citrulline (Cit), Phenylalanine, Lysine, Leucine, and Glycine.
  • Amino acid residues which comprise an amino acid linker component include those occurring naturally, as well as minor amino acids and non-naturally occurring amino acid analogs, such as citrulline.
  • Exemplary dipeptides include valine-citrulline (vc or val-cit) and alanine-phenylalanine (af or ala-phe).
  • Exemplary tripeptides include glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly).
  • the linker includes a dipeptide such as Val-Cit, Ala-Val, or Phe-Lys, Val-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Arg, or Trp-Cit.
  • Linkers containing dipeptides such as Val-Cit or Phe-Lys are disclosed in, for example, U.S. Pat. No. 6,214,345, the disclosure of which is incorporated herein by reference in its entirety as it pertains to linkers suitable for covalent conjugation.
  • the linker includes a dipeptide selected from Val-Ala and Val-Cit.
  • a dipeptide is used in combination with a self-immolative linker.
  • Linkers suitable for use herein further may include one or more groups selected from C 1 -C 6 alkylene, C 1 -C 6 heteroalkylene, C 2 -C 6 alkenylene, C 2 -C 6 heteroalkenylene, C 2 -C 6 alkynylene, C 2 -C 6 heteroalkynylene, C 3 -C 6 cycloalkylene, heterocycloalkylene, arylene, heteroarylene, and combinations thereof, each of which may be optionally substituted.
  • Non-limiting examples of such groups include (CH 2 ) n , (CH 2 CH 2 O) n , and —(C ⁇ O)(CH 2 ) n — units, wherein n is an integer from 1-6, independently selected for each occasion.
  • the linker may include one or more of a hydrazine, a disulfide, a thioether, a dipeptide, a p-aminobenzyl (PAB) group, a heterocyclic self-immolative group, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 1 -C 6 heteroalkyl, an optionally substituted C 2 -C 6 alkenyl, an optionally substituted C 2 -C 6 heteroalkenyl, an optionally substituted C 2 -C 6 alkynyl, an optionally substituted C 2 -C 6 heteroalkynyl, an optionally substituted C 3 -C 6 cycloalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, acyl, —C( ⁇ O)—, or —(CH 2 CH 2 O) n — group, wherein n is an integer from
  • the linker includes a p-aminobenzyl group (PAB).
  • PAB p-aminobenzyl group
  • the p-aminobenzyl group is disposed between the cytotoxic drug and a protease cleavage site in the linker.
  • the p-aminobenzyl group is part of a p-aminobenzyloxycarbonyl unit.
  • the p-aminobenzyl group is part of a p-aminobenzylamido unit.
  • the linker comprises PAB, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, or Ala-PAB.
  • the linker comprises a combination of one or more of a peptide, oligosaccharide, —(CH 2 ) n —, —(CH 2 CH 2 O) n —, PAB, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, or Ala-PAB.
  • the linker comprises a —(C ⁇ O)(CH 2 ) n — unit, wherein n is an integer from 1-6.
  • the linker comprises a —(CH 2 ) n — unit, wherein n is an integer from 2 to 6.
  • the linker of the ADC is N-beta-maleimidopropyl-Val-Ala-para-aminobenzyl (BMP-Val-Ala-PAB).
  • Linkers that can be used to conjugate an antibody, or an antigen-binding fragment thereof, to a cytotoxic agent include those that are covalently bound to the cytotoxic agent on one end of the linker and, on the other end of the linker, contain a chemical moiety formed from a coupling reaction between a reactive substituent present on the linker and a reactive substituent present within the antibody, or an antigen-binding fragment thereof, that binds CD5.
  • Reactive substituents that may be present within an antibody, or an antigen-binding fragment thereof, that binds CD5 include, without limitation, hydroxyl moieties of serine, threonine, and tyrosine residues; amino moieties of lysine residues; carboxyl moieties of aspartic acid and glutamic acid residues; and thiol moieties of cysteine residues, as well as propargyl, azido, haloaryl (e.g., fluoroaryl), haloheteroaryl (e.g., fluoroheteroaryl), haloalkyl, and haloheteroalkyl moieties of non-naturally occurring amino acids.
  • haloaryl e.g., fluoroaryl
  • haloheteroaryl e.g., fluoroheteroaryl
  • haloalkyl e.g., fluoroheteroaryl
  • linkers useful for the synthesis of drug-antibody conjugates include those that contain electrophiles, such as Michael acceptors (e.g., maleimides), activated esters, electron-deficient carbonyl compounds, and aldehydes, among others, suitable for reaction with nucleophilic substituents present within antibodies or antigen-binding fragments, such as amine and thiol moieties.
  • electrophiles such as Michael acceptors (e.g., maleimides), activated esters, electron-deficient carbonyl compounds, and aldehydes, among others, suitable for reaction with nucleophilic substituents present within antibodies or antigen-binding fragments, such as amine and thiol moieties.
  • linkers suitable for the synthesis of drug-antibody conjugates include, without limitation, succinimidyl 4-(N-maleimidomethyl)-cyclohexane-L-carboxylate (SMCC), N-succinimidyl iodoacetate (SIA), sulfo-SMCC, m-maleimidobenzoyl-N-hydroxysuccinimidyl ester (MBS), sulfo-MBS, and succinimidyl iodoacetate, among others described, for instance, Liu et al., 18:690-697, 1979, the disclosure of which is incorporated herein by reference as it pertains to linkers for chemical conjugation.
  • SMCC succinimidyl 4-(N-maleimidomethyl)-cyclohexane-L-carboxylate
  • SIA N-succinimidyl iodoacetate
  • MBS m-maleimidobenzoyl-N-hydroxysuccin
  • Additional linkers include the non-cleavable maleimidocaproyl linkers, which are particularly useful for the conjugation of microtubule-disrupting agents such as auristatins, are described by Doronina et al., Bioconjugate Chem. 17:14-24, 2006, the disclosure of which is incorporated herein by reference as it pertains to linkers for chemical conjugation.
  • Linkers useful in conjunction with the antibody-drug conjugates described herein include, without limitation, linkers containing chemical moieties formed by coupling reactions as depicted in Table 2, below. Curved lines designate points of attachment to the antibody, or antigen-binding fragment, and the cytotoxic molecule, respectively.
  • antibody-drug conjugates useful in conjunction with the methods described herein may be formed by the reaction of an antibody, or antigen-binding fragment thereof, with a linker or cytotoxin-linker conjugate, as described herein, the linker or cytotoxin-linker conjugate including a reactive substituent Z, suitable for reaction with a reactive substituent on the antibody, or antigen-binding fragment thereof, to form the chemical moiety Z.
  • examples of suitably reactive substituents on the linker and antibody or antigen-binding fragment thereof include a nucleophile/electrophile pair (e.g., a thiol/haloalkyl pair, an amine/carbonyl pair, or a thiol/ ⁇ , ⁇ -unsaturated carbonyl pair, and the like), a diene/dienophile pair (e.g., an azide/alkyne pair, or a diene/ ⁇ , ⁇ -unsaturated carbonyl pair, among others), and the like.
  • a nucleophile/electrophile pair e.g., a thiol/haloalkyl pair, an amine/carbonyl pair, or a thiol/ ⁇ , ⁇ -unsaturated carbonyl pair, and the like
  • a diene/dienophile pair e.g., an azide/alkyne pair, or a diene/ ⁇ , ⁇ -unsaturated
  • Coupling reactions between the reactive substitutents to form the chemical moiety Z include, without limitation, thiol alkylation, hydroxyl alkylation, amine alkylation, amine or hydroxylamine condensation, hydrazine formation, amidation, esterification, disulfide formation, cycloaddition (e.g., [4+2] Diels-Alder cycloaddition, [3+2] Huisgen cycloaddition, among others), nucleophilic aromatic substitution, electrophilic aromatic substitution, and other reactive modalities known in the art or described herein.
  • the linker contains an electrophilic functional group for reaction with a nucleophilic functional group on the antibody, or antigen-binding fragment thereof.
  • Reactive substituents that may be present within an antibody, or antigen-binding fragment thereof, as disclosed herein include, without limitation, nucleophilic groups such as (i)N-terminal amine groups, (ii) side chain amine groups, e.g. lysine, (iii) side chain thiol groups, e.g. cysteine, and (iv) sugar hydroxyl or amino groups where the antibody is glycosylated.
  • nucleophilic groups such as (i)N-terminal amine groups, (ii) side chain amine groups, e.g. lysine, (iii) side chain thiol groups, e.g. cysteine, and (iv) sugar hydroxyl or amino groups where the antibody is glycosylated.
  • Reactive substituents that may be present within an antibody, or antigen-binding fragment thereof, as disclosed herein include, without limitation, hydroxyl moieties of serine, threonine, and tyrosine residues; amino moieties of lysine residues; carboxyl moieties of aspartic acid and glutamic acid residues; and thiol moieties of cysteine residues, as well as propargyl, azido, haloaryl (e.g., fluoroaryl), haloheteroaryl (e.g., fluoroheteroaryl), haloalkyl, and haloheteroalkyl moieties of non-naturally occurring amino acids.
  • haloaryl e.g., fluoroaryl
  • haloheteroaryl e.g., fluoroheteroaryl
  • haloalkyl e.g., fluoroheteroaryl
  • the reactive substituents present within an antibody, or antigen-binding fragment thereof as disclosed herein include, are amine or thiol moieties.
  • Certain antibodies have reducible interchain disulfides, i.e. cysteine bridges.
  • Antibodies may be made reactive for conjugation with linker reagents by treatment with a reducing agent such as DTT (dithiothreitol).
  • DTT dithiothreitol
  • Each cysteine bridge will thus form, theoretically, two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into antibodies through the reaction of lysines with 2-iminothiolane (Traut's reagent) resulting in conversion of an amine into a thiol.
  • Reactive thiol groups may be introduced into the antibody (or fragment thereof) by introducing one, two, three, four, or more cysteine residues (e.g., preparing mutant antibodies comprising one or more non-native cysteine amino acid residues).
  • cysteine residues e.g., preparing mutant antibodies comprising one or more non-native cysteine amino acid residues.
  • U.S. Pat. No. 7,521,541 teaches engineering antibodies by introduction of reactive cysteine amino acids.
  • the reactive moiety Z attached to the linker is a nucleophilic group which is reactive with an electrophilic group present on an antibody.
  • Useful electrophilic groups on an antibody include, but are not limited to, aldehyde and ketone carbonyl groups.
  • the heteroatom of a nucleophilic group can react with an electrophilic group on an antibody and form a covalent bond to the antibody.
  • Useful nucleophilic groups include, but are not limited to, hydrazide, oxime, amino, hydroxyl, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.
  • Z is the product of a reaction between reactive nucleophilic substituents present within the antibodies, or antigen-binding fragments thereof, such as amine and thiol moieties, and a reactive electrophilic substituent Z.
  • Z may be a Michael acceptor (e.g., maleimide), activated ester, electron-deficient carbonyl compound, or an aldehyde, among others.
  • the ADC comprises an anti-CD5 antibody conjugated to an amatoxin of any of formulae I, IA, IB, II, IIA, or IIB as disclosed herein via a linker and a chemical moiety Z.
  • the linker includes a dipeptide.
  • the linker includes a dipeptide selected from Val-Ala and Val-Cit.
  • the linker includes a para-aminobenzyl group (PAB).
  • PAB para-aminobenzyl group
  • the linker includes the moiety PAB-Cit-Val.
  • the linker includes the moiety PAB-Ala-Val.
  • the linker includes a —((C ⁇ O)(CH 2 ) n — unit, wherein n is an integer from 1-6. In some embodiments, the linker is -PAB-Cit-Val-((C ⁇ O)(CH 2 ) n —.
  • the linker includes a —(CH 2 ) n — unit, where n is an integer from 2-6. In some embodiments, the linker is -PAB-Cit-Val-((C ⁇ O)(CH 2 ) n —. In some embodiments, the linker is -PAB-Ala-Val-((C ⁇ O)(CH 2 ) n —. In some embodiments, the linker is —(CH 2 ) n —. In some embodiments, the linker is —((CH 2 ) n —, wherein n is 6.
  • the chemical moiety Z is selected from Table 1. In some embodiments, the chemical moiety Z is selected from Table 1.
  • S is a sulfur atom which represents the reactive substituent present within an antibody, or antigen-binding fragment thereof, that binds CD5 (e.g., from the —SH group of a cysteine residue).
  • linker L and the chemical moiety Z, taken together as L-Z is
  • linker-reactive substituent group structure prior to conjugation with the antibody or antigen binding fragment thereof, includes a maleimide as the group Z.
  • group Z includes a maleimide as the group Z.
  • linker moieties and amatoxin-linker conjugates are described, for example, in U.S. Patent Application Publication No. 2015/0218220 and Patent Application Publication No. WO2017/149077, the disclosure of each of which is incorporated herein by reference in its entirety.
  • the linker-reactive substituent group structure prior to conjugation with the antibody or antigen binding fragment thereof, is:
  • an antibody or antigen binding fragment thereof is conjugated to one or more cytotoxic drug moieties (D), e.g. about 1 to about 20 drug moieties per antibody, through a linker L and a chemical moiety Z as disclosed herein.
  • D cytotoxic drug moieties
  • the ADCs of the present disclosure may be prepared by several routes, employing organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) reaction of a reactive substituent of an antibody or antigen binding fragment thereof with a bivalent linker reagent to form Ab-Z-L as described herein above, followed by reaction with a drug moiety D; or (2) reaction of a reactive substituent of a drug moiety with a bivalent linker reagent to form D-L-Z, followed by reaction with a reactive substituent of an antibody or antigen binding fragment thereof as described herein above to form an ADC of formula D-L-Z-Ab, such as Am-Z-L-Ab. Additional methods for preparing ADC are described herein.
  • the antibody or antigen binding fragment thereof has one or more lysine residues that can be chemically modified to introduce one or more sulfhydryl groups.
  • the ADC is then formed by conjugation through the sulfhydryl group's sulfur atom as described herein above.
  • the reagents that can be used to modify lysine include, but are not limited to, N-succinimidyl S-acetylthioacetate (SATA) and 2-Iminothiolane hydrochloride (Traut's Reagent).
  • the antibody or antigen binding fragment thereof can have one or more carbohydrate groups that can be chemically modified to have one or more sulfhydryl groups.
  • the ADC is then formed by conjugation through the sulfhydryl group's sulfur atom as described herein above.
  • the antibody can have one or more carbohydrate groups that can be oxidized to provide an aldehyde (—CHO) group (see, for e.g., Laguzza, et al., J. Med. Chem. 1989, 32(3), 548-55).
  • the ADC is then formed by conjugation through the corresponding aldehyde as described herein above.
  • Other protocols for the modification of proteins for the attachment or association of cytotoxins are described in Coligan et al., Current Protocols in Protein Science, vol. 2, John Wiley & Sons (2002), incorporated herein by reference.
  • linker-drug moieties to cell-targeted proteins such as antibodies, immunoglobulins or fragments thereof are found, for example, in U.S. Pat. Nos. 5,208,020; 6,441,163; WO2005037992; WO2005081711; and WO2006/034488, all of which are hereby expressly incorporated by reference in their entirety.
  • a fusion protein comprising the antibody and cytotoxic agent may be made, e.g., by recombinant techniques or peptide synthesis.
  • the length of DNA may comprise respective regions encoding the two portions of the conjugate either adjacent one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the conjugate.
  • Hematopoietic stem cell transplant therapy can be administered to a subject in need of treatment so as to populate or re-populate one or more blood cell types.
  • Hematopoietic stem cells generally exhibit multi-potency, and can thus differentiate into multiple different blood lineages including, but not limited to, granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g., megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B-cells and T-cells).
  • granulocytes e.g., promyelocytes, neutrophils, eosinophils,
  • Hematopoietic stem cells are additionally capable of self-renewal, and can thus give rise to daughter cells that have equivalent potential as the mother cell, and also feature the capacity to be reintroduced into a transplant recipient whereupon they home to the hematopoietic stem cell niche and re-establish productive and sustained hematopoiesis.
  • Hematopoietic stem cells can thus be administered to a patient defective or deficient in one or more cell types of the hematopoietic lineage in order to re-constitute the defective or deficient population of cells in vivo, thereby treating the pathology associated with the defect or depletion in the endogenous blood cell population.
  • the compositions and methods described herein can thus be used to treat a non-malignant hemoglobinopathy (e.g., a hemoglobinopathy selected from the group consisting of sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome).
  • compositions and methods described herein can be used to treat an immunodeficiency, such as a congenital immunodeficiency. Additionally or alternatively, the compositions and methods described herein can be used to treat an acquired immunodeficiency (e.g., an acquired immunodeficiency selected from the group consisting of HIV and AIDS). The compositions and methods described herein can be used to treat a metabolic disorder (e.g., a metabolic disorder selected from the group consisting of glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, and metachromatic leukodystrophy).
  • a metabolic disorder e.g., a metabolic disorder selected from the group consisting of glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, and metachromatic leukodystrophy.
  • compositions and methods described herein can be used to treat a malignancy or proliferative disorder, such as a hematologic cancer, myeloproliferative disease.
  • a malignancy or proliferative disorder such as a hematologic cancer, myeloproliferative disease.
  • the compositions and methods described herein may be administered to a patient prior to hematopoietic stem cell transplantation therapy in order to deplete a population of immune cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cells, such as those expressing one or more non-self MHC antigens.
  • Exemplary hematological cancers that can be treated using the compositions and methods described herein include, without limitation, acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, and non-Hodgkin's lymphoma, as well as other cancerous conditions, including neuroblastoma.
  • Additional diseases that can be treated with the compositions and methods described herein include, without limitation, adenosine deaminase deficiency and severe combined immunodeficiency, hyper immunoglobulin M syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, and juvenile rheumatoid arthritis.
  • compositions and methods described herein may be used to induce solid organ transplant tolerance.
  • the compositions and methods described herein may be used to deplete or ablate a population of immune cells prior to hematopoietic stem cell transplantation.
  • a population of stem or progenitor cells from an organ donor e.g., hematopoietic stem cells from the organ donor
  • a temporary or stable mixed chimerism may be achieved, thereby enabling long-term transplant organ tolerance without the need for further immunosuppressive agents.
  • compositions and methods described herein may be used to induce transplant tolerance in a solid organ transplant recipient (e.g., a kidney transplant, lung transplant, liver transplant, and heart transplant, among others).
  • a solid organ transplant recipient e.g., a kidney transplant, lung transplant, liver transplant, and heart transplant, among others.
  • the compositions and methods described herein are well-suited for use in connection the induction of solid organ transplant tolerance, for instance, because a low percentage temporary or stable donor engraftment is sufficient to induce long-term tolerance of the transplanted organ.
  • compositions and methods described herein can be used to treat cancers directly, such as cancers characterized by cells that are CD5+.
  • cancers characterized by cells that are CD5+.
  • the compositions and methods described herein can be used to treat leukemia, particularly in patients that exhibit CD5+ leukemic cells.
  • the compositions and methods described herein can be used to treat various cancers directly.
  • Exemplary cancers that may be treated in this fashion include hematological cancers, such as acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, and non-Hodgkin's lymphoma,
  • compositions and methods described herein can be used to treat autoimmune disorders.
  • an antibody, or antigen-binding fragment thereof can be administered to a subject, such as a human patient suffering from an autoimmune disorder, so as to kill a CD5+ immune cell.
  • the CD5+ immune cell may be an autoreactive lymphocyte, such as a T-cell that expresses a T-cell receptor that specifically binds, and mounts an immune response against, a self antigen.
  • an antibody, or antigen-binding fragment thereof can be administered to a subject, such as a human patient suffering from an autoimmune disorder, so as to kill a CD5+ immune cell.
  • the CD5+ immune cell may be an autoreactive lymphocyte, such as a T-cell that expresses a T-cell receptor that specifically binds, and mounts an immune response against, a self antigen.
  • the compositions and methods described herein can be used to treat autoimmune pathologies, such as those described below.
  • compositions and methods described herein can be used to treat an autoimmune disease by depleting a population of endogenous hematopoietic stem cells prior to hematopoietic stem cell transplantation therapy, in which case the transplanted cells can home to a niche created by the endogenous cell depletion step and establish productive hematopoiesis. This, in turn, can re-constitute a population of cells depleted during autoimmune cell eradication.
  • Autoimmune diseases that can be treated using the compositions and methods described herein include, without limitation, psoriasis, psoriatic arthritis, Type 1 diabetes mellitus (Type 1 diabetes), rheumatoid arthritis (RA), human systemic lupus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), lymphocytic colitis, acute disseminated encephalomyelitis (ADEM), Addison's disease, alopecia universalis, ankylosing spondylitisis, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune lymphoproliferative syndrome (ALPS), autoimmune oophoritis, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Chagas' disease, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Crohn
  • one of skill in the art can administer to a subject suffering from an autoimmune disorder an anti-CD5 antibody, or antigen-binding fragment thereof, in a quantity sufficient to treat the autoimmune pathology.
  • the subject may be suffering from scleroderma, multiple sclerosis, ulcerative colitis, Chrohn's disease, and/or Type 1 diabetes.
  • a physician of skill in the art can prescribe and administer to the subject an anti-CD5 antibody, or fragment thereof, such as an antibody, or fragment thereof, that is bound to a cytotoxic agent.
  • the antibody, or fragment thereof may be conjugated to a cytotoxic agent using conjugation techniques and linkers detailed above.
  • cytotoxic agents can be conjugated to an anti-CD5 antibody, or antigen-binding fragment thereof, in order to deplete a population of endogenous, autoreactive CD5+ T cells, B cells, or NK cells in a subject.
  • the antibody or antigen-binding fragment thereof may be conjugated to an amatoxin or another cytotoxin moiety described herein.
  • the physician may assess the quantity or concentration of autoreactive T cells, B cells, and/or NK cells in a sample isolated from a subject. This may be done, for instance, using FACS analysis techniques known in the art. One of skill in the art may then administer to the subject an antibody, or fragment thereof, either alone or conjugated to a cytotoxin, so as to deplete the population of autoreactive T cells, B cells, and/or NK cells. To evaluate the efficacy of the therapy, the physician may determine the quantity or concentration of autoreactive T cells, B cells, and/or NK cells in a sample isolated from the patient at a time subsequent to the administration of the anti-CD5 antibody, or fragment thereof.
  • a determination that the quantity or concentration of autoreactive T cells, B cells, and/or NK cells in a sample isolated from the subject following therapy relative to the quantity or concentration of T cells, B cells, or NK cells prior to therapy provides an indication that the patient is responding to the anti-CD5 antibody, or fragment thereof.
  • Antibody drug conjugates comprising anti-CD5 antibodies, or antigen-binding fragments thereof, can also be used in combination with CAR T therapy. Specifically, an effective amount of an anti-CD5 antibody drug conjugate can be administered to a patient in need thereof prior to CAR T treatment in order to deplete native T cells. Depletion of native T cells expressing CD5 using the methods and compositions described herein can provide for more effective transfer of engineered T cells used in CAR T therapy.
  • Antibodies, or antigen-binding fragments thereof, described herein can be administered to a patient (e.g., a human patient in need of hematopoietic stem cell transplant therapy) in a variety of dosage forms.
  • a patient e.g., a human patient in need of hematopoietic stem cell transplant therapy
  • antibodies, or antigen-binding fragments thereof, described herein can be administered to a patient in need of hematopoietic stem cell transplant therapy and/or suffering from cancer or an autoimmune disease in the form of an aqueous solution, such as an aqueous solution containing one or more pharmaceutically acceptable excipients.
  • exemplary pharmaceutically acceptable excipients for use with the compositions and methods described herein are viscosity-modifying agents.
  • the aqueous solution may be sterilized using techniques known in the art.
  • the antibodies, and antigen-binding fragments, described herein may be administered by a variety of routes, such as orally, transdermally, subcutaneously, intranasally, intravenously, intramuscularly, intraocularly, or parenterally.
  • routes such as orally, transdermally, subcutaneously, intranasally, intravenously, intramuscularly, intraocularly, or parenterally.
  • the most suitable route for administration in any given case will depend on the particular antibody or antigen-binding fragment administered, the patient, pharmaceutical formulation methods, administration methods (e.g., administration time and administration route), the patient's age, body weight, sex, severity of the diseases being treated, the patient's diet, and the patient's excretion rate.
  • the effective dose of an antibody, or an antigen-binding fragment thereof, described herein can range, for example from about 0.001 to about 100 mg/kg (e.g., about 0.001 mg/kg to about 0.01 mg/kg, about 0.01 mg/kg to about 0.1 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 1 mg/kg to about 10 mg/kg, about 10 mg/kg to about 100 mg/kg) of body weight per single (e.g., bolus) administration, multiple administrations, or continuous administration, or to achieve an optimal serum concentration (e.g., a serum concentration of about 0.0001-about 5000 ⁇ g/mL (e.g., about 0.0001-0.001 ⁇ g/mL, about 0.001-0.01 ⁇ g/mL, about 0.01-0.1 ⁇ g/mL, about 0.1-1 ⁇ g/mL, about 1-10 ⁇ g/mL, about 10-100 ⁇ g/mL, about 100-1000 ⁇ g/mL, about 1000
  • the dose may be administered one or more times (e.g., 2-10 times) per day, week, or month to a subject (e.g., a human) undergoing conditioning therapy in preparation for receipt of a hematopoietic stem cell transplant.
  • a subject e.g., a human
  • the antibody or antigen-binding fragment thereof can be administered to the patient at a time that optimally promotes engraftment of the exogenous hematopoietic stem cells, for instance, at a time that optimally depletes CD5+ T cells, B cells, or NK cells that cross-react with a non-self hematopoietic stem cell antigen, such as a non-self MHC antigen, prior to hematopoietic stem cell transplantation.
  • anti-CD5 antibodies, and antigen-binding fragments thereof may be administered to a patient undergoing hematopoietic stem cell transplant therapy from about 1 hour to about 1 week (e.g., about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days) or more prior to administration of the exogenous hematopoietic stem cell transplant.
  • the half-life of the antibody may be between about 1 hour and about 24 hours (e.g., about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11, hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours).
  • an anti-CD5 antibody (or Fc containing fragment thereof) has a reduced half life (compared to a wild type Fc region) where the Fc region of the antibody comprises an H435A mutation (numbering according to the EU index).
  • a physician of skill in the art can condition a patient, such as a human patient, so as to promote the engraftment of exogenous hematopoietic stem cell grafts prior to hematopoietic stem cell transplant therapy.
  • a physician of skill in the art can administer to the human patient an antibody, or antigen-binding fragment thereof, capable of binding CD5, such as an anti-CD5 antibody described herein.
  • the antibody, or fragment thereof may be covalently conjugated to a toxin, such as a cytotoxic molecule described herein or known in the art, or an Fc domain.
  • an anti-CD5 antibody, or antigen-binding fragment thereof can be covalently conjugated to a cytotoxin, such as pseudomonas exotoxin A, deBouganin, diphtheria toxin, an amatoxin, such as ⁇ -amanitin, saporin, maytansine, a maytansinoid, an auristatin, an anthracycline, a calicheamicin, irinotecan, SN-38, a duocarmycin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, an indolinobenzodiazepine, an indolinobenzodiazepine dimer, or a variant thereof.
  • a cytotoxin such as pseudomonas exotoxin A, deBouganin, diphtheria toxin
  • an amatoxin such as ⁇ -amanitin, saporin
  • maytansine a may
  • This conjugation can be performed using covalent bond-forming techniques described herein or known in the art.
  • the antibody, antigen-binding fragment thereof, or antibody-drug conjugate can subsequently be administered to the patient, for example, by intravenous administration, prior to transplantation of exogenous hematopoietic stem cells (such as autologous, syngeneic, or allogeneic hematopoietic stem cells) to the patient.
  • exogenous hematopoietic stem cells such as autologous, syngeneic, or allogeneic hematopoietic stem cells
  • the anti-CD5 antibody, antigen-binding fragment thereof, or antibody-drug conjugate can be administered in an amount sufficient to reduce the quantity of endogenous T cells, B cells, and/or NK cells, such as bone marrow resident T cells, for example, by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, or more prior to hematopoietic stem cell transplant therapy.
  • the anti-CD5 antibody, antigen-binding fragment thereof, or antibody-drug conjugate can be administered in an amount sufficient to reduce the quantity of endogenous T cells, B cells, and/or NK cells, such as bone marrow resident T cells, for example, by about 10%-20%, by about 20-30%, by about 30-40%, by about 40-50%, by about 50-60%, by about 60-70%, by about 70%-80%, by about 80%-90%, by about 90%-95%, or more prior to hematopoietic stem cell transplant therapy.
  • the anti-CD5 antibody, antigen-binding fragment thereof, or antibody-drug conjugate can be administered in an amount sufficient to reduce the quantity of endogenous T cells, B cells, and/or NK cells, such as bone marrow resident T cells, for example, by at least about 10%, by at least about 20%, by at least about 30%, by at least about 40%, by at least about 50%, by at least about 60%, by at least about 70%, by at least about 80%, by at least about 90%, by at least about 95%, or more prior to hematopoietic stem cell transplant therapy.
  • the reduction in T cell count can be monitored using conventional techniques known in the art, such as by FACS analysis of cells expressing characteristic T cell surface antigens in a blood sample withdrawn from the patient at varying intervals during conditioning therapy. For instance, a physician of skill in the art can withdraw a bone marrow sample from the patient at various time points during conditioning therapy and determine the extent of endogenous T cell reduction by conducting a FACS analysis to elucidate the relative concentrations of T cells in the sample using antibodies that bind to T cell marker antigens.
  • the physician may conclude the conditioning therapy, and may begin preparing the patient for hematopoietic stem cell transplant therapy.
  • the anti-CD5 antibody, antigen-binding fragment thereof, or antibody-drug conjugate can be administered to the patient in an aqueous solution containing one or more pharmaceutically acceptable excipients, such as a viscosity-modifying agent.
  • aqueous solution may be sterilized using techniques described herein or known in the art.
  • the antibody, antigen-binding fragment thereof, or antibody-drug conjugate can be administered to the patient at a dosage of, for example, from about 0.001 mg/kg to about 100 mg/kg prior (e.g., about 0.001 mg/kg to about 0.01 mg/kg, about 0.01 mg/kg to about 0.1 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 1 mg/kg to about 10 mg/kg, about 10 mg/kg to about 100 mg/kg) to administration of a hematopoietic stem cell graft to the patient.
  • a dosage of for example, from about 0.001 mg/kg to about 100 mg/kg prior (e.g., about 0.001 mg/kg to about 0.01 mg/kg, about 0.01 mg/kg to about 0.1 mg/kg, about 0.1 mg/kg to about 1 mg/kg, about 1 mg/kg to about 10 mg/kg, about 10 mg/kg to about 100 mg/kg) to administration of a hematopoietic stem cell graft
  • the antibody, antigen-binding fragment thereof, or antibody-drug conjugate can be administered to the patient at a time that optimally promotes engraftment of the exogenous hematopoietic stem cells, for instance, from about 1 hour to about 1 week (e.g., about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days) or more prior to administration of the exogenous hematopoietic stem cell transplant.
  • about 1 hour to about 1 week e.g., about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours
  • the patient may then receive an infusion (e.g., an intravenous infusion) of exogenous hematopoietic stem cells, such as from the same physician that performed the conditioning therapy or from a different physician.
  • the physician may administer the patient an infusion of autologous, syngeneic, or allogeneic hematopoietic stem cells, for instance, at a dosage of from about 1 ⁇ 10 3 to about 1 ⁇ 10 9 hematopoietic stem cells/kg (about 1 ⁇ 10 3 hematopoeitic stem cells to about 1 ⁇ 10 4 , about 1 ⁇ 10 4 hematopoeitic stem cells to about 1 ⁇ 10, about 1 ⁇ 10 5 hematopoeitic stem cells to about 1 ⁇ 10 6 , about 1 ⁇ 10 6 hematopoeitic stem cells to about 1 ⁇ 10 7 , or about 1 ⁇ 10 8 hematopoeitic stem cells to about 1 ⁇ 10 9 ).
  • the physician may monitor the engraftment of the hematopoietic stem cell transplant, for example, by withdrawing a blood sample from the patient and determining the increase in concentration of hematopoietic stem cells or cells of the hematopoietic lineage (such as megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T lymphocytes, and B lymphocytes) following administration of the transplant.
  • hematopoietic stem cells or cells of the hematopoietic lineage such as megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, gran
  • This analysis may be conducted, for example, from about 1 hour to about 6 months, or more, following hematopoietic stem cell transplant therapy (e.g., about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, or more).
  • a finding that the concentration of hematopoietic stem cells or cells of the hematopoietic lineage has increased (e.g., by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, about 200%, about 500%, or more) following the transplant therapy relative to the concentration of the corresponding cell type prior to transplant therapy provides one indication that treatment with the anti-CD5 antibody, antigen-binding fragment thereof, or antibody-drug conjugate, has successfully promoted engraftment of the transplanted hematopoietic stem cell graft.
  • anti-CD5 antibody 5D7 hIgG1 To determine the binding characteristics of anti-CD5 antibody 5D7 hIgG1, antibody binding studies were performed at 25 degrees Celsius in 1 ⁇ PBS supplemented with 0.1% w/v bovine serum albumin with a Pall ForteBio Octet Red96 using biolayer interferometry (BLI).
  • the purified human anti-CD5 antibody (5D7) was immobilized onto anti-human Fc biosensors (AHC; Pall ForteBio 18-5063) and incubated with 50 nM of purified human CD5 ectodomain).
  • the binding characteristics of anti-CD5 antibody 5D7 are shown in Table 3.
  • Anti-human CD5 antibody 5D7 as used in Examples 1 to 5 is a humanized version of murine antibody 5D7 (see US 2008/0254027).
  • the sequences of antibody 5D7 as used herein are described in SEQ ID Nos: 257 and 258 (heavy and light chain variable region amino acid sequences) and SEQ ID Nos
  • MOLT-4 cells i.e., an immortalized human T lymphoblast cell line
  • MOLT-4 cells were plated at 20,000 cells/well and stained with a titration of the indicated murine anti-CD5 antibodies (i.e., L17F12, UCHT2, 205919, and CRIS-1) for 2 hours at 4° C.
  • the anti-CD5 antibody 5D7 was conjugated to an amatoxin (amanitin) with a cleavable linker to form an anti-CD5 5D7ADC.
  • Anti-CD5 5D7-ADCs having a drug to antibody ratio (DAR) of about 6 (interchain DAR6) were tested, as well as anti-CD5 5D7-ADCs having a DAR of about 2 (prepared using site-specific conjugation via a D265C mutation). Further, a fast half-life variant of the anti-CD5 5D7-ADC was generated through the introduction of an H435A mutation within the Fc region.
  • Each anti-CD5 5D7-ADC was assessed using an in vitro human T-cell killing assay. Cryopreserved negatively-selected primary human T cells were thawed and stimulated with anti-CD3 antibodies and IL-2. At the start of the assay, 2 ⁇ 10 4 T cells were seeded per well of a 384 well plate and the indicated ADCs or non-conjugated anti-CD5 antibody were added to the wells at various concentrations between 0.003 nm and 30 nm before being placed in an incubator with 37° C. and 5% CO 2 . Following five days of culture, cells were analyzed by flow cytometry. Cells were stained with a viability marker 7-AAD and run on a volumetric flow cytometer.
  • FIGS. 3A and 3B Numbers of viable T-cells ( FIGS. 3A and 3B ) were determined by FSC vs SSC and 7-AAD. A non-conjugated anti-CD5 5D7 antibody served as a comparator ( FIG. 3A ).
  • the fast-half life variant of the anti-CD5 5D7-ADC H435A
  • Anti-CD5 antibody 5D7 was conjugated to amatoxin (amanitin) with a cleavable linker to form an anti-CD5 5D7-ADC.
  • Anti-CD5 5D7-ADCs were prepared either as a DAR of about 6 or aDAR of about 2, as described above.
  • Each anti-CD5 5D7ADC (DAR6 or DAR2) was administered as a single intravenous injection (0.3 mg/kg, 1 mg/kg, or 3 mg/kg for DAR6 ADCs, or 1 mg/kg or 3 mg/kg for DAR2 ADCs) to the humanized mouse.
  • Peripheral blood cells, bone marrow, or thymic samples were collected on Day 7 and the absolute number of CD3+ T-cells was determined by flow cytometry (see FIGS. 4A-4C for DAR2 ADCs, and 5 A- 5 C for DAR6 ADCs).
  • humanized NSG mice treated with 0.3 mg/kg, 1 mg/kg, or 3 mg/kg DAR6 anti-CD5 5D7-ADCs exhibited potent T-cell depletion in peripheral blood or bone morrow while thymic T-cells were depleted following treatment with 1 mg/kg or 3 mg/kg of DAR6 anti-CD5 5D7-ADCs.
  • Negative controls used in this in vivo experiment included a human IgG1 not specific to CD5 (as a naked antibody (huIgG1) and conjugated to an amatoxin (huIgG1-AM). As described in FIGS.
  • the huIgG1 naked and conjugated controls had no impact on T cell depletion in peripheral blood ( FIG. 4A ) and bone marrow ( FIG. 4B ) as these controls were comparable to the PBS control.
  • An anti-CD52 antibody (antibody YTH34.5) was used as a control as well, and was also able to deplete peripheral and bone marrow T cells at a dose of 25 mg/kg.
  • FIGS. 5A-5C humanized NSG mice treated with 1 mg/kg site or 3 mg/kg site-specific DAR2 anti-CD5 5D7-ADC exhibited potent T-cell depletion in peripheral blood, bone morrow, and thymic T-cells.
  • naked antibody 5D7 was also used as a control.
  • Antibody 5D7 was able to deplete peripheral T cells (relative to a non-specific human IgG1 control or PBS) as described in FIG. 5A , but was unable to deplete either marrow T cells or thymic T cells whereas the 5D7-AM ADC was effective at depleting both marrow and thymic as described in FIGS. 5B and 5C .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US16/851,082 2017-11-29 2020-04-16 Compositions and methods for the depletion of cd5+ cells Abandoned US20200276326A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/851,082 US20200276326A1 (en) 2017-11-29 2020-04-16 Compositions and methods for the depletion of cd5+ cells
US17/244,721 US20210369854A1 (en) 2017-11-29 2021-04-29 Compositions and methods for the depletion of cd5+ cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762592214P 2017-11-29 2017-11-29
PCT/US2018/063175 WO2019108863A1 (en) 2017-11-29 2018-11-29 Compositions and methods for the depletion of cd5+ cells
US16/851,082 US20200276326A1 (en) 2017-11-29 2020-04-16 Compositions and methods for the depletion of cd5+ cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/063175 Continuation WO2019108863A1 (en) 2017-11-29 2018-11-29 Compositions and methods for the depletion of cd5+ cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/244,721 Continuation US20210369854A1 (en) 2017-11-29 2021-04-29 Compositions and methods for the depletion of cd5+ cells

Publications (1)

Publication Number Publication Date
US20200276326A1 true US20200276326A1 (en) 2020-09-03

Family

ID=66664223

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/851,082 Abandoned US20200276326A1 (en) 2017-11-29 2020-04-16 Compositions and methods for the depletion of cd5+ cells
US17/244,721 Pending US20210369854A1 (en) 2017-11-29 2021-04-29 Compositions and methods for the depletion of cd5+ cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/244,721 Pending US20210369854A1 (en) 2017-11-29 2021-04-29 Compositions and methods for the depletion of cd5+ cells

Country Status (14)

Country Link
US (2) US20200276326A1 (ru)
EP (1) EP3717022A4 (ru)
JP (2) JP7458975B2 (ru)
KR (1) KR20200094181A (ru)
CN (1) CN111670052A (ru)
AU (1) AU2018374283A1 (ru)
BR (1) BR112020010662A2 (ru)
CA (1) CA3082310A1 (ru)
CO (1) CO2020006865A2 (ru)
EA (1) EA202090947A1 (ru)
IL (1) IL274839A (ru)
MX (1) MX2020004910A (ru)
SG (1) SG11202004294XA (ru)
WO (1) WO2019108863A1 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230159654A1 (en) * 2021-11-24 2023-05-25 International - Drug - Development - Biotech Anti-cd5 antibodies and methods of use thereof
EP4238990A4 (en) * 2020-11-01 2024-10-02 Nanjing Iaso Biotechnology Co Ltd FULLY HUMAN ANTIBODY TARGETING CD5, FULLY HUMAN CHIMERIC ANTIGEN RECEPTOR (CAR) AND USE THEREOF

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3107383A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
EP3980034A4 (en) * 2019-06-05 2024-02-28 Heidelberg Pharma Research GmbH T-CELL DEPLETION THERAPIES
CN116829600A (zh) * 2021-01-12 2023-09-29 南京驯鹿生物技术股份有限公司 靶向cd5的全人源抗体
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1249051B (it) * 1991-02-26 1995-02-11 Italfarmaco Spa Immunotossina da anticorpi monoclonali anti-cd5
ES2202310T3 (es) * 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
WO2008121160A2 (en) * 2006-11-21 2008-10-09 Xencor, Inc. Optimized antibodies that target cd5
EP3192529B1 (en) * 2009-04-08 2020-03-25 Faulstich, Heinz, Dr. Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
ES2738115T3 (es) * 2010-08-18 2020-01-20 Theresa Deisher Dexametasona para su uso en el tratamiento de osteoartritis, fallo hepático, diabetes mellitus tipo-2, ictus y enfermedad de Parkinson, en combinación con un tratamiento con células madre
US9540612B2 (en) * 2012-01-30 2017-01-10 Icahn School Of Medicine At Mount Sinai Methods for programming differentiated cells into hematopoietic stem cells
US9938323B2 (en) * 2014-11-06 2018-04-10 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
AU2016228415B2 (en) * 2015-03-09 2021-04-01 Heidelberg Pharma Gmbh Amatoxin-antibody conjugates
MX2018015684A (es) * 2016-06-17 2019-08-29 Magenta Therapeutics Inc Composiciones y metodos para el agotamiento de celulas cd117.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4238990A4 (en) * 2020-11-01 2024-10-02 Nanjing Iaso Biotechnology Co Ltd FULLY HUMAN ANTIBODY TARGETING CD5, FULLY HUMAN CHIMERIC ANTIGEN RECEPTOR (CAR) AND USE THEREOF
US20230159654A1 (en) * 2021-11-24 2023-05-25 International - Drug - Development - Biotech Anti-cd5 antibodies and methods of use thereof
US12077597B2 (en) * 2021-11-24 2024-09-03 International-Drug-Development-Biotech Anti-CD5 antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP3717022A4 (en) 2021-11-10
SG11202004294XA (en) 2020-06-29
IL274839A (en) 2020-07-30
US20210369854A1 (en) 2021-12-02
JP2021504412A (ja) 2021-02-15
JP2024096703A (ja) 2024-07-17
CO2020006865A2 (es) 2020-07-31
AU2018374283A1 (en) 2020-06-04
JP7458975B2 (ja) 2024-04-01
EP3717022A1 (en) 2020-10-07
CA3082310A1 (en) 2019-06-06
MX2020004910A (es) 2020-10-05
KR20200094181A (ko) 2020-08-06
BR112020010662A2 (pt) 2020-11-10
WO2019108863A4 (en) 2019-08-08
CN111670052A (zh) 2020-09-15
WO2019108863A1 (en) 2019-06-06
EA202090947A1 (ru) 2020-08-26

Similar Documents

Publication Publication Date Title
US20210162063A1 (en) Compositions and methods for the depletion of cd117+ cells
US10624973B2 (en) Methods for the depletion of cells
US11572411B2 (en) Anti-CD117 antibodies and conjugates
US20200276326A1 (en) Compositions and methods for the depletion of cd5+ cells
US20200368363A1 (en) Compositions and methods for the depletion of cd2+ cells
US20220249683A1 (en) T-cell depleting therapies
US20220177578A1 (en) Anti-cd117 antibodies and uses thereof
EP3958902A1 (en) Anti-cd117 antibodies and uses thereof
US20210101990A1 (en) Compositions and methods for the depletion of cd134+ cells
US20210095039A1 (en) Anti-cd252 antibodies, conjugates, and methods of use

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION